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Preface
Theileria parva, a tick-transmitted protozoan parasite, causes a severe disease of cattle,
variously referred to as East Coast fever (ECF), January Disease or Corridor Disease. The
disease continues to be a major constraint to livestock production in much of eastern,
central and southern Africa. The control of the disease through intensive acaricide
application has been successful but is becoming increasingly unacceptable for several
reasons including pollution of the environment, contamination of livestock food products
and high cost. Over the past 20 years, a research programme to control ECF was developed
by the Food and Agriculture Organization of the United Nations (FAO). The principal aim
of the programme, funded by a number of donor agencies including the United Nations
Development Programme, the Governments of Denmark, United Kingdom, The
Netherlands and Belgium, was to develop a vaccine against ECF. This multi-donor
programme resulted in the development of a first generation live-vaccine, referred to as the
infection and treatment method of immunisation. Further research, including numerous
field trials, has resulted in significant modification of the method since its first description.
This evolution of the infection and treatment method, together with a better understanding
of the epidemiology of the disease and the existence of parasite diversity, has culminated in
the use of a number of vaccine stabilates. These vaccine stabilates are based on different T.
parva stocks and include the Muguga cocktail, Marikebuni, Boleni and Katete stocks.
A series of regular formal meetings has been held to discuss progress in the control of T.
parva and other tick-borne pathogens among the representatives of the national veterinary
departments, researchers from various international and national research institutions and
the donors. The first such meeting in this series was in held in 1984 at the International
Laboratory for Research on Animal Diseases (ILRAD, now the International Livestock
Research Institute (ILRI)). Five more meetings have since been held in Malawi, Uganda and
Kenya. The meeting recorded in this proceedings was held in the form of a workshop at ILRI
in March 1997 and was jointly organised by the Organization of African Unity/Inter-
African Bureau of Animal Resources (OAU/IBAR), FAO and ILRI. The workshop
participants discussed the deployment of live ECF vaccines and focused on the problems
associated with their delivery and the solutions to these problems. This proceedings
provides a record of all the country presentations, invited papers, group discussions and
recommendations of the workshop.
Representatives from all the countries within eastern, central and southern Africa,
where tick and tick-borne diseases (T & TBDs) constitute a major economic constraint to
livestock development attended the meeting. In addition, a number of scientists from the
Kenyan National Veterinary Research Centre, the International Centre of Insect
Physiology and Entomology (ICIPE) and ILRI participated in the workshop. The FAO and
donor representatives from The Netherlands, Denmark and the United Kingdom were also
represented. The workshop participants hope that the recommendations made at this
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workshop will be implemented and will help stimulate positive development and progress
in the control of T & TBDs.
I would like to thank all the participants from the countries in the region and
representatives from international and national research institutions for their input, which
resulted in the success of the workshop. The donors (Belgium, The Netherlands, Denmark
and the United Kingdom), the FAO and OAU/IBAR, are thanked for their continued
support and commitment to improved control of T & TBDs in the region, and the members
of the organising committee for their assistance in planning and formulating the
programme. Special thanks go to the Department for International Development of the
United Kingdom (DFID) and OAU/IBAR for providing financial support towards the
compilation of the summary of the recommendations (annexed) from all the previous
meetings in this series and publication of the current proceedings, respectively. Dr Rob
Eleys assistance in providing logistical support in the organisation of the workshop is also
gratefully acknowledged. I also thank Joel Mwaura and Susan McMillan for their help in the
design of the cover, and David Elsworth and the staff of the Graphics section in Nairobi for
their input in preparing the illustrations of this proceedings.
Subhash Morzaria
International Livestock Research Institute
Nairobi
Kenya
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Preface
Objectives of the Workshop
A. Irvin
Background
At a meeting of the Programme Steering Committee (PSC) of the Food and Agriculture
Organization of the United Nations (FAO)/Multidonor Regional Programme on control
of ticks and tick-borne diseases (TBDs) in Lilongwe in June 1996, it was agreed that this
Workshop should be held to identify research needs to improve the present live Theileria
parva vaccines and their delivery, and to consider new developments which could lead to
improved vaccines.
Purpose of the workshop
1. To consider the present method of immunisation against East Coast fever (ECF) and
other forms of T. parva infection using the infection and treatment method or infection
without treatment, and to identify needs for further research to improve vaccine quality
and suitability.
This will include an evaluation of production, storage and delivery techniques; vaccine
production standards including quality control, safety and assurance issues; strain and stock
composition of vaccines (how to identify and select strains); and specific country
requirements. In addition, specific research needs will be identified and a programme for
future research developed.
2. To consider present and future demands for T. parva vaccine and how these can be met.
This will include an assessment of present demands by country; consideration of how
the demands can be met and requirements for increasing production; and projected
demand for the future.
3. To review recent progress in developing alternative vaccines for the control of
theileriosis caused by T. parva.
This will include a review of present research to develop subunit vaccines and future
research needs; consideration of ways in which research programmes on present and future
vaccines can be more closely integrated; prospects for alternative vaccines.
4. To consider related research needs.
This will include consideration of the need for improved diagnostics and
characterisation methods; improved methods of identifying demand and target groups;
improved methods of vaccine delivery; impact assessment. In this context, the workshop
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will also review progress in the implementation of the recommendations of the
Epidemiology Workshop held in Harare in March 1996.
5. To identify training and information needs.
This will include consideration of training needs in respect of vaccine production,
handling, delivery and monitoring; improved communications and information exchange.
Outputs
1. The main output will be jointly publishing the proceedings, which will document:•
• the current status of each country with respect to ECF immunisation,
• key areas of research to improve the quality and suitability of the vaccine, including
an outline research programme
• key areas of research for development of improved vaccines, and future prospects
that such vaccines offer
• needs for research in other areas which will help improve application and uptake of
vaccine
• training and information needs.
2. An additional output will be the opportunity for participants to exchange information
and review current operations at the International Livestock Research Institute (ILRI)
and the Kenya Agricultural Research Institute (KARI).
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Objectives of the Workshop
Current country
status reports
East Coast fever (ECF) immunisation in
Kenya
D. Kariuki
National Veterinary Research Centre (NVRC), Muguga,
P.O. Box 32, Kikuyu, Kenya
Background
Kenya has a human population of over 25 million people and covers an area of 582,670
km2. Twenty per cent of the total land area has high to medium agricultural potential and is
suitable for crops, intensive forestry and livestock raising. These zones support 80% of the
total human population. Kenya also has an estimated 13.5 million cattle of which 3.2
million head are exotic dairy and beef cattle in large- and small-scale holdings in the high and
medium potential agricultural zones. The remaining 10.3 million head are indigenous zebu
cattle found in the arid and semi-arid areas, which form approximately 80% of the country.
The livestock sector contributes about 10% of the countrys gross domestic product,
accounts for over 30% of the farm-gate value of agriculture commodities and employs over
50% of the agricultural labour force.
Smallholder production dominates Kenyas agricultural sector. There are about 3
million smallholder farms of which 80% are less than 2 ha with women providing the bulk
of labour and heading a third of the households. Despite their small sizes, smallholder farms
account for over 75% of total agricultural production and over 50% of marketed
production. In the livestock sector, smallholders likewise account for the production of over
80% of all milk, and 70% of beef and other meat. For the small-scale farmers in Kenya, the
dairy industry is therefore, a very important income-generating enterprise.
This industry is, however, beset with numerous constraints. These include inadequate
water and animal feeds (fodder and pasture), high cost of concentrates, diseases requiring
control and treatment, poor marketing information, diminishing land resources for
livestock keeping due to increasing population pressure, poor animal husbandry practices,
inadequate credit facilities for dairy farmers and poor rural infrastructure. These
constraints coupled with the rapid increase in population testify that the demand for major
livestock products will outstrip the current rate of production (Table 1).
Table 1. Output and demand for beef and milk in Kenya.
Product Output in 1992 Demand in 2000
Beef (000 t) 252.0 336.0
Milk (billion kg) 2.4 3.2
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East Coast fever (ECF), caused by Theileria parva and transmitted by the tick,
Rhipicephalus appendiculatus, poses one of the major challenges to the development of the
cattle industry. Of the estimated 13 million cattle, 76% are at risk from ECF since the
distribution of the tick vector correlates closely with the highest concentration of cattle,
both indigenous and exotic. The disease is associated with a 10% mortality in zebu calves in
ECF endemic areas and can cause up to 100% mortality in susceptible exotic and
indigenous breeds. In addition, high productivity losses in animals recovering after
treatment and the presence of the disease inhibits the introduction of high producing exotic
and crossbred cattle in areas infested by the vector. In 1993, the Veterinary Department
reported 24,000 ECF cases representing only an estimated 10% of the actual cases occurring
in the field annually.
Five species of Theileria have so far been described in Kenya (Table 2). T. parva cattle-
derived and maintained between cattle, manifests itself in the form of classical ECF while T.
parva buffalo-derived when transmitted to cattle causes Corridor Disease. Theileria mutans,
T. velifera and T. taurotragi infections usually cause mild transient fever and anaemia and are
not often reported in the field. Theileria buffeli was recently isolated in Kenya and also causes
mild transient fever in cattle.
Table 2. Species of Theileria recognised in Kenyan cattle.
Theileria species Disease Vector
T. parva (cattle-
derived)
East Coast fever Rhipicephalus
appendiculatus
T. parva (buffalo-
derived)
Corridor Disease R. appendiculatus
T. taurotragi Usually benign R. appendiculatus and R.
pulchellus
T. mutans Usually benign Amblyomma spp
T. velifera Benign Amblyomma spp
T. buffeli Usually benign ?
Since 1904, when the disease was first recognised in Kenya, the strategy for tick and tick-
borne disease (T &TBD) control in Kenya has been predominately based on controlling R.
appendiculatus through intensive application of acaricides. The acaricides are applied once
or twice a week to prevent transmission of T. parva and to allow introduction of improved
exotic breeds of cattle and upgrading of the indigenous cattle population in ECF affected
areas. However, in the past decade or so, it has become apparent that intensive tick control
using acaricide is becoming prohibitively expensive. In addition, strict acaricide application
that prevents any contact of cattle with ticks does not allow calves to develop immunity to
TBDs other than ECF at an early age. In addition, the method does not allow cattle to
develop immunity to ticks. Thus, strict acaricide application creates endemic instability as
animals remain susceptible to tick-borne diseases. If for any reason the dipping programme
is interrupted, there will be a potential danger of a TBD upsurge of epidemic proportion.
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East Coast fever (ECF) immunisation in Kenya
With the introduction of the infection and treatment method of immunising cattle against
ECF, however, it should be possible to relax the frequency of acaricide application.
Progress on East Coast fever immunisation
Currently, the only available method of immunisation against ECF requires injecting an
animal with a potentially lethal parasite preparation together with a therapeutic dose of a
long-acting oxytetracycline. A small proportion of the immunised animals may develop the
disease and must be treated. These animals are commonly referred to as reactors and are
identified through follow-up monitoring between days 10 and 14 after immunisation.
The major costs associated with this method of immunisation include those of the
oxytetracycline, monitoring exercise, antitheilerial drugs to treat reactors and the possible
loss of milk due to milk withdrawal after administering drugs to lactating cows. The cost of
treating a reactor animal completely negates the cost benefit of immunising the animal as
the farmer has to cover the full cost of treatment. Despite antitheilerial treatment, the
animal could also die leading to litigation and subsequent compensation.
Over the past few years a lot of human and financial resources have been invested in
developing an ECF vaccine. The main objective of the research and field trials in Kenya has
been to produce a vaccine that is affordable, safe, effective, easily manageable and acceptable
to the user. The other important aim is to produce an acceptable integrated T &TBD
control package for the farmer.
Cost reduction
• Research has confirmed that oxytetracycline preparations much cheaper than those
used previously, are equally effective. This is important in animal health since
oxytetracyclines are used to treat other livestock diseases.
• Follow-up monitoring has been reduced from daily to once every three days.
• Calves can be successfully immunised from one month of age. Calves are easier to
handle and require less of the drug. They also run no risk of milk withdrawal or
abortions if they react.
• A T. parva isolate of low pathogenicity has been identified which provides a broad
spectrum of protection. Due to its low pathogenicity, if it were used for immunisation
the administration of an oxytetracycline would be unnecessary and the risk of reactors
low making follow-up monitoring redundant. The isolate is also known to produces low
schizont parasitosis with no clinical reaction.
Making the procedure more manageable
Stabilates are stored in 0.5 ml straws, which are much easier to handle than the 2.8 ml vials
previously used. It has also been shown that the stabilate is infective after 24 hours and
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protective after 4 hours when kept on ice. The field staff can reconstitute the stabilate and use
it for the next four hours instead of just one hour. This has eliminated the need to carry ice
buckets and liquid nitrogen containers to the field, both of which are not readily available.
Making the procedure safer
The stabilate undergoes quality control in the laboratory to avoid transmission of other
diseases. Quality control includes titration studies to determine a safe but protective level of
dose. During the field trials, it has been shown that immunisation with the current parasite
does not precipitate clinical cases of other TBDs, a fear expressed because ECF is immuno-
suppressive. Since 1987, when the field trials started, 5729 cattle have been immunised in
various parts of the country (Coast, Rift Valley, Central and Western provinces) and none
have contracted extraneous diseases associated with the stabilate prepared at the National
Veterinary Research Centre (NVRC), Muguga.
Staff training
An ECF immunisation-training manual has been prepared and an elaborate training is
given to the immunising personnel together with information on how to handle the risks
involved. As a precaution, the long-acting oxytetracycline is administered before the
stabilate in case cattle escape during the immunisation.
Stabilate production
Currently, a large volume of the immunising stabilate (T. parva Marikebuni), enough to
immunise 120,000 cattle, has been produced, titrated and tested. This stock has been
supplied to a group of recently-trained veterinarians for immunisation in smallholder dairy
farms in Coast Province.
Country perspectives
The system has proved effective at the Coast with farmers willing to pay for immunisation.
Demand for immunisation at the Coast is quite high. Farmers have asked for the
immunisation through their veterinarians who have been trained by staff at Muguga and
have immunised around 600 animals with minimum logistical support from the laboratory.
The farmers have accepted the technology more readily than the professionals (field
veterinarians). Smallholder dairy farmers in Kiambu District (Central Province) are also
quite willing to have their animals immunised.
During 1994 and 1995, a number of field staff were trained and approximately 2250
cattle were immunised in various ecological zones for T. parva (Marikebuni). Sixty-five calves
aged between one and seven months were also successfully immunised at the Coast.
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To prove that the procedure is cost-effective, a model has been developed to compare
the financial implications of immunisation of calves, immunisation of whole herds,
treatment of clinical cases without immunisation and a no immunisation option. These
factors are considered before immunisation is undertaken.
Experience during the past few years has shown that, for the ECF immunisation
programme to succeed, it should have an economic consideration. Two criteria seem to be
necessary for immunisation to succeed. These are ECF should be a major production
constraint to the farmer and that there are veterinarians in private practice or government
employment who are willing to be trained to deliver the ECF immunisation.
For ECF immunisation by the infection and treatment method to be a sustainable
technology, the beneficiaries (the small dairy cattle owner and others) have to be willing to
take the risk of possible reactors as the present vaccine stabilate is potentially pathogenic.
The veterinarians need to have the ability to immunise with confidence.
Country needs and policy
The current government policy promotes a shift from subsidised services to increased cost-
sharing and, eventually, to full-cost recovery and privatisation of some aspects of veterinary
services including management of dips. Although ECF is a notifiable disease, immunisation
against the disease is not amenable to mass campaigns such as those conducted for
rinderpest or Foot-and-Mouth diseases. The disease affects individual animals and
vaccination will depend on the willingness of the farmer to pay for it. With the escalating
costs of acaricides and the environmental issues related to their use, immunisation offers an
alternative method of controlling the disease. Although ECF is the major constraint to the
dairy industry, the policy views immunisation against the diseaseas a private good putting
minimal pressure on the farmer to immunise his or her cattle. The policy however, gives the
Director of Veterinary Services the overall responsibility of guiding where immunisation is
to be carried out. The Director is also responsible for monitoring the immunisation services
both by private veterinary practitioners or those in the civil service in their private capacity
and ensuring that the delivery process is carried out in accordance with regulations
governing disease control in the country.
The stabilate currently being used in field trials was produced at NVRC, Muguga, and it
is expected that this laboratory will continue with that role for the country.
With the above in mind, immunisation against ECF in Kenya could be guided by the
following principles:
1. To immunise cattle through private approaches in areas where field trials have shown
that the current stabilate is efficacious and farmers are willing to have their cattle
immunised.
2. To continue producing the stabilate at the laboratory in Muguga and conduct research
to improve the vaccine. Such research should include the assessment of other T. parva
stabilates that do not require the use of tetracycline. The capacity of the national
laboratory to produce stabilate and conduct research and development must therefore,
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continue to be strengthened to ensure appropriate, effective and efficient technical
support to the immunisation programme.
3. To continue to train veterinarians in the private sector and in the government service
and strengthen the infrastructure to ensure that immunisation is carried out with
confidence. This includes production and dissemination of information about ECF
immunisation and control of other TBDs to veterinary professionals, the extension
services and farmers. The field veterinary staff should likewise have adequate facilities to
make accurate parasitological diagnoses.
4. To continue research to understand the epidemiological implications of ECF
immunisation so that farmers can be given information that allows them to use less
acaricide to control ticks and other TBDs that may be present.
Proposals for Kenya
• The full benefits of ECF immunisation will only be realised if it is accompanied by
reduced acaricide application to control ticks through strategic tick control methods.
For immunisation to succeed the area selected should therefore have very good tick
control with functional dips using effective acaricides at the correct strength. In some
parts of the country, since R. appendiculatus co-exists with the vectors of other TBDs,
there is a need to establish the incidence and severity of other TBDs, their distribution
and seasonality and also the tick species involved. The Project should therefore support
tick control by providing seed acaricide and funds to generate the above information to
help advise on strategic tick control,
• The Project should strengthen and support research on improving the vaccine at
NVRC, Muguga,
• The Project should support vaccine delivery in selected parts of the country.
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ECF immunisation in Malawi
C. Chizonda
Animal Health and Industry, P.O. Box 2096,
Lilongwe, Malawi
Introduction
East Coast fever (ECF) is endemic in the central and northern regions of Malawi, while the
southern region is free of the disease although the vector is present. Higher mortality is
observed in calves than in adult animals.
In the past, Malawi controlled ECF by dipping animals every week, at times twice a
week, in an attempt to control the vector. Due to economic constraints however, the
Veterinary Department was forced to review its dipping policy in 1993 and a tick ecology
survey was undertaken. Using the results of the survey, the department recommended
dipping animals fortnightly between November and April. However, in areas where
nymphal transmission occurs after April, due to a prolonged wet season in some parts of
northern Malawi, it has been recommended that dipping should continue beyond
April.
In recent years, irrespective of this change in the policy, animals have not been
dipped as recommended because of lack of funds to buy the required acaricides. Instead,
some individual livestock farmers have resorted to applying their own tick control
methods using pour-on preparations or dip wash. Farmers with valuable animals,
however, have combined vaccination with tick control using pour-on preparations to
control ECF.
Currently, there is an urgent need to study the impact of the past few years of
intermittent dipping on the health and productivity of the livestock population and
particularly those indigenous cattle which predominate in rural areas.
Following an Organization of African Unity/Scientific, Technical and Research
Commission (OAU/STRC) resolution in Algiers (October 1976) to establish regional
centres for the control of tick-borne diseases (TBDs), a TBD control centre was set up at the
Central Veterinary Laboratory in Lilongwe, Malawi, for countries in eastern, central and
southern Africa.
Subsequently, Malawi requested assistance from various donors to support the
initiative. A series of projects with an overall objective of creating a self-supporting
centre for the control of ticks and TBDs has since been implemented by the Food and
Agriculture Organization of the United Nations (FAO) between 1979 and 1993. The
initiative culminated in the establishment of the vaccine production centre (VPC). The
VPC was formally opened in April 1994 after vaccine production laboratories were
built.
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Current status of the VPC
Shortly after its inauguration the VPC encountered several problems, including the loss of 4
of its 5 external technical assistance staff and nearly half of its national technical support
staff later in the year. Vaccine production was then indefinitely suspended due to concerns
that products from the centre might not be of satisfactory standard, despite indications that
farmers and veterinarians in the field were happy with the vaccine. To bring activities of the
VPC to a pre-closure level will require firm commitment from personnel and continued
funding of the various operations. Revitalising the VPC seems to be the desire of the
recipient countries which hope that this can now be initiated for the greater benefit of the
region.
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ECF immunisation in Rwanda
S. Mbarubuyeke
National Veterinary Laboratory, P.O. Box 804, Kigali, Rwanda
Introduction
Tick-borne diseases (TBDs), especially East Coast fever (ECF), are a major constraint to the
development of improved livestock systems in parts of Rwanda. They are estimated to
account for 30% of young and 9% of adult mortality in improved dairy breeds. Before the
Rwandan civil war of 1994, ECF posed a major obstacle to the implementation of livestock
projects using crossbred or pure-bred cattle other than local Ankole. As a result of the civil
war, the Rwandan veterinary service has lost many of its facilities and personnel. However,
various efforts are well under way on the part of the government and private farmers to
initiate new and rehabilitate existing livestock improvement projects. These projects are
based on the premise that ECF is a major obstacle to the development of the livestock
industry in Rwanda.
This report describes the nature of the cattle population of Rwanda and highlights the
different measures currently applied to control ECF. The author also presents the salient
features of the national project for integrated tick and tick-borne disease control (ITTBD
project) for Rwanda, the result of an agreement between the Government of Rwanda and
the Food and Agricultural Organization of the United Nations (FAO) which is being
considered for funding.
Cattle population of Rwanda
The number of cattle in Rwanda, including improved milking cattle, was drastically reduced
during the 1994 civil war. From 1994 onwards, milking breeds (Friesian, Brown Swiss) have
been imported and large Ankole herds have entered Rwanda from neighbouring countries.
The total cattle population is estimated to number approximately 600,000 head of
which 5% are presumed to be improved dairy breeds. Thus, an estimated 30,000 animals
could be potential targets for ECF immunisation.
Disease diagnosis and control
The disease diagnosis and control potential of the Rwandan veterinary service has also
fallen victim of the civil war. The National Veterinary Laboratory of Rubilizi has been
rehabilitated and has now begun to carry out disease diagnosis, which for ECF involves
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Giemsa staining and serology. Apart from ECF, other important diseases include
contagious bovine pleuro-pneumonia (CBPP) and helminthiasis. To tackle these, the
veterinary services are being improved. However, some important sections of the laboratory,
including the bacteriology department are not yet operational.
Acaricides are still being used to prevent ECF and other TBDs. When disease occurs,
ECF is treated using buparvaquone. However, this has proved very expensive with a 40 ml
bottle costing 18,000 Rwandan francs (US$ 60).
Widespread vaccination is implemented for the control of CBPP and deworming
programmes to control helminthiasis are undertaken on a massive scale twice a year.
Although, there is a net improvement in livestock activities, much remains to be done in
terms of providing veterinary services in remote areas that often depend on help from non-
governmental organisations (NGOs).
The ITTBD Project for Rwanda
Following the Lilongwe meeting of June 1995, Rwanda has made a formal request for
assistance through FAO representation to mobilise existing funds (US$ 12,754) allocated to
the Rwanda national project, which failed to start in 1994. Rwanda is reliant on the release
of these project funds for the effective control of ECF and to implement a vaccine
programme. With the collaboration of the Ugandan ITTBD project, the Rwanda project
description has been revised and adapted to reflect the present situation. The Ministry of
Agriculture and Livestock has submitted a funding request to FAO.
The main activities to be implemented by the project are:
• To test the efficiency of the Muguga cocktail on cattle reared in Rwandan conditions.
Selected local T. parva strains, which were to be used to immunise the animals, were
unfortunately lost during the war due to lack of liquid nitrogen. Male calves will be
imported from Uganda and raised in Rwanda to test the Muguga cocktail. Most, if not
all, the pure- and crossbred milking cattle have been imported from Uganda, and there
would not be enough calves available in Rwanda for use as experimental animals.
• To train veterinarians and animal health technicians in the correct methods for ECF
immunisation so that the necessary personnel is avialable to do the immunisation once
the project starts in Rwanda.
The project is scheduled to last 9 months with a possible extension phase, if the outcome
of the immunisation trials is satisfactory and the Muguga cocktail causes no harm to cattle in
Rwanda.
Conclusion
After the war of 1994, some encouraging results have been registered in the effort to
rehabilitate the livestock system though much remains to be done. Any successful use of
improved dairy cattle in Rwanda presupposes an effective ECF and other TBDs control
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programme. This will involve acaricide use coupled with immunisation. A request for rapid
funding of a national project for tick and tick-borne disease control, which was originally
due to start in 1994, has been submitted to FAO.
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ECF immunisation in Tanzania
J. Melewas,1 M. Majaliwa1 and L. Lynen2
1 Livestock Development, P.O. Box 9152, Dar es Salaam, Tanzania
2 Veterinary Investigation Centre, P.O. Box 1068, Arusha, Tanzania
Background
Tanzania covers an area of 945,027 km2 with an estimated 26 million people. According to
the National Sample Census of Livestock by the Ministry of Agriculture in 1994/95,
Tanzania has more than 15.6 million cattle, 98% of which are found in the traditional
sector. Cattle dominate the livestock industry of Tanzania. Despite the large population and
vast rangeland resources, their contribution to both agriculture and national gross domestic
product is relatively low. The major constraints to the development of the livestock industry
in Tanzania include poor nutrition and husbandry, genetic limitations, an unco-ordinated
marketing system and disease.
Vector-borne diseases, grouped into tick and tick-borne diseases (TBDs), constitute a
major obstacle to the industry. East Coast fever (ECF) is the major cause of cattle deaths
and losses in livestock production, followed by tsetse and trypanosomosis. Animal disease
control in Tanzania has been prioritised according to these observations. The main form
of control of ECF has been the use of acaricides, either by dipping or spraying. The
Germans built the first dip in 1905 at Mwapwa and a country-wide network of facilities
has since been constructed totalling 2100 plunge dips. However, most proved inefficient
and suffered a number of other problems including poor dip management, high acaricide
costs, unreliable dip wash testing, and the emergence of acaricide resistant tick strains;
these dips are not currently operational. While hand spraying or pour-on acaricides are
commonly used in the smallholder dairy sector, their application is irregular and not
entirely efficient.
A joint Food and Agriculture Organization of the United Nations (FAO)-United
Nations Development Programme (UNDP) programme for East Africa for the control of
ticks and TBDs was initiated in 1967 (UNDP Project RAF/67/007). The Tanzanian
component was project URT/72/009. In its final phase, this project conducted an
important trial on the use of the Muguga cocktail in experimental cattle held at Pugu
holding ground outside Dar es Salaam. One of the recommendations in the final report of
this project was the routine use of this method of immunisation against ECF on a large-
scale to protect valuable animals at risk, combined with additional immunisations against
other TBDs where deemed necessary (Uilenberg 1977).
With the collapse of the East African Community in 1977, United Nations funding
ceased. FAO, which had been the executing agency for the UNDP-financed projects in
Kenya, Uganda and the United Republic of Tanzania, obtained support from the Danish
16 FAO/OAU–IBAR/ILRI Workshop
International Development Agency (DANIDA) in 1980 for a series of projects in Malawi,
Zambia, Zimbabwe and Kenya.
Tanzania was left out of the project until 1990 when DANIDA reintroduced the
programme (document GCP/URT/098/DEN). The Tanzanian government in November
1990 approved a revision of this project document. The programme was extended up to
October 1993, and a follow-up project (document GCP/RAF/299/NET) covered activities
to the end of February 1997.
Objectives of the project
The overall objective of the Regional Programme for East Africa was: The development of a
cost-effective strategy for the control of ticks and tick-borne diseases in the region.
Phase I of the programme saw the development phase of the immunisation method,
while Phase II involved the field application and expansion to other countries in the region.
Together the two phases led to the establishment of a central tick-borne disease vaccine
production unit (VPU). The overall objective of Phase III was to ensure the availability of
appropriate methods, including vaccination throughout the region by manufacturing
sufficient quality vaccine and testing the delivery systems at an economically sustainable
cost.
The immediate objectives of the Tanzanian national component were to evolve an
effective, sustainable and environmentally friendly integrated tick and tick-borne disease
control programme by:
• introducing a sustainable delivery system for immunisation against TBD in Tanzania,
eventually to be used with reduced acaricide application
• establishing a system for monitoring the effectiveness and socio-economic impact of the
immunisation programme
• training national staff with the aim of handing over the above activities.
The long-term objective of this project was to improve the general standard of living
through the improved health and productivity of cattle in the country.
Immunisation activities
Tanzania mainland
From 1990 to February 1997, animals were immunised using different batches of the
trivalent vaccine (Muguga cocktail) supplied by the VPU. A total of 14,628 dairy animals
and their crosses (4.5% of the improved high-grade cattle) were immunised and
monitored by project staff for 30 days after immunisation. Of a total of 576 animals, 3.9%
were reactors to immunisation and 0.27% of these died during the monitoring period,
while 4 animals (0.03%) died of anaphylactic shock immediately after immunisation
(Table 1).
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Table 1. Summary of number of animals immunised and results of monitoring by region.
Region
No.
immunised
ECF reactor Anaphylaxis ECF deaths
No. % No. % No. %
Iringa 6993 209 2.9 3 0.04 26 0.37
Mbeya 364 0 0 0 0 0 0
Morogoro 348 23 6.6 0 0 3 0.86
Dar and Coast 1379 18 1.3 6 0.45 4 0.29
Tanga 295 7 2.4 1 0.34 3 1.02
Kilimanjaro 529 129* 24.4 0 0 5 0.95
Arusha 1186 89 7.5 50 4.22 4 0.34
Mwanza 2737 98 36 1 0.04 8 0.29
Kagera 797 3 0.4 0 0 1 0.13
Total 14628 576 3.9 61 0.42 54 0.37
*Includes 44 calves which reacted during the October 1996 immunisation; calves were dewormed
one week post-immunisation and developed diarrhoea during the monitoring period.
The number of reactors occurring appears to be seasonal only in Morogoro and Iringa
regions. This could be linked to concurrent ECF field challenge and the tick-control
method of the livestock owner, since tick control is neglected during the months July to
September when adult ticks are virtually absent, leaving the cattle exposed to nymphal
challenge.
In all regions, the most obvious reason for a high or low number of reactors is directly
linked to the experience of the delivery veterinarian. Areas with long-standing activities
report low numbers of immunisation reactors, while individuals undertaking the delivery
for the first time tend to begin with 815% reactors and decrease to 3% or less after a 68
month period.
An unexpectedly high number of anaphylactic shock cases were recorded in Karatu and
Mbulu Districts (Arusha region) between September and November 1996. The animals
were treated with adrenaline (1/1000 at 0.1 ml/kg IV) and recovered. It is presumed that
the tick antigen in the stabilate causes anaphylactic reactions. This high number could thus
be linked to severe exposure to Rhipicephalus appendiculatus during the previous rainy season
when up to 30% losses due to TBDs, particularly ECF, were recorded in the dairy
population of these districts.
Tanga coastal region
Tanga region supports over 600,000 cattle, most of them indigenous Tanzanian zebu, under
traditional management. Approximately 12,000 grade dairy cattle are present, under zero-
or semi-zero grazing management. ECF is the most important cause of adult and calf
mortality in highgrade dairy cattle in the region. Existing tick control practices are expensive
and not 100% effective. The Tanga Smallholder Dairy Development Project was willing to
18 FAO/OAU–IBAR/ILRI Workshop
ECF immunisation in Tanzania
adopt ECF immunisation using the trivalent vaccine provided protection against the
prevalent field strains could be demonstrated.
To formulate an integrated ECF control strategy for Tanga region, a series of activities
were undertaken:
• assessment of the efficacy of the trivalent vaccine
• sero-survey to determine the target groups for immunisation and the potential risk of
other TBDs
• monitoring of previously immunised animals•
• assessment of the interest of farmers in adopting new control strategies.
Immunisation trials
Three trials were conducted between January 1995 and November 1996 to determine the
efficacy of the trivalent vaccine. Results of the first trial initiated by the Tanga Dairy Project
were inconclusive and no serology result reports were available pre- and post-immunisation.
In the second trial (October 1995April 1996) only a few deaths due to ECF occurred in
each group: 3 out of 20 immunised animals and 2 out of 12 control animals. Six clinical
cases of heartwater (HW), three of which died, complicated the clinical presentations in a
number of animals. Serology pre- and post-exposure showed 100% sero-conversion to
Cowdria ruminantium. The results of this trial were inconclusive. A third trial in July 1996,
synchronised the period of field exposure with the season of high ECF challenge
(AugustSeptember). Acaricide application (tick grease) at the predilection sites of
Amblyomma spp was used in an attempt to avoid complications with HW during exposure.
The average number of R. appendiculatus during field exposure ranged between 150 and 280
ticks per animal (Table 2).
Table 2. ECF immunisation and field exposure trial 3: July 1996November 1996.
Total
no. NR/MR SR/FR
Overall
mortality
Cause of death
ECF ECF/HW HW Other
Immunised 15 8 7 8 3 1 1 3
Controls 14 7 7 13 7 0 1 5
Significance Fisher Exact p=0.57 p=0.02 p=0.10.
NR = non-reactor; SR = severe reactor; MR = moderate reactor; FR = fatal reactor.
A significant difference [p=0.02] was found in the overall survival rate between the
immunised and the control animals. However, the number of deaths due to ECF, although
higher in the control group, is not significantly different [p=0.10] from the number
recorded in the immunised group. Given these results, it appears that in Tanga, the trivalent
vaccine elicits partial protection of between 25% and 75%.
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Isolation of local T. parva strain
An attempt to isolate a local strain during the first trial in Tanga failed (Musisi 1995).
During the second trial, another attempt was made by applying clean laboratory-reared R.
appendiculatus nymphs to three clinically sick control calves. Tick engorgement, harvesting
and subsequent moulting was successful and the resultant adult ticks were sent to the
International Livestock Research Institute (ILRI) for stabilate production and further
characterisation. Although the parasitaemia in the calves at the time of nymphal feeding was
relatively low (46%), a high tick infection rate was observed. Stabilate production (stabilate
4134) was successful and characterisation is under way. In view of the unsatisfactory results
of the Tanga immunisation trials using the trivalent vaccine, this local isolate may have
potential for use in Tanga region and merits further investigation.
Cost recovery for delivery activities
Cost-recovery was initiated in 1992 after encouraging results were achieved with
immunisation activities in southern highlands during Phase II (Project GCP/URT/
098/DEN). The vaccine package was handed over to delivery veterinarians at a price of
Tanzanian shilling (Tsh) 1000 (US$ 3.1) per dose, which was later raised to Tsh 1500 (US$
4.1) in 1993. At the National Steering Committee Meeting, held in Morogoro in February
1996, a proposal to once again review the price of the vaccine package and move gradually
forward to full cost-recovery was accepted and permission was given to open additional ECF
accounts in the regions to facilitate collection of revenue. The package price has gradually
increased and now stands at Tsh 4000 (US$ 7) per adult animal and Tsh 3000 (US$ 5) per
calf. A final price increase is expected in March 1997, to reach full cost-recovery of the
vaccine package. Veterinarians have been allowed to fix their own farm-delivery price, which
ranges between Tsh 5500 and 10,000 (US$ 917). No major problems have been
experienced in introducing this level of pricing in the areas where activities have begun
recently. Cost-recovery was more readily accepted in areas where ECF causes high losses in
the dairy population. Most outstanding debts are related to Government Livestock
Multiplication Units (LMU), which did not budget in anticipation of immunisation
activities and have subsequently experienced difficulties in releasing payment for
immunisations carried out on their farms.
ECF immunisation follow-up activities
Serology
Serology data have been compiled from serum samples collected from smallholder farming
systems, commercial farms and traditional indigenous herds. Sera were tested by the
indirect fluorescent antibody test (IFAT) using T. parva schizont antigen, and, when
possible, also by the enzyme-linked immunosorbent assay (ELISA) test at ILRI. The majority
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(83%) of serum samples were collected from adult animals. Routine pre- and post-
immunisation serum sampling was undertaken in most regions. Pre-immunisation sero-
prevalence for Theileria parva ranged from 0% to 40%. Seroconversion 30 days after
immunisation ranged between 57% and 100%. Pre-immunisation serum samples from
commercial farms were tested for antibodies to the major TBDs (ECF, anaplasmosis,
babesiosis) to formulate a rational tick control strategy after immunisation. Results clearly
indicated that endemic stability existed for anaplasmosis on most of the farms, with
seroprevalence ranging between 21% and 77%, while for babesiosis an endemically
unstable situation was found with seroprevalence ranging between 0% and 36%. Detection
of animals seropositive to Babesia bovis using the IFA test in the northern and lake zone
regions was surprising as its vector, Boophilus microplus, has only been identified in the
southern highlands and parts of Dar es Salaam and Tanga coastal area (Yeoman and Walker
1967). Confirmation of clinical disease due to Babesia bovis was made in Arusha (Imani
Estate) and Mwanza (Mabuki farm) and further investigations are warranted to establish the
new geographical range of this disease and its vector.
Adjustment of tick control
The high cost of acaricides has been the most important reason for commercial farmers to
take on ECF immunisation. Therefore, a revised tick control practice had to be formulated
to allow for a reduction in acaricide costs and to increase the chances of boosting immunity
naturally in immunised animals. Half-body tick collections are carried out in all the regions
to investigate tick loads and tick dynamics during the year. Depending on the TBD serology
profile of the farm, the acaricide formulation in use and the tick dynamics (based on tick
collection records), a 2550% reduction in acaricide use was recommended as being safe,
while a further reduction (threshold applications) was recommended if no problems were
experienced during the period of high tick challenge (rainy season). Most farmers have
reduced acaricide applications by up to 50%, while others have gone from dipping twice a
week with organophosphate formulations (OPD) to once a month dipping without
reporting any problems.
Epidemiology studies
Serological survey in Tanga coastal region
A serosurvey was carried out in Tanga coastal region in April 1996 with the objectives of
selecting target populations for ECF immunisation, assessing levels of exposure of animals
under different management systems and investigating the possibility of lack of natural
challenge after immunisation in zero-grazing animals. Fifty-three farms were visited and
serum samples from approximately 350 animals have been tested to assess seroprevalence
rates of TBDs under different management systems. Results so far indicate a situation of
endemic stability for anaplasmosis in every farming system and, in most farms, an unstable
situation for Babesia bovis and T. mutans. Endemic stability for ECF was recorded in the
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indigenous population and most of the smallholder farms practising free grazing, while an
unstable situation was found on the majority of zero-grazing farms. All samples were tested
by IFAT against T. parva, T. mutans and Babesia bovis, while only a proportion was tested
against Anaplasma (Table 3).
Table 3. Breakdown of seroprevalence to Theileria parva (T.p.), T. mutans (T.m.), Babesia bovis (B.b.)
and anaplasmosis (An) by farming system.
Positive
(% )
Zero-grazed farms (no.) Semi-zero-grazed farms (no.) Traditional herds (no.)
T.p. T.m. B.b. An T.p. T.m. B.b. An T.p. T.m. B.b. An
010 19 26 27 0 1 2 3 0 0 0 1 0
1170 16 13 11 5 4 5 5 1 1 3 2 0
71100 6 2 3 1 4 2 1 7 2 0 0 2
Total 41 41 41 6 9 9 9 8 3 3 3 2
Low seroprevalence for Babesia bovis was unexpected, as Boophilus microplus has been
identified in this region. Tick control may have disrupted endemic stability for Babesia bovis,
although very few clinical cases are reported. This could indicate effective tick control where
Babesia bovis infection rates are reduced to very low level, with minimum losses being
recorded.
Heartwater serology
As limited information was available to assess the presence and risk of heartwater in
Tanzania, serology was attempted with assistance from the United States Agency for
International Development (USAID) heartwater project in Harare, Zimbabwe. A
representative sample of sera from different regions was sent to Harare, together with
collections of live Amblyomma spp from Tanga and Arusha regions to try and isolate Cowdria
ruminantium. All serum samples were tested in the MAP-1B ELISA which is more specific
than Western blotting, although cross-reactions with Ehrlichia canis still occur. The results
implied that endemic stability exists in most of the regions where Amblyomma species are
present and that on most of the farms, calfhood exposure is ensured.
For most regions where Amblyomma spp are present, relatively low seroprevalence was
recorded. However, it has been observed that heartwater seroprevalence in endemic areas may
be low using the MAP -1B ELISA test (Dr S. Mahan, personal communication) and this is
thought to occur because animals down-regulate their antibody response after repeated
challenge with Cowdria ruminantium. Further investigation is required, especially following
conclusions by the Tanga study that heartwater can be a serious threat to improved livestock.
Recommendations
Control of ticks and TBDs can no longer be achieved by relying on acaricide application
alone. An integrated approach combining tick resistant cattle, creation of enzootic stability,
immunisation, chemotherapy and strategic acaricide use is recommended.
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Immunisation
Immunisation of high-grade and crossbred cattle against ECF by the infection and
treatment method has been carried out successfully. The results of immunisation and
follow-up activities and data analysis have resulted in the following recommendations:
Smallholder dairy farming systems
In ECF endemic areas, immunisations should be carried out to protect all susceptible
animals. Adjustment of tick control is not advocated as it is already done erratically and
inefficiently. Anaplasma vaccination is not recommended but Babesia bovis and
heartwater immunisation may be considered in the future depending on the results of
further work.
Commercial dairy and beef farms
ECF immunisation of adults and calves is recommended together with reduced acaricide
use. A 50% reduction can be justified as safe and further reduction will depend on the
results of TBD studies at farm-level. Anaplasma vaccination is not recommended. Exposure
of calves to ticks and TBDs should be maximised to increase endemic stability for heartwater
and babesiosis.
Traditional herds
It would be unwise to embark on ECF immunisation in traditional herds if offtake is not
guaranteed. Cross-boundary movement of traditional herds also makes it almost impossible
to organise the logistics for an initiative at national level. ECF immunisation of calves in the
traditional sector will only be initiated if progress has been achieved in the livestock
marketing sector and regional activities have begun in the traditional sector.
Tick control
The vast number of different acaricides currently on the market will make it difficult to
provide national guidelines for adjusted tick control. New legislation to control acaricide
importation and stricter supervision of its use is needed. Routine tests on the strength of
acaricides in use should be carried out and pharmaceutical companies should be obliged to
provide the recommended test kits.
Training
Delivery veterinarians and paraveterinarians should be trained on an individual basis.
Institutional capacity should be built up by developing local expertise, further training of
national experts and supporting diagnostic and training facilities.
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Co-ordination
Those involved in tick and TBD control need contact and co-operation with relevant
institutions and projects both within Tanzania and elsewhere. Co-ordination of
investigative activities should be strengthened between existing projects at Sokoine
University of Agriculture (SUA) and the Animal Disease Research Institute (ADRI) in Dar
es Salaam as well as with international groups, such as ILRI and the USAID HW project.
Extension of project activities as well as data collection should capitalise on existing
extension networks, especially, those of dairy projects. Open dialogue is recommended
between existing projects working on tick and TBD control and any prospective donor-
funded livestock project. It may thus be necessary to establish a tick and TBD unit to co-
ordinate and act as counterpart agency to all related projects. Activities on Zanzibar and
Pemba should be incorporated into the mainland programme or free exchange of
information and better collaboration should be guaranteed.
Delivery and cost recovery
Adequately trained personnel should perform vaccine delivery at full cost-recovery.
Administrative arrangements for the management of revenue from cost-recovery should be
strengthened, preferably by establishing a decentralised livestock-development fund.
Immediate research needs
More research is required in some areas to support ongoing immunisation activities:
• defining the distribution of Babesia bovis and its vector, Boophilus microplus
• conducting heartwater studies, which will require expert laboratory assistance
• if immunisation failures are recorded, a local vaccine strain may be needed;
investigations should clarify the potential of the local isolate for use alone in its area of
origin or for incorporation into the trivalent vaccine
• economic impact assessment of the different control methods used should be an
integral part of any future project proposal, as results will be a valuable tool in
promotional and extension activities
• alternative effective and acceptable vaccines against ECF and other TBDs should be
developed with commercial and private sector participation in production, marketing
and distribution.
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Introduction
Land-locked Uganda covers a total of 241,000 km2 including 44,000 km2 of inland water.
The human population is approximately 20 million. Over the past few years, the country
registered a remarkable increase in gross domestic product (GDP) from 1% in 1986 to 8%
in 1996. Agriculture remains the mainstay of the economy where 88% of the population is
rural. Agriculture contributes 50% of the GDP and over 90% of the countrys export
earnings. An integral part of the agricultural sector, livestock accounts for 8% of the GDP.
The livestock population is estimated at 5.3 million cattle, 6.2 million goats, 1 million
sheep, 1.5 million pigs and 22 million poultry. Animal disease is the main constraint to
livestock production in the country. Ticks and tick-borne diseases (TBDs), in particular, are
major impediments to the introduction of improved livestock to farms and cause high
mortality in exotic cattle. Ticks infest all the 39 districts of Uganda, the most prevalent being
Rhipicephalus spp. It transmits East Coast fever (ECF) which constitutes approximately 67%
of the clinically reported TBD cases in the country. Boophilus ticks transmit both
anaplasmosis and babesiosis which together make up 21% of the clinically reported cases;
Amblyomma spp are vectors for heartwater which accounts for the remaining 12% of
reported TBD cases.
The control of ticks and TBDs in Uganda has depended heavily on the use of acaricides,
which have inherent problems of being expensive, creating tick resistance, polluting the
environment and leaving residues in food. Worse still, over 70% of the dips are in a state of
disrepair contributing to the failure of acaricides to control ticks.
ECF immunisation project
Immunisation against ECF using the infection and treatment method in Uganda was first
carried out in the early 1970s under the auspices of the East Africa Veterinary Research
Organisation, Muguga, Kenya. A study was carried out at the Animal Health Research
Centre, Entebbe, where zebu cattle were immunised using separate inoculations with three
isolates; Theileria parva Muguga, T. parva Entebbe l and T. parva Entebbe ll. In spite of a very
heavy ECF challenge and the concurrent incidence of other TBDs, the ECF vaccinates were
found to be significantly protected as compared to the controls.
Uganda later joined the Danish International Development Agency (DANIDA) / Food
and Agriculture Organization of the United Nations (FAO) Regional Programme for Ticks
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and TBDs during the second phase in 1990 along with Burundi, Tanzania, Malawi, and
Zambia with the objectives of evaluating the efficacy of the Muguga cocktail vaccine. The
long-term aim for the Ugandan project was to develop and evaluate cost-effective strategies
for the control of ticks and TBDs in Uganda. The specific objectives were to assess the
protection afforded by the Muguga cocktail against Ugandan field stocks, to isolate
breakthrough stocks and, if necessary, incorporate them into the vaccine cocktail and, to
identify future strategies required to achieve the long-term objectives for the control of ticks
and TBDs.
The primary objective of evaluating the Muguga cocktail vaccine for use in Uganda was
achieved by four immunisation trials in which protection was recorded in excess of 80% of
the vaccinated cattle. Consequently, it was recommended that Uganda incorporates ECF
vaccination as a major disease-control strategy, to be carried out in an integrated approach
towards the control of ticks and TBDs.
Present state of the ECF immunisation project
Following the recommendation to incorporate ECF vaccination as a major disease-control
strategy, the ECF immunisation programme was extended to private farms with effect from
August 1994. The programme was systematically conducted beginning with the training of
veterinary staff and private veterinary practitioners and the farmers before embarking on
vaccination and post-vaccination monitoring.
Training of staff, private veterinarians and farmers
A total of 118 staff and private veterinarians from 23 districts were trained in all aspects
TBD control including the ECF immunisation technique to equip them with the skills
necessary to handle the vaccine and carry out the post-immunisation monitoring. Twelve
sensitisation meetings were also conducted for a total of 454 farmers from 13 districts.
ECF immunisation activities
Twenty-five immunisation programmes were carried out in 12 districts covering 138 farms
during which 2005 animals were immunised. The results showed that 91% experienced
mild to moderate reactions while mortality was recorded in 0.16% of the animals. The
protection in vaccinated cattle was 86%.
Post-immunisation monitoring
Monitoring covers a period of 28 days after the vaccination and requires the participation of
both the farmer and a veterinarian. The farmer takes the temperature daily and records it on
charts. He/she is urged to report any abnormal behaviour to the veterinarian immediately.
The veterinarians make about six visits to ensure that the temperature is being taken
correctly, to reassure the farmer when the temperature starts rising, to take blood/lymph
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smears and to provide treatment as required. The project staff make 23 visits to reassure
and give advice to the veterinarian and the farmer. The laboratory staff examine slides and
carry out the indirect fluorescent antibody test to determine serological status pre- and post-
immunisation. Data analysis is carried out to determine the responses of the animals to
vaccination.
Introduction of cost-recovery
For the vaccination programme to be sustainable, it was recommended that cost-recovery be
introduced. Consequently, partial cost-recovery was introduced in two districts where
farmers initiated introduction of the vaccine after being impressed by the results. Such
farmers pay US$ 5 per animal to be vaccinated. This goes towards the cost of drugs,
transport and the staff welfare. Under this partial cost-recovery arrangement a total of 672
head of cattle have been vaccinated on 61 farms.
Tick control following immunisation
Modification of tick control method following introduction of TBD vaccination is an
important incentive for introducing ECF immunisation to the farmer since he/she
should be able to reduce his/her acaricide use and thus make a financial saving.
Consequently, on-farm investigations were initiated on four farms where vaccination had
been carried out and the farmers had been engaged in intensive tick control. The results
showed that the farmers could reduce the dipping interval from twice a week to once a
fortnight, depending on the type of acaricide used, farming system, environment and tick
population. From this exercise, a 5060% reduction in tick control using acaricide is
recommended.
Setting up the infrastructure for vaccine delivery
To manage and run a country-wide TBD vaccination programme effectively, it was
suggested that a co-ordinating unit be set up at Entebbe with an administrative office and a
highly secured store for keeping drugs, chemicals, and equipment. The project has the
support of the Technology Validation Committee on ECF immunisation that met twice
and made favourable recommendations on its performance. A building has already been
refurbished to serve both as an office and store for the project.
Future activities of the ECF immunisation programme
The ECF immunisation programme has stimulated much enthusiasm amongst the dairy
farmers and many agree the programme is operating satisfactorily. Therefore, there is
potential for expansion of the programme in the country.
The number of target cattle for ECF immunisation in Uganda is projected as follows:
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Improved dairy cattle
Present population 232,000
Primary emphasis on young stock: 218 months
(25% of total)
58,000
Secondary group: 50% of adult cattle 86,000
Replacement stock per year (20,000) over 5 years 100,000
Total dairy cattle to be immunised over 5 years 244,000
Improved beef cattle
Population of beef stock on ranches 200,000
Target calves 26 months 25,000
Replacement stock (20,000/year) for 5 years 100,000
Total beef cattle to be immunise over 5 years 125,000
The potential number of dairy and beef cattle to be immunised over a 5-year period is
369,000 head at an annual average of over 70,000 head.
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ECF immunisation in Zambia
M. Mangani
Department of Veterinary Services, P.O. Box 50060, Lusaka, Zambia
Tick and tick-borne disease (TBD) control in Zambia is mainly orientated towards the
prevention of East Coast fever (ECF). The activities are supported by the Belgian
government under a programme called Assistance to the Veterinary Services of Zambia
(ASVEZA). This programme operates in Eastern (ASVEZA east) and Southern (ASVEZA
south) Provinces. The information in this report is mainly obtained from the ASVEZA
annual report for 1996. The separation of activities into ASVEZA east and ASVEZA south
is due to differences in the epidemiology of the disease in the two Provinces; ECF is endemic
in Eastern Province and epidemic in Southern Province.
ASVEZA East
Control
Control of ECF using the infection and treatment method of immunisation (ITM) began in
the late 1980s. To date, approximately 120,000 calves have been immunised in this
Province. Immunisation is based on the use of a local T. parva Katete isolate as vaccine.
Immunisation was initiated in Chipata District and was then extended to neighbouring
Districts in Eastern Province (Table 1).
Table 1. Areas immunised in Eastern Province.
District Area
Chipata Whole district
Katete Southern part of Great East road (except Mtandaza)
veterinary camps of Vuramboko, Kwenje
Chadiza Whole district (except Sinalo crush pen)
Lundazi Whole district (except Chikomeni, Magodi and
Chama veterinary camps)
Petauke Sinda and Nyangwe veterinary camps
Until 1995, immunisation was performed free of charge to the farmer. However, since
1996 cost-recovery for immunisation has been introduced, initially at a nominal charge of
US$ 15, which represents about 20% of the actual current cost of immunisation in
Eastern Province. The amount charged will be steadily increased until the full cost of
immunisation is covered. Before cost recovery was implemented, an extensive
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information campaign was conducted in all districts to let the farmers appreciate the need
for immunisation and allow them to decide on the strategy they wished to use for ECF
control. Questionnaires collected from farmers during this information campaign
showed that they were convinced of the need to control ECF and that, usually, failure to
take up immunisation was due to lack of available money. Table 2 summarises the
immunisations performed.
Table 2. Summary of immunisations administered.
Campaign
No. calves
immunised
Overall
seroconversion
T. parva stabilate
used
Oct 1995Jan 1996
(free of charge)
12,611 76% V 13
JulyOct 1996
(with charge)
2,469 45% V 16
Delivery
Since mid-1994, the Department of Animal Production and Health (DAPH) has been
responsible for carrying out all immunisations. Under this arrangement, the District
Veterinary Officers (DVOs) are in charge of the field implementation of campaigns and
managing the funds, while the ASVEZA project provides logistical support and field
equipment. The farmers cover the full cost of any theilericidal treatments which may arise
and the money collected from the immunisations contributes to a revolving fund and is
used to purchase oxytetracycline locally.
Trials on the viability of sporozoites on ice
If it were possible to transport and maintain thawed vaccine stabilate on ice, the cost of
immunisation would be lower. Some trials were carried out in the laboratory to assess the
threshold point of viability of sporozoites on ice. A field trial was also carried out in which
100 calves were immunised with stabilate, which had been thawed and kept on ice, while
another 100 calves were immunised using the usual method. The experiment started in
December 1996 and initial results are quite encouraging. Details will be made available as
soon as a full evaluation has been completed.
ASVEZA South
In Southern Province, the government policy stipulates the use the local strains to control
ECF by immunisation.
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T. parva Mandali stock
The infectivity of the Mandali stock available has been found to be very low for both cattle
and ticks. Use of this stock has been discontinued pending further studies.
T. parva Chitongo stock
Chitongo was isolated in the mid-1980s from Chitongo village (Namwala District) and a
bulk stabilate has since been produced. Preliminary titration trials have shown that high
doses are required for immunisation, which indicates a low virulence. Chitongo may be
considered as a mild stock and, if used as a vaccine, may not require the use of long-acting
tetracycline. However, this mildness may be a disadvantage when producing stabilates for
mass immunisation.
Cross-immunity trials
T. parva Chitongo versus T. parva Katete and reciprocal: breakthrough of T. parva Katete in a
T. parva Chitongo immunised animal excluded the use of T. parva Katete in the Southern
Province.
T. parva Chitongo versus T. parva trivalent vaccine: two trials have so far been carried out
and a third experiment is under way to help refine the protection rate. Initial results are
encouraging since animals immunised with T. parva Chitongo do not react when
challenged with a lethal dose of T. parva trivalent vaccine. A field immunisation trial will
begin on completion of the current experiment.
ECF control
The only viable alternative to immunisation in Southern Province is chemotherapy. Vector
control in the traditional sector has been ineffective since acaricides and veterinary services
are no longer free of charge and farmers are not yet accustomed to paying for them. The
DAPH sells theilericidal drugs through ASVEZA on a full cost-recovery basis. The sales are
organised through a network in the districts of Mazabuka, Choma, Kalomo, Monze and
Gwembe. The system has improved the availability of theilericides in the Province allowing
the farmer to choose which control option to use. The impact of this system is currently
evaluated only through the amount of sales. The number of requests for treatment
increased during the peak of the ECF season (Table 3).
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Table 3. Sale of theilericidal drugs during the period November 1995 to
December 1996.
Period
Turnover
(ZK) Days
Turnover/day
(ZK)
Nov-1995 150,000 29 5,172
Dec 1995Feb 1996 930,700 91 10,227
March 1996 170,000 23 7,391
AprilMay 1996 776,200 55 14,113
JuneAugust 1996 4,157,300 88 51,635
SeptDec 1996 5,647,000 148 38,155
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Immunisation against theileriosis in
Zimbabwe
U. Ushewokunze-Obatolu
Veterinary Research Laboratory, P.O. Box CY551,
Causeway, Harare, Zimbabwe
Policy background
Agricultural framework
The agricultural sector is central to the economy, contributing on average, 23% of the
gross domestic product and occupying nearly 70% of the population. The current
agricultural policy, while supportive of the commercial sector, focuses on the
smallholder producer and aims to address issues of poverty, malnutrition and low
income by supporting agricultural production and the growth of a rural based agro-
industry. Cattle are central to this sector, which contains about 67% of the national
herd, and are dual purpose. They are also important for crop cultivation and
transportation.
Control of ticks and tick-borne diseases
The integrated approach to the control of ticks and tick-borne diseases (TBDs) has been
attractive to the Department of Veterinary Services for its biological advantages and its
economic benefits. It has thus been an area of research for much of the last decade with
financial assistance from Danish International Development Agency (DANIDA) and, in
more recent years, from the Belgian Government through the Food and Agriculture
Organization of the United Nations (FAO). This work resulted in the adoption of an
approach based on a locally produced live vaccine, BOLVAC, which has now been
registered for use without simultaneous tetracycline treatment.
The use of this vaccine must however, be complemented by concurrent coverage with
vaccines against anaplasmosis and babesiosis (Babesia bigemina), both of which are produced
by the departments laboratory. The use of a B. bovis vaccine, also produced by the
laboratory, is being considered in particular risk areas.
The second component of the integrated approach entails the continued reduction of
dipping. The dipping policy has shifted from an intensive system to a reduced regime that
encourages the establishment of enzootic stability while maintaining effective tick control,
and this has been promoted by changes in the regulations.
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The approach to immunisation centred around the use of vaccines in problem herds.
Veterinarians who have been trained over the last two years in various aspects of vaccine
delivery and monitoring for theileriosis identify these herds. The Directorate must also
agree for an identified herd to be immunised. Vaccination is then carried out in the dry
season primarily to avoid the risk of exacerbating field exposure in the wet tick-active season
and, secondly, to ascertain that immunity is due to the vaccine. Likewise, monitoring of the
immunised herds by both clinical and serological means is mandatory. This is greatly
assisted by the rapidly improving field disease monitoring system.
So far, 17,000 cattle have been immunised, 11,000 head on commercial properties and
6000 head in communal areas. Well over 13,000 cattle have been immunised over the last
two years without the use of tetracycline, a feature which supports the agricultural policy
through cost reduction. A charge of Zimbabwean Dollar (Z$) 5.00 per head is levied which
goes to a Departmental revolving fund.
The vaccine has been largely successful, with seroconversion in 93100% of immunised
animals. Its success is further confirmed by evidence of disease only in unvaccinated animals
in some immunised herds.
Pending issues
Research
• An effective, safe and economical heartwater vaccine is anxiously awaited, particularly
in view of changing heartwater epidemiology and the presence of the disease in areas
where only theileriosis occurred previously.
• knowledge is needed to help describe the exact regimes for farmers to follow for tick
control in various ecological zones.
• tests still need to be developed to help determine the impact of the vaccine and
differentiate it from related field parasites.
• More information is required on the carrier state resulting from the vaccine and its
implications for the epidemiology of theileriosis
• Studies should look into buffalo-derived theileriosis and its implications for the
integrated control of TBDs.
Capacity and sustainability
• The cattle population at risk in theileriosis endemic zones in the five provinces (see
map) is estimated to range between 15,000 and 20,000 head. There are questions about
the Departments ability to meet an increasing demand for vaccine as currently, the
basis for immunisation is highly selective and therefore coverage is low.
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• At present, the department enjoys a core of trained staff with the required skills to
produce the vaccines but a high staff turn-over rate may cause problems in staff capacity
in the future.
• Much remains to be done to help ensure the Departments capability to meet the
increasing demand. This needs to be supported by socio-economic and epidemiological
studies to determine the viability of the immunisation service while continually looking
into possibilities for alternative production arrangements.
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Figure 1. Theileriosis distribution in the five provinces  endemic zones  of Zimbabwe.
Tick-borne disease (TBD) immunisation in
Swaziland
R. Thwala
Veterinary Services, P.O. Box 162, Mbabane, Swaziland
Introduction
Swaziland has a dual livestock production system composed of the communal sector, which
is mostly on Swazi Nation Land (SNL) and a commercial sector, which is mostly on Title
Deed Land (TDL). Swaziland has a cattle population of 641,979 and a goat and sheep
population of 459,362 (Ministry of Agriculture and Co-operatives, 1995 livestock census).
Around 77% of the cattle are produced in the communal sector and about 21% in the
commercial sector. The dairy herd of 8184 animals is mostly composed of Friesian/
Holstein and Jersey breeds and approximately equal numbers of dairy animals are found in
the communal and commercial sectors.
Background
Recent studies by the Ministry of Agriculture and Co-operatives and the Food and
Agriculture Organization of the United Nations (FAO) staff in 1995/96 have revealed that
the significant tick-borne diseases (TBDs) in Swaziland, in order of importance, are
babesiosis (Asiatic redwater), caused by Babesia bovis, heartwater caused by Cowdria
ruminantium, and anaplasmosis caused by Anaplasma marginale. Since the introduction of
Babesia bovis into Swaziland in the late 1970s, there have been epidemics of the disease on
both SNL and TDL sector farms. Most cattle on SNL are indigenous Nguni crossed with
Brahman, Simmental, Friesian or Jersey breeds. In these cattle, indications are that
outbreaks are usually severe at first introduction of the disease after which only a small
proportion of the population is affected, according to tick population dynamics. In the TDL
sector, where dipping is more stringent and effective, the immunity of the herds to all four
TBDs is low and outbreaks, although not common, can be very severe. From serological
survey results and disease outbreak reports, heartwater and babesiosis due to Babesia
bigemina (African redwater) seem to be more prevalent in the communal sector, although
deaths from these diseases are negligible compared to those from Asiatic redwater and, to a
lesser extent, anaplasmosis.
Goats in both SNL and TDL farms are highly susceptible to heartwater and morbidity
and mortality rates may be high, especially in exotic breeds.
Disease diagnosis at the Central Veterinary Laboratory indicates that TBDs constitute
between 20% and 40% of the total number of cases of disease diagnosed in cattle. Although
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this may be a biased conclusion, diagnoses made in the field give a similar picture. The
economic losses incurred through death, loss of production and drug costs, as a result of
TBDs have yet to be assessed.
Tick-borne disease immunisation
Field trials using TBD vaccines in Swaziland were started in 1990 by Dr Gavin Ramsay who
used Australian Babesia bovis, Babesia bigemina and Anaplasma centrale vaccines on over 200
cattle of various ages on one of the government cattle breeding stations (GBS) in the
highveld. The objective was to test a TBD control strategy for Swaziland based on the lessons
learned from the vaccination and strategic dipping. The results were promising with 100%
seroconversion to all three parasites after immunisation and no clinical losses. However, the
trial was discontinued due to lack of funding.
In 1995, the government of Swaziland, with the assistance of FAO, initiated the
immunisation of cattle against TBDs. The main objective was to assist the Department of
Veterinary Services in the development of an integrated tick and TBD control strategy that
could be tested and adapted nationally. Such a strategy would need to be both
environmentally friendly and economically and scientifically sustainable. Work began on
four government breeding stations and two private ranches. Calves below 12 months of age
were given Cowdria ruminantium (Ball 3 strain), Anaplasma centrale, B. bovis and B. bigemina
blood vaccines from Onderstepoort Veterinary Institute (OVI). These trials later included
adult animals and threshold dipping within the herds. Studies were extended to immunise
animals on a voluntary basis in communal areas (SNL) starting at two dip tanks. Six SNL
pilot sites were then selected from the different physiographic zones. Currently, 700
animals (mostly calves aged below 12 months) on GBS, and 500 calves with 160 adults on
SNL have been immunised with all four vaccines.
Heifers vaccinated on GBS have been put under a threshold tick management
programme. To date, the results from the 1996 study have been encouraging. At the
highveld ranch site, for example, vaccinated animals were dipped four times during the year
instead of the usual 30 or more dippings carried out on the unvaccinated herd. During the
same period, five confirmed cases of TBD occurred in the unvaccinated animals while the
vaccinated group registered none. This should be interpreted with caution as continued
dipping of unvaccinated animals meant that they were acting as sweepers of ticks thus,
leading to a reduced TBD challenge. However, once all the cattle are under threshold
dipping a more conclusive result can be expected. It is vital that this work be continuously
monitored and extended to other sites.
Conclusion
The trials conducted so far have revealed some very promising results in relation to the
project objectives. Therefore, it is likely that the commercial sector will be willing to adopt
this integrated strategy once the relevant legislation has been reviewed to make this possible.
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The trials should also be extended to the SNL to determine the most appropriate
management and delivery system before the strategy can be implemented on a national
scale. As the project funding came to an end in December 1996, there is a danger that this
important work may suffer another serious blow if funding is not found in time to address
the outstanding issues for a sustainable national programme to be put in place.
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TBD immunisation in South Africa
D. De Waal
ARC Onderstepoort Veterinary Institute, Private Bag X05,
Onderstepoort 0110, South Africa
Summary
In South Africa (SA), three tick-borne diseases (TBDs) occur which are of great economic
importance to the livestock industry in the country. They are babesiosis, anaplasmosis and
heartwater (cowdriosis). East Coast fever (ECF), caused by Theileria parva, was introduced
into the country at the turn of the century. Fortunately, however, an intensive eradication
campaign over a 50-year period finally eliminated the disease in 1954 at a cost of 100 million
South African Rands (R)(US$ 22 million).
At present, more than 90% of the total cattle population in the country occurs within
the known Boophilus spp distribution area and is therefore potentially at risk to babesiosis
and anaplasmosis. Nearly 38% of the cattle, 8% of the sheep and 5% of the goat populations
occur in the Amblyomma distribution area. Official veterinary reports indicate that TBDs
contribute for more than 19% of total annual livestock losses. TBDs cost SA in the region of
R 400 million (US$ 88 million) per annum, 20% of which is the cost of acaricides alone,
while 40% is due to production losses.
Four methods of control (or combinations thereof) are generally applied to fight TBDs
in SA. These include specific treatment of clinical cases, tick control, chemoprophylaxis and
vaccination. Control of these diseases by intensive tick control alone, is not a solution to the
problem in areas where vectors are well established and is generally not recommended. The
recommended long-term approach to managing ticks and TBDs in SA is integration of the
strategic use of acaricides to allow natural exposure of young animals (calves/lambs/kids) to
TBDs when they are naturally resistant to or protected by passively-acquired maternal
antibodies, with vaccination. This compensates for epidemiological factors that may inhibit
the exposure of these animals to infected ticks when young.
The use of vaccines to protect animals against TBDs is not new to SA and vaccines
against Babesia bigemina and Anaplasma have been produced since 1912, with B. bovis being
included in 1953. Early attempts at the turn of the century to vaccinate animals against
heartwater were less successful as most animals died of vaccination reactions, which could
not then be controlled. Neitz and Alexander used the innate resistance of young animals to
vaccinate them against heartwater. However, the discovery of chemotherapeutic drugs with
which heartwater reactions could be treated in the 1940s, made it possible to extend
vaccination to older animals.
Since the early 1980s, attenuated strains of B. bovis (S-strain) and B. bigemina (G-strain)
have been used to vaccinate cattle against babesiosis. Both monovalent frozen and bivalent
unfrozen (chilled) Babesia vaccines are routinely available and approximately 200,000 doses
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of vaccine are sold per annum. The original isolate of Anaplasma centrale, identified and used
by Theiler as a vaccine for A. marginale, is still used to produce the live blood vaccine today.
Both a frozen and an unfrozen (chilled) Anaplasma vaccine is produced and approximately
220,000 doses are sold per annum. The Ball-3 isolate of Cowdria ruminantium is used for
producing the heartwater vaccine (frozen only) and approximately 120,000 doses are sold
per annum.
Each batch of blood vaccine has to pass a number of strict quality control checks before
it is issued. These include freedom from bacterial and fungal contamination, absence of
adventitious agents and innocuity. Strict measures are also taken to prevent the inadvertent
spread of other blood-borne infections with the blood vaccine. Potency tests are also
performed on all the frozen vaccines.
Ever since these vaccines started being used, outbreaks of disease have occasionally been
reported in previously vaccinated animals. Many factors may play a role in the occurrence of
the disease, such as storage failures, mishandling of the vaccine, incorrect administration,
incorrect diagnosis of the cause of the outbreak, treatment of animals with sterilising drugs
during or after vaccination and rigorous tick control following vaccination. Insufficient
cross-immunity between vaccine strains and certain field strains is known to occur in A.
centrale and C. ruminantium. However, laboratory investigations indicate that antigenic/
strain variation in the case of Babesia probably plays only a minor role, if any, in disease
outbreaks in previously vaccinated cattle in SA.
Chemoprophylaxis, as a method of short-term control, is often used in SA, particularly
in situations where the temporary residence of susceptible animals is in an infected area (e.g.
agricultural shows), when pregnant cows are at risk and in the control of disease outbreaks.
In babesiosis, imidocarb is most commonly used; however, no chemoprophylactic drugs are
available for the control of anaplasmosis and heartwater. The chemoprophylaxis of both
anaplasmosis and heartwater is, therefore, based on the repeated administration of chemo-
therapeutic drugs (tetracyclines) to control parasitaemias in naturally infected animals.
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Vaccine
production
Production of Theileria parva stabilates for
immunisation against theileriosis
F. Musisi
Food and Agriculture Organization of the United Nations (FAO) Office,
P.O. Box 30750, Lilongwe 3, Malawi
Introduction
Tick-borne diseases (TBDs), especially East Coast fever (ECF), have traditionally been
controlled by dipping or spraying cattle. However, due to the increasing cost of acaricides
and an increased awareness of their impact on the environment, alternative methods are
being sought. The search for a vaccine against ECF began as early as 1914 (Spreull).
However, practical means of immunising against ECF were only developed in the 1970s.
Even then, application of the technique on a large scale did not begin until the mid-1980s.
Immunisation is a useful way of reducing reliance on acaricides to control tick-borne
diseases. ECF vaccine production in Malawi was set up in conjunction with production of
other TBD vaccines at the Tick-borne Diseases Vaccine Production Centre. Construction
of the Vaccine Production Centre (VPC) in Lilongwe started towards the end of the 1980s.
The government of Malawi set up the VPC with the technical assistance of the Food and
Agriculture Organization of the United Nations (FAO) and financial co-operation of
various donors, principally the governments of Denmark and the Netherlands and United
Nations Development Programme (UNDP). The objectives were to look into the available
technologies for immunisation against TBDs and to subsequently evolve production
systems that would meet the minimum standards of registerable vaccines under Good
Manufacturing Practices (GMP).
This presentation outlines the salient features of the premises, the methods of
production and the quality control mechanism instituted for the manufacture of Theileria
parva stabilates for immunisation. It describes how these aspects were managed at the VPC
before production activities were suspended.
Premises for vaccine manufacture and organisation
of technical management
During the development phase, the four TBD vaccines were managed on a project basis
according to the technology involved in production. Thus the ECF vaccine was developed
as the ECF project based on tick culture technology, while the Anaplasma, Babesia and
heartwater vaccines were handled within a separate project since all three are based on the
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utilisation of blood from splenectomised animals. During this phase, the technologies and
facilities required for vaccine production were developed.
It was decided that the two product-development projects had been sufficiently
successful to warrant advancing all four vaccines to a production phase.
Premises
Purpose-built facilities were developed for the manufacture and technical servicing of the
TBD vaccines as follows:
• A farm comprising an animal quarantine station, fields for growing feed crops and grass
for silage and a tick-free, multi-unit housing facility for up to 300 cattle.
• An animal isolation compound with tick-proof pens for holding infected cattle.
• An isolation unit for holding up to 160 rabbits.
• A vaccine manufacturing laboratory with separate wings for production (Figure 1) and
quality control (Figure 2).
• A separate building for veterinary advisory work, including the handling of field
samples and training (Figure 3).
• A hostel with accommodation for up to 16 trainees and scientists from countries in the
region.
Responsibilities
The Technical Manager had overall responsibility for technical aspects of the VPC with
three technical departments, each reporting independently to him/her. The departmental
distribution of responsibilities was as follows:
Production
• Production of all vaccines, namely, ECF, Anaplasma, Babesia, heartwater.
• Production of antigens and reagents for serology and diagnosis.
• Maintenance of the vaccine seed banks.
• Cleaning and sterilising all glassware used in Production and Quality Assurance
departments
• Preparation of media.
• Repair and maintenance of vaccine production equipment.
Quality Assurance (QA) and Product Improvement
• Quality control (QC) of the seed bank.
• Quality control of all raw materials including donor animals.
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• In-process control testing during the manufacture of all vaccines.
• Quality control testing of the final products (vaccines, serological antigens and reagents)
including commissioning of external testing and QC certification.
• Good manufacturing practice (GMP) /QA monitoring of the vaccine facilities
including validation of processes and monitoring of good laboratory practice (GLP) and
safety in the laboratories.
• Documentation including batch records, Standard Operating Procedures (SOP) and
Manufacturing Instructions (MI) for all vaccines.
• Serological and microscopical diagnostic support to the Veterinary Advisory
Department.
• Co-ordination of the Product Improvement and Cost Reduction Programme.
Veterinary Advisory Service
• Farm and experimental animal facilities.
• Selection and acquisition of all animals.
• Performance and co-ordination of field trials.
• Product complaint register analysis.
• Isolation and characterisation of field parasites associated with possible vaccine
breakthrough.
• Support for making differential diagnosis.
• Co-ordination of training.
• Conducting experiments using target animal species in support of the Product
Improvement and Cost Reduction Programme.
Short-term priority areas for the Product
Improvement and Cost Reduction Programme
In-house activity
• In vitro quantification of the immunising parasite.
• Determination of the immunising and/or field dose.
• Preparation and standardisation of challenge stocks for the vaccines.
• Optimisation of batch size.
• Vaccine stock development for ECF vaccines.
External research support
• Antigenic analysis and characterisation of field isolates of epidemiological significance.
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• In vitro quantification of the immunogenic forms of the parasites and/or the immunising
antigen.
• Enzyme-linked immunosorbent assay (ELISA) technology for QC of TBD vaccines.
• Vaccine stabilisation, preservation, storage and minimisation of dependence on the
liquid nitrogen chain.
Description of trivalent T. Parva vaccine stabilate
This tick-derived stabilate consists of sporozoites of three T. parva stocks: cattle-derived
Muguga, cattle-derived Kiambu 5 and buffalo-derived Serengeti-transformed. Each is
harvested in Minimum Essential Medium containing bovine plasma albumin (MEM/BPA)
and glycerol, and stored frozen in liquid nitrogen. The stabilates are supplied in 2 ml vials
containing 5, 10, or 20 doses. Radley (1981) noted that a pool of these parasite stocks
protected cattle against challenge with stocks from Kenya, Malawi, Tanzania and Uganda.
Inoculation of the trivalent stabilate and simultaneous administration of an
appropriate tetracycline allows these three stocks to establish in the animal. The animal
develops immunity to immunologically related T. parva infections. Immunity is usually fully
developed within four weeks of immunsation.
Production process
The essential features of the production process are summarised in Figure 4. Most of the
steps are common to the routine laboratory production of T. parva stabilates. However, the
process differed from routine stabilate preparation described by Cunningham et al (1973)
in the following ways:
1. Stabilates of individual component stocks were mainly cryopreserved in transfusion
bags (Njuguna and Musisi 1996) with only 6080 ml of stabilate being dispensed and
cryopreserved in 2 ml cryoampoules. Both transfusion bags and cryoampoules were
kept at 70°C.
2. Viability and appropriate mixing ratios of component parasite stocks were determined
on the basis of prepatent periods to parasite and fever detection in three pairs of cattle
using cryoampoule-preserved stabilate. Usually the mixing ratios were 1:1:2 or 1:1:3
(Muguga: Serengeti-transformed: Kiambu 5).
3. Based on the mixing ratios, a sample pool of the trivalent stabilate was prepared using
stabilate from transfusion bags for each parasite stock. The pool was then diluted and
titrated at twofold dilutions starting from undiluted through to 210 using 4 cattle per
dilution.
4. A practical immunising dose was worked out based on sample pool titration results in
combination with Karbers (1931) method to determine the ID50.
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5. The actual vaccine pool was prepared using stabilate in transfusion bags for each parasite
stock by mixing them in the predetermined proportions. To obtain 5-, 10- and 20-dose
packs, the vaccine pool received an appropriate amount of stabilate diluent after which
the vaccine was dispensed.
Outline of quality control methods
Selection of cattle for vaccine production
Historically, cattle used for ECF vaccine production originated from the southern region of
Malawi where no East Coast fever has been recorded. Furthermore, the farms from which
such cattle originated practised a strict tick control regime. When brought in, the cattle were
quarantined for 7 days before being transferred to the VPC farm. None of the cattle
obtained from outside the VPC farm were used for vaccine production until a minimum
period of 8 weeks of clinical monitoring had been completed. More recently, virtually all
bovine used in the production (but not testing) of the vaccines were produced on the VPC
farm.
The cattle used were confirmed to be free from and serologically negative to Anaplasma
spp, Babesia spp, Theileria parva and Theileria mutans. Taurine breeds, particularly Friesians,
and their crosses were used for immunisation. Normally, the animals were between 9
months to 2 years of age and weighed a minimum of 120 kg. The cattle were fed silage and
concentrates; no hay or fodder was given to the animals.
The TBD farm is double fenced and human and animal traffic is restricted.
Sterility testing
Special attention was paid to checking the sterility of the following samples:
• Media for stabilate preparation.
• Surface-sterilised T. parva-infected ticks before grinding.
• Ground-up tick supernate, at the start of dispensing, mid-dispensing and at the end of
dispensing.
• Pooled components making up the ultimate vaccine as described above.
All the samples collected were tested for bacterial contamination as described in the
Production manual. Essentially this involved incubating samples in Fluid Thioglycollate
Medium (FTM) or Soyabean Casein Digest Medium. Upon detecting growth, identification
of the organism was undertaken as described in the manual.
Viability testing
Stabilates of the three stocks in the trivalent T. parva stabilate vaccine were prepared
separately. The viability of each stabilate was assessed using a twofold dilution in cattle as
described in the Vaccine Production manual. Assuming the stabilates were infective, the
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results obtained were used to determine the appropriate mixing ratios for the 3 stock
stabilates.
Potency testing
The potency of the vaccine was initially assessed by determining the ID50 and PD50 of a
sample vaccine pool, made on the basis of the viability and mixing ratios as described above.
This was followed by inoculation of small groups of cattle to determine a practical
immunising vaccine dose. Finally, potency of the final vaccine stabilate pool was confirmed
by inoculation of the working vaccine dose and twice the working dose as determined using
the sample vaccine pool. Using double the recommended vaccine dose helped provide data
on the safety of the vaccine in cattle.
Freedom from contaminating viruses
To confirm freedom from Enzootic Bovine Leucosis (EBL) and Bovine Viral Diarrhoea
(BVD) viruses, 20ID50 ECF vaccine doses were injected into pairs of cattle known to be free
from EBL and BVD viruses. The serology of these cattle was monitored for evidence of EBL
and BVD infection on days 0, 14, 21, 28, 35, and 42 after injection. Concurrently, the
development of schizonts and fever were monitored. When the cattle became clinically ill,
they were treated with anti-theilerial drugs to allow their survival for the detection of EBL
and BVD virus contamination in the vaccine.
Innocuity and safety
To help confirm safety of the vaccine stabilate batch prepared, guinea pigs and suckling mice
were inoculated with 0.5 ml and 0.1 ml, respectively, of freshly reconstituted trivalent T.
parva stabilate. A pair of uninoculated guinea pigs and 4 suckling mice were kept as controls
together with the inoculated animals. Essentially, if all the inoculated animals survived
three weeks without any clinical disease or death, the vaccine was considered safe for use.
Other considerations
Effect of freeze-thaw of the vaccine
Whilst, during preparation of the trivalent T. parva stabilate vaccine, it is possible to thaw,
pool and refreeze the stocks under controlled conditions, this must not be done with
vaccine in the field. Freeze-thaw of the vaccine under field conditions would inactivate it
completely; thus any unused thawed vaccine must be discarded. It is recognised that, even
under controlled laboratory conditions, there is a limited loss of viability. But, this is
considered necessary to make the trivalent T. parva stabilate user-friendly. If pooling was left
to field personnel with varying competency in laboratory techniques, there would be a risk
of over- or under-dosing with vaccine.
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Stability of thawed vaccine
Experiments, in which the vaccine was thawed and subsequently maintained on ice, show
that the vaccine remains viable for up to 18 hours (Musisi et al 1996). However, for routine
field use, the vaccine should be thawed and maintained on ice for no more than 8 hours (i.e.
a working day). This is because repeated opening and closing of the vaccine container affects
the pH resulting in loss of viability of T. parva sporozoites.
Diluent packaging
Diluent was prepared for the different vaccine dose packs. It was sterilised, dispensed and
sealed in such a manner that the pH remained stable. Stabilate was transferred from the
cryoampoule to the diluent vial with a syringe and needle. This approach eliminated potential
mistakes that could be made by vaccinators attempting to implement their own dilutions.
Conclusion
The above description outlines the minimum acceptable standards regarding the premises,
organisation and methodology for production of T. parva stabilates for wide-scale field
immunisation. Efforts at the VPC took the process from a routine laboratory approach
towards professional and Good Manufacturing Practices. The VPC management
recognised that further research was needed to help make the products user-friendly and to
investigate various aspects, such as how to avoid losses from thawing and re-freezing during
production; safety of the vaccines in different breeds and during pregnancy; minimum age
to immunise and post-immunisation reactions. These issues were being addressed at the
time that VPC operations were suspended and, therefore, require attention when vaccine
production is resumed.
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The preparation of a composite stabilate for
immunisation against East Coast fever
S. Morzaria, P. Spooner, R. Bishop and S. Mwaura
International Livestock Research Institute (ILRI),
P.O. Box 30709, Nairobi, Kenya
Background
The preparation of Theileria parva sporozoite stabilates has been described by Cunningham
et al (1973). The method is detailed in the FAO report (1978) and the FAO Tick and Tick-
borne Disease Manual (1984). Theileria parva stabilates are a source of viable sporozoites that
can be used to immunise cattle by infection and treatment. This method involves
inoculating cattle with a potentially lethal dose of sporozoites and simultaneous treatment
with an oxytetracycline formulation to control the severity of the disease (reviewed by
Radley 1981). After the development of the infection and treatment method of
immunisation in the mid-1970s, an immunising stabilate referred to as the Muguga
cocktail, comprising three stocks of T. parvaMuguga, Kiambu 5 and Serengeti-
transformed  was prepared. This pool of stocks was selected because it gave broader
protection than the individual immunising components in cattle cross-immunity trials
(Radley et al 1975a; Radley et al 1975b).
The International Livestock Research Institute (ILRI) was requested by the Food and
Agriculture Organization of the United Nations (FAO) to prepare a batch of the Muguga
cocktail. This was because a shortage of the immunising stabilate was predicted due to
increasing demand and the Vaccine Production Centre (VPC) in Malawi not functioning at
full capacity to meet this demand. ILRI agreed to prepare the vaccine stabilate since, at the
time of the request, no other institution within the region was able to produce the cocktail.
Following consultations with FAO, the technical staff at VPC in Malawi and a number of
other scientists working in the field of theileriosis, a protocol for the preparation of a
composite stabilate comprising the three stocks was developed. A number of modifications
from the original VPC protocol were introduced, some of which have been adopted as part
of the standard ILRI procedure for stabilate preparation. Other amendments were also
introduced to fulfil the requirements of the Office International des Epizooties (OIE)
recommended standards for biological products (OIE 1996) and the proposed new
standards that have been set by the Standards Committee, representing the Organization of
African Unity (OAU), FAO and ILRI. The detailed protocol for the preparation and the in
vitro and in vivo characterisations of the composite stabilate, designated FAO 1, are
described below.
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Protocol for a composite stabilate
Laboratories producing T. parva stabilates have made various modifications to the
recommended protocol (FAO 1984). There have been variations in media used, containers
for cryopreservation, methods of tick grinding and equilibration periods. More recently,
freezethawfreeze steps have been introduced to combine the individual components of
cocktail stabilates, before release for use.
After examining various options for the preparation of the cocktail stabilate, a modified
protocol was formulated. This protocol was circulated for comments to various scientists
involved in the preparation of vaccine stabilates. These included scientists from VPC,
Malawi; National Veterinary Research Centre, Kenya; Onderstepoort Veterinary Institute,
South Africa; Centre for Tropical Veterinary Medicine, UK; and the University of Utrecht,
The Netherlands. Subsequently, a clearer protocol was developed in a detailed step-wise
form with time-bound objectives for each step. The protocol took into account the quality
control procedures and general standards recommended by OIE (1996), and those drafted
by the OAU/FAO/ILRI Standards Committee (OAU/FAO/ILRI 1996). Special attention
was given to both Good Manufacturing Practice, for the tick unit, animals, tissue culture
media, serology, contamination with extraneous organisms, and for in vitro and in vivo
methods of characterisation. In the protocol, reference was also made to the standards
applied at each stage of preparation. The final protocol was approved by the members of the
Programme Steering Committee of the Regional Tick and Tick-borne Diseases Control
Programme and the FAO.
The significant changes to previous methods for preparation of Muguga cocktail
stabilates were:
1. The stabilate was prepared from pooled ticks so that equal numbers of infected acini were
present from each component stock, Muguga, Kiambu 5 and Serengeti-transformed.
2. No freezethawfreeze steps were required to mix component stocks.
3. The ticks used dropped from cattle during a range of low to high piroplasm parasitaemia.
4. Theileria infection rates in ticks were critically assessed.
5. In vitro characterisation was carried out, beginning with the seed stock and at various
stages during the production to confirm the stability and integrity of the component
parasite stocks.
6. The stabilate was prepared as concentrated as possible (the highest number of infected
acini per ml) given the restrictions outlined in point 3.
7. Plastic straws of 0.5 ml capacity were used.
Stabilate preparation
A diagrammatic representation of the procedure for stabilate preparation is given in Figure
1. During preparation of the composite stabilate, parasite isolations in tissue culture were
made from cattle infected with the individual seed stocks, from in vitro infections using the
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composite stabilate and from cattle infected with the composite stabilate. Again, these
isolates were subjected to in vitro characterisation using a panel of monoclonal antibodies
(MAb) and a set of DNA probes. The MAb and DNA profiles of these isolates were
compared with those obtained from earlier isolates of these seed stocks. The MAb profiles of
isolates, taken as biopsies from cattle infected with the three individual seed stocks, were
similar to those obtained previously and confirmed the similarity between the Muguga and
Serengeti-transformed stocks. The profile of the Kiambu 5 stock was similar to profiles of
earlier isolates of this stock, but significantly different from the Muguga and Serengeti-
transformed stocks.
Profiles from in vitro infections, using reference stabilates prepared from ticks which fed
on cattle infected with the individual stocks, were also similar to the parent stabilates. These
ticks were then pooled together to prepare the composite stabilate which, when used in in
vitro and in vivo studies, gave isolates with profiles consistent with a pooled profile of the
three seed stocks. These findings, combined with those above, demonstrating the integrity
of the individual seed stabilates, indicated that each seed component was present in the
composite stabilate, although profiles of the Muguga and Serengeti-transformed stocks
would be similar. Similarly, using the four DNA-based probes, the TpR, telomeric, LA6 and
minisatellite sequences, the stability of all the three components was maintained
throughout the preparation of the stabilate. The final stabilate, referred to as FAO 1, was
first used to test the infectivity in susceptible cattle and secondly serial dilutions were used to
immunise cattle using the infection and treatment method. After immunisation, recovered
cattle were challenged with a lethal dose of each of the seed stocks. All animals that were
immunised down to a 1:80 dilution, the highest dilution tested in this initial titration of the
stabilate, were protected. Thus, both the in vitro and in vivo characterisations showed that
the integrity of all the components of the cocktail was maintained in the FAO 1 composite
stabilate.
Time-frames
The timeframe for the preparation of a vaccine stabilate depends on several factors, most
importantly on whether the stock to be used is already fully characterised or is a new isolate.
A number of important steps need to be taken for a new isolate to be considered a potential
candidate vaccine stock. These include the preparation of a reference stabilate from the
isolate, preparation of a working stabilate, in vitro characterisation, in vivo cross-immunity
tests and field immunisation trials. This could take a variable period of up to 24 months.
Assuming that satisfactory results are obtained, a decision can then be made to use the
isolate to make a large vaccine stabilate. This preparation can take an additional 57
months, followed by laboratory titration in cattle requiring an additional 68 months. For
FAO 1 the preparation of the large stabilate took 10 months, which included the testing of
the seed stabilates, a preliminary titration in cattle and a comprehensive in vitro
characterisation of the composite stabilate. Full in vivo characterisation, including the three-
stage titration, will require an additional 68 months.
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Since many isolates contain mixed T. parva populations, it is important that a vaccine
stabilate is made using characterised seed (working) stabilate(s). This vaccine seed stabilate
should be made in sufficient quantity so that it can be used for all subsequent stabilate
preparations. Otherwise, product variability may be encountered which might affect the
efficacy of the vaccine batches.
Summary and conclusions
• A large composite stabilate (FAO 1), of 10,000˝0.5 ml straws, containing the
components of the Muguga cocktail was produced.
• A modified method of preparing bulk composite stabilates was developed, applying the
recommended standards. The method may be considered suitable for other stabilates
requiring single or mixed parasite stocks.
• In a preliminary titration, the stabilate successfully immunised exotic cattle, by
infection and treatment, at a 1:80 dilution. These cattle were protected against a
simultaneous, potentially lethal challenge of the three parent stocks included in the
bulk stabilate.
• The full economic production costs (1996) are in the region of US$ 120,000 (3060
cents/dose).
• The total time taken to prepare the stabilate was 10 months.
• The FAO 1 stabilate requires a comprehensive titration in cattle using a three-stage
design to identify a safe and efficacious dose.
• The total time, using characterised seed stocks, from cattle quarantine to completed
titration is estimated at 1618 months.
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Preparation of stabilates for immunisation
against East Coast fever at NVRC, Muguga,
Kenya
R. Payne
National Veterinary Research Centre (NVRC), Muguga,
P.O. Box 32, Kikuyu, Kenya
A marketing strategy to deliver East Coast fever immunisation using the Marikebuni stock
(ECFiM) on an economically sustainable basis is being developed by the Kenya Agricultural
Research Institute (KARI) and arrangements are under way to involve a private sector
partner in this undertaking. The approach is detailed in a document prepared by the
National Veterinary Research Centre (NVRC) entitled ECFiMA Marketing Strategy.
This paper highlights some of the issues being addressed by KARI and the KARI/Overseas
Development Administration of the United Kingdom (ODA) Tick-borne Diseases Project
on the way towards commercialisation of stabilate production and immunisation.
Preliminary activities
Selection of an immunising parasite stock
The Theileria parva Marikebuni stock has been selected as the vaccine strain for use in Kenya.
This decision was based on available information, which suggests a broad spectrum of cross-
immunity against other parasite stocks.
Refurbishment of facilities and improvement
of security at NVRC
In order to comply with commercially acceptable production standards, the facilities used
for stabilate production will be refurbished. In addition, security fencing is being erected
around each of the outside units; only designated personnel will be allowed to enter these
areas and protective overalls of a colour specific for each unit will be worn.
Standards for stabilate production and quality control
Stabilates to be used for ECFiM will be prepared at NVRC, Muguga, in accordance with the
standards for production described in the document Standards for Preparation of
Stabilates for Immunisation against East Coast fever in Kenya. A modified Standard
Operating Procedure is being developed which takes these into consideration.
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DVS approval
The standards for stabilate preparation have been approved by the Director of Veterinary
Services (DVS), Kenya. The DVS will be kept informed of all relevant aspects of
immunisation in the field.
Selection of a commercial partner
Putative commercial partners have been contacted and the process of selection is underway.
Laboratory activities
Stabilate production
Stabilates for field immunisation are prepared at NVRC from a seed stock of T. parva,
Marikebuni stabilate 3014, originally isolated from the Coast Province of Kenya. Safety and
quality testing may be done elsewhere, if an appropriate agency is identified.
Cattle for stabilate production
Cattle are purchased from a farm where ECF has not been reported for more than two years.
Before purchase, sera are tested for antibodies to tick-borne diseases (Theileria parva, T.
mutans, Babesia bigemina and Anaplasma marginale) and enzootic bovine leucosis (EBL) and
blood smears are examined for haemoparasites. Only animals whose tests are negative will
be considered suitable. Cattle are quarantined at NVRC in tick-free accommodation for
two months. Acaracides are not applied to ensure low residual levels when animals are
washed before tick application. Blood smears are taken three times a week during
quarantine and examined for haemoparasites while serology to detect antibodies to Theileria
is performed at four-week intervals. Steers of 250300 kg body weight are used for tick-
feeding, as they are more likely to survive the infection than smaller calves.
The severity of disease is a common constraint when feeding ticks on infected cattle,
treatment with a curative drug or euthanasia may be required before a sufficiently high
number of ticks have dropped. Treatment with a diuretic (fruzemide) has been found to
relieve pulmonary oedema, one of the major symptoms, thus allowing tick-feeding to
continue until completion. Cattle are treated with the antitheilerial buparvaquone once
tick-feeding has finished.
Database
A database is being set up to accommodate clinical observations from cattle infected with
the seed stabilate 3014, data on tick infection rates and stabilate infectivity. It is anticipated
that this information will help to identify factors influencing tick infection rates and
ultimately to produce tick batches of predictable and uniform infectivity.
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Characterisation
In vitro: To check homogeneity of stabilates prepared from the seed stock, schizont cultures
for characterisation studies are established routinely from cattle infected for tick-feeding
and subsequently from the animals used to check stabilate viability after it has been frozen in
liquid nitrogen.
In vivo: A panel of stabilates is being prepared from a number of T. parva isolates, these will
provide infective material for standardised cross-immunity studies and will enable
comparison of future batches of vaccine stabilates.
Field activities
Efficacy trials
Field trials are currently being conducted in different areas of Kenya to test the efficacy of
ECFiM against natural challenge.
Monitoring field vaccination
All aspects of field vaccination will be monitored in conjunction with the commercial
partner and field veterinarians.
Data on ticks and other tick-borne diseases (TBDs)
It is anticipated that tick control will be reduced on farms where cattle have been
immunised. The effect of changes in dipping regimes on tick infestations and other tick-
borne diseases (TBDs) will be assessed and the socio-economic benefits of such programmes
analysed. Data on ticks and other TBDs will be collated at NVRC. This information will be
made available to the DVS and used as a basis for the formulation of policies governing
control of ticks and TBDs.
Responsibilities of NVRC and the commercial partner
ECFiM delivery
An appropriate and sustainable method of ECFiM delivery will be developed.
Training field veterinarians
Since October 1994, training of private veterinarians has been the responsibility of the
KARI/ODA TBD Project. In the future, the commercial partner will play a role in
recruiting and training veterinarians.
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Extension to farmers
An extension package to help farmers appreciate the potential benefits and risks of
immunisation is being designed and tested.
Technical support to veterinarians
Both NVRC and the commercial partner will have an ongoing responsibility to provide
technical support to field veterinarians involved in the immunisation programme.
Advice on alternative tick control strategies
The possibility that tick control may be reduced in groups of immunised cattle is mentioned
above. It is the responsibility of NVRC and the commercial partner to help formulate
integrated tick and TBD control strategies.
Feedback of information to the DVS
All activities under this programme will be reported to the DVS. This includes the number
of stabilates produced, areas where efficacy trials are being conducted, veterinarians trained,
results from the vaccination programme, information on the incidence of ECF and results
from investigations on ticks and other TBDs.
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Application of molecular tools in support of
deployment of Theileria parva live vaccines
R. Bishop,1 V. Nene,1 P. Spooner,1 S. Mbogo,2 D. Kariuki,2 R. Payne2 and S. Morzaria1
1 International Livestock Research Institute (ILRI), P.O. Box 30709, Nairobi, Kenya
2 National Veterinary Research Centre (NVRC), Muguga, P.O. Box 32, Kikuyu, Kenya
Goals of characterisation
The primary goals of applying molecular tools, developed at the International Livestock
Research Institute (ILRI), in conjunction with the use of infection and treatment
immunisation are:
• quality control of vaccines
• monitoring of possible vaccine breakthrough and breakdown
• assessment of the impact of introducing new parasite types on long-term efficacy of the
vaccine.
There are two main categories of tools available for use; serological, such as schizont-
specific monoclonal antibodies which are now in routine use in some regional laboratories,
and DNA-based, which are mainly used at ILRI but are likely to be deployed for routine use
in regional laboratories in the near future.
Serological techniques
A panel of monoclonal antibodies (MAbs) has been raised against the schizont stage of the
parasite. These are used in an immunofluorescence assay to determine which monoclonals
react with the schizonts in antigen prepared from isolates in tissue culture. The reaction is
scored as positive (+) or negative (). The monoclonal antibody profile obtained is useful but
does not discriminate all isolates. Most of the MAbs are against epitopes on the
polymorphic immunodominant molecule (PIM) and therefore give limited information.
DNA-based techniques
Southern blotting
This technique generates unique fingerprints from multiple loci throughout the genome
using cloned Theileria parva DNA sequences as probes. The fingerprints produced allow the
discrimination of most T. parva isolates and, collectively, are useful for vaccine
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characterisation. The method will only work on DNA purified from tissue culture of an
isolate. Four T. parva polymorphic probes are currently available:
Tpr repetitive Protein-encoding;
expressed only in piroplasm stage
Telomeric located at ends of chromosomes;
detects variation at 8 loci
LA6 repetitive Protein-encoding;
expressed in schizonts and piroplasms
Minisatellite Non-coding;
at multiple loci on all chromosomes
Polymerase chain reaction (PCR)
In the polymerase chain reaction (PCR) method, specific DNA sequences are amplified and
large quantities of target DNA may be produced and detected making this method
important for diagnosis particularly where the quantities of T. parva in the samples may be
minute, for example, in the blood of T. parva carriers. The method works on whole blood or
tick salivary glands.
Single strand conformation polymorphism (SSCP)
Here, PCR is used to amplify DNA from different sites in the genome, followed by single
strand conformation polymorphism (SSCP) to detect small DNA sequence differences
(small genetic differences) at each of the sites (loci). This technique works on whole blood
and is useful as a research tool for the direct analysis of T. parva populations in the field.
Oligonucleotide primers are available to study 10 loci. Once amplified by PCR, the gene
sequence at a locus can be characterised by SSCP, restriction enzyme digestion or direct
nucleotide sequencing. The gene sequences involved are located on all four chromosomes
and include antigen genes, such as PIM.
Quality control and markers for vaccine stocks
Using a combination of the above techniques, the vaccines in use can be identified and
differentiated. Molecular characterisation has revealed that vaccine stocks, like field
isolates, are heterogeneous. Application of this characterisation during vaccine production
is an essential part of quality control.
It would be very useful if there were a unique marker for each of the vaccine stocks used
which is not found in field parasites. Apart from being able to determine if an animal had
been immunised, such markers would enable some important questions about the
immunising parasite to be investigated, for example, whether it:
• replaces local strains resulting in a homogeneous parasite population
• undergoes sexual recombination with local strains potentially creating parasites with
altered virulence or antigenicity
FAO/OAU–IBAR/ILRI Workshop 67
R. Bishop, V. Nene, P. Spooner, S. Mbogo, D. Kariuki, R. Payne and S. Morzaria
• alters significantly in genetic composition during tick/cattle passage for stabilate
production.
Currently, vaccine markers are only available for Kiambu 5 and Marikebuni. They were
derived from the 3 conserved region of Tpr. To apply them, PCR is used to amplify the
sample and the PCR product, if present, is detected by hybridisation with the radio-labelled
specific oligonucleotide.
Ongoing collaboration in a three-year project, funded by the Department for
International Development (DFID) of the United Kingdom, between ILRI and the
National Veterinary Research Centre (NVRC), Kenya, is addressing the issues raised above.
The Marikebuni vaccine is being used in the infection and treatment method in Kenya and
this research will continue alongside its use in the field. A large number of isolates will be
characterised with MAbs and the full panel of DNA probes pre- and post-vaccination. A
PCR-based marker is to be generated for the Marikebuni stock and will be used to test field
ticks and unimmunised cattle for the presence of the Marikebuni stock. This project will
also have a role in strengthening the capacity of NVRC staff to support immunisation
programmes, through training.
Investigating possible vaccine breakdown and
breakthrough
In situations where vaccine breakdown (failure to immunise) or breakthrough
(immunisation successful but failure to protect against a field strain) are suspected,
characterisation could assist the investigation, together with all the other relevant
information about the disease outbreak. The PCR assay can be used on whole blood to
establish whether the carrier state has been induced by the vaccine stock. Southern blotting
can be used to examine the DNA of tissue culture isolates prepared from the same animals
to check whether the animals have been infected with parasites other than the vaccine
strain. At present, there is no in vitro method of characterisation that can predict whether
cross-immunity will occur between the vaccine and another parasite. Therefore,
characterisation is primarily useful in distinguishing breakdown from breakthrough.
Molecular epidemiology of ECF
The application of vaccine markers to studying the impact of the immunising parasite on
the epidemiology of ECF has been mentioned above. Other areas in which molecular
characterisation is used to study the epidemiology of theileriosis include:
Role of other Theileria species
PCR-based assays derived from ribosomal RNA or antigen genes are available to distinguish
the various Theileria species that may be encountered in the field.
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Genetic variation between T. parva isolates
The DNA from different isolates can be examined to determine whether the isolates are
made up of several types or a single clone, and to study to what degree they vary from each
other. Two examples of such studies are given below.
In Zimbabwe, in association with immunisation using the local Boleni stock, 40 isolates
from 12 farms in buffalo-free areas were characterised using two probes. Most isolates
appeared very similar using the Tpr probe. However, these could be discriminated from
each other by the telomeric probe, which highlights the need for using a comprehensive
panel of probes.
ILRI and ITM, Antwerp, collaborated to characterise Eastern and Southern Zambian
isolates using all four DNA probes mentioned above. These revealed limited diversity,
perhaps consistent with recent divergence from a single clone. A single isolate was obtained
from Southern Zambia after deployment of Muguga cocktail vaccination. This appeared
similar to Muguga with one probe and one SSCP marker but different with others. The
significance of this is uncertain since the probes and markers have not yet been validated on
a wide enough range of T. parva isolates.
Population genetics
These studies aim to quantify some parameters in the Theileria life cycle, such as, the
frequency of multiple infections with different T. parva isolates in ticks and cattle and the
extent of sexual recombination in field populations. The approach being used is to generate
specific markers which differentiate field isolates and, also, to look at the frequencies of
different polymorphic loci (using PCR-SSCP) and test whether they associate randomly.
One significant outcome of this work will be that it will provide an insight into how rapidly
resistance to a multivalent vaccine can evolve.
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Standards for live tick-borne disease
vaccines
T. Dolan
Livestock Services, P.O. Box 24720, Nairobi, Kenya
Standards have been published for live tick-borne disease (TBD) vaccines by the Standards
Commission of the Office International des Epizooties (OIE) (OIE, 1990, 1991) and a
revision is in press (OIE, 1997). In the preparation of these standards, specialists prepared
drafts for each vaccine, which were then circulated for comments to the 114 member
countries. Experts in these countries reviewed the drafts and, where appropriate, modified
them before approval. The countries in the eastern, central and southern African region,
together with the Food and Agriculture Organization of the United Nations (FAO), the
Organization of African Unity/Inter-African Bureau of Animal Resources (OAU/IBAR)
and the International Laboratory for Research on Animal Diseases (ILRAD, now the
International Livestock Research Institute (ILRI)) also established a Standards Committee
(in 1991) to prepare draft standards for these vaccines; particularly stabilate vaccines for East
Coast fever (ECF).
Live vaccines for anaplasmosis and babesiosis are produced in Australia, South Africa
and elsewhere, and for cowdriosis in South Africa, on a commercial or cost-recovery basis.
Standards and an industrial attitude to quality assurance and safety have been in force for
these products for some time. The stabilates used in infection and treatment immunisation
against ECF have been more experimental in nature and generally produced in small
batches. These stabilates are prepared using cattle and ticks, and are potential sources of
extraneous infections. In addition, the concentration of infective material, Theileria parva
sporozoites, will vary between batches and, when more than one stock is used in a vaccine,
the implications of the relationship of dose of each component stock has to be addressed.
The use of infection and treatment immunisation is being vigorously promoted in the
region as one element of integrated tick and TBD control. If ECF stabilate vaccines are to be
used widely, they must conform to high standards of safety and reliability. Donor support
for delivery of integrated tick and TBD control is a short-term option and private delivery
must replace it, if it is to be sustained. The production of the vaccines must also be
commercialised or at least be capable of cost-recovery. Thus, the whole process from
production to delivery must become commercial in outlook. Products that are
manufactured according to strict protocols and that meet defined standards of quality and
safety are essential to achieve this.
A final draft Standards, drawn up by the Regional OAU/FAO/ILRAD Committee, was
circulated to all countries and agencies involved in August 1996. Minor alterations were
proposed and these were referred to the Task Force now in place to guide the restructuring
of the new regional tick and TBD control programme. The standards for anaplasmosis,
babesiosis and cowdriosis are based upon, and closely resemble, those already in place in
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Australia and South Africa. The ECF standards are the result of years of accumulated
experience and expertise in a number of national laboratories, ILRAD (ILRI) and the
Vaccine Production Centre (VPC) in Lilongwe, Malawi, with input from consultants from
protozoal and virological vaccine laboratories, supported through FAO.
The draft standards include recommendations on the sources and screening of cattle
and rabbits, sources of ticks, seed stabilates of immunising stocks, the in vitro and in vivo
characterisation of stabilates, and titration and safety testing of stabilates for use in the field.
The list of organisms given in the standards that might contaminate stabilates is long, but
not exhaustive. Each government must consider the screening it requires for disease security
and for the safety of its cattle. It must also consider the national requirements with regard to
characterisation of immunising stocks. The fact that some countries produce their own
stabilates while others use stabilates produced at the VPC means that different standards are
likely to be applied. The in vivo cross-immunity characterisation of a stock stabilate(s) may
differ if the stabilate(s) is to be used in different countries or even different areas of a
country, because of antigenic differences of parasites in the different areas. The decisions on
safety screening and characterisation are direct responsibilities of the user governments and
must be part of the contract with the production facility.
Infection and treatment immunisation uses potentially lethal stabilate(s) of T. parva and
an oxytetracycline to control the infection. Countries in the region have different
regulations regarding registration of veterinary products. The stock used for vaccination in
Zimbabwe, T. parva Boleni, has been registered for use with and without tetracycline (under
the name Bolvac). In other countries, the vaccine stocks have been approved by the
respective Veterinary Departments but not formally registered. This may become an issue as
countries develop, strengthen or enforce registration of such products.
In the production of the vaccine it is usual to test the efficacy of one long-acting
oxytetracycline for the control of a particular stabilate batch. Not all long-acting oxyte-
tracycline formulations perform equally even though the concentration of antibiotic in
different formulations is the same. The vehicle may be different and therefore, the
pharmacokinetics and pharmacodynamics may differ. One product is used routinely in
producing each batch of the trivalent combination at the VPC in Lilongwe while two
products have been shown to be efficacious in controlling the T. parva Marikebuni stabilate
stock in Kenya. A product profile for the tetracycline was presented at the regional meeting
held in Lilongwe in April 1994 (Musisi and Dolan 1997) and although the meeting agreed
that commissioning a reasonably priced and specially labelled product for the region was a
good idea, it did not make a specific recommendation as there was concern about limiting
the provision of tetracycline to one company. Failure of a tetracycline to control the
immunising infection has been recorded on more than one occasion and it is difficult to
accept a vaccine package that does not contain a specific product(s) recommendation. If this
is not possible, the package must contain a caution that the use of another product might
lead to clinical reactions if it has not been shown to be effective before use in the field. The
efficacy testing would be the responsibility of the user country or company, if the vaccine
was being distributed and delivered privately.
Standards for live TBD vaccines are available and those published by the Standards
Commission of the OIE. Once the Standards drawn up by the Regional Committee are
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approved, they will be forwarded through FAO to the OIE and will be integrated into the
OIE Standards (revised version 1996) in the next edition of the OIE Manual. It is then the
responsibility of the Veterinary Department of each country to communicate its
requirements to the production facility . The Standards may be modified over time to
accommodate specific needs and to adopt new recommendations. For instance, the in vitro
characterisation methods now in use for T. parva (see Bishop, this proceedings) may be
replaced by newer and more specific methods as this is a rapidly developing field of research.
The only standard that is still being developed is on titration of T. parva (see draft
Regional Standards, item 21). A three-stage titration has been proposed and is being
evaluated with a new bulk combination stabilate produced for the Regional Project (VPC)
by ILRI (see Morzaria and Spooner this proceedings). It may also be necessary to institute re-
testing for stabilates stored for extended periods (perhaps five years) and a titration
procedure used to determine if there has been decay. Also, there is a need for an
independent review and inspection process of production facilities, their records and
products. If industry becomes involved in production, rigorous enforcement of quality
assurance and safety is expected to be in place, but independent inspection may still be
necessary to ensure that standards of quality and safety are maintained.
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Summary of discussion: Vaccine production
Facilitator: C.G.D. Brown
Rapporteurs: S. Mbogo and M. Moran
The five papers presented in this session described many of the practical aspects of stabilate
production and the associated activities required to maintain vaccine standards, such as
characterisation of stocks and testing for contamination with extraneous organisms.
Method of stabilate production, storage and
handling
At present, there is no standard protocol for stabilate production and it was agreed that it
would be useful for the various groups making stabilates to meet and standardise their
procedures. The participants emphasised the importance of storing seed stocks separate
from other stabilates, and ideally also in other laboratories. These seed stocks should be well
characterised in vitro and in vivo. It was suggested that characterisation of both seed and
vaccine stabilates should be repeated every 5 years to determine the degree of decay during
storage, how this might be done was not discussed. Issues proposed for further research
included the influence of cattle breed on quality and quantity of the tick pick-up, and the
need for an alternative method to replace manual plucking of ticks from rabbit ears. It was
emphasised that the most susceptible breed of cattle and line of tick must be used and a
separate tick line should be maintained in case the tick colony used for tick pick-up has a
problem. Accurate standardised techniques for assessment of infection rates in ticks must
be applied. Packaging of stabilate in straws for storage in liquid nitrogen was recommended.
Many participants felt that the medium used for the grinding and the diluent is not user-
friendly and need to be improved. In relation to this, it was considered that the viability of
stabilate on melting ice should be determined and that there should be a system of
monitoring pH changes in thawed stabilate and ensuring that the stabilate is discarded at
the correct time.
Quality control and assurance
It was generally agreed that quality control monitoring requires internal and external
expertise and independent assessors, that production and quality control should be
separate, that independent OIE certified laboratories be used for certain tests and that the
laboratory producing stabilate should provide a form of certification of the product with a
guarantee of defined quality. Stabilate producing laboratories need experience of the use of
stabilates in the field to enable backstopping. The importance of giving clear instructions on
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how the product should be used to avoid inappropriate procedures being employed was also
emphasised. The conditions recommended for maintaining stabilate after thawing e.g. on
ice or at room temperature (Zambia) need to be clarified. Only one occurrence of an
adventitious agent in an ECF vaccine was reported; this was an ILRI stabilate which caused
abscesses. The problem of bovine leucosis virus contamination of blood vaccines in
Australia and Zimbabwe was also mentioned. Anaphylactic shock due to tick antigens or the
cryoprotectant has occurred following stabilate inoculation but incidence appears to vary, it
was recommended that adrenaline should always be available to treat cases that arise.
Stocks, strains and characterisation
The main vaccine stocks in use are Marikebuni, Muguga cocktail and Boleni, each of these is
characterised and contains a mixed parasite population. Numerous buffalo-derived T. parva
stocks exist but are not well characterised. The methods of characterisation were reviewed in
Bishops paper and were again outlined prior to discussion; in vitro methods using
monoclonal antibodies and DNA probes can be used to characterise parasites in vaccine
stabilates, reactor animals, carrier animals and field cases; in vivo methods include infectivity
testing (measures virulence), cross-immunity (indicates immunogenic types present) and
infectivity to ticks. The primary reproductive rate of different stocks was mentioned as an
area requiring further study. The need for a standardised approach to characterisation,
particularly of vaccine stocks, was emphasised. It was considered important that vaccine
stocks should be fully characterised, especially as the history of some immunising parasites is
not entirely clear. The rationale behind selection of immunising parasites as potential
vaccine stocks was discussed. Three important criteria are that the stock must have a broad
spectrum of protection, must be blocked with recommended oxytetracyclines and must be
easily produced, for example, good pick-up of infection in ticks. It was admitted that there is
a degree of trial and error in identifying protective parasites since only a limited number of
stocks can be tested in cross-immunity trials. In the case of Zimbabwe, it was thought that an
important reason behind the selection of T. parva Boleni was its low virulence. The possible
need to conduct a large cross-immunity trial using representative country stocks was raised.
Another issue discussed was whether immunising stocks generate the carrier status in
immunised animals. The Muguga component of the Muguga cocktail does not induce
carrier status, while the capacity of the other two components, Kiambu 5 and Serengeti-
transformed, to do so remains unknown. The other immunising stocks (Boleni, Katete,
Marikebuni and Zanzibar) do cause carrier status to develop. The discussion then moved on
to ask whether it would be better to work with a clone, containing a single parasite
population, rather than a stock, which contains a mixed parasite population. Evidence
suggests that, although a clone is likely to be easier to work with, it is unlikely to confer
sufficient protection. Results from experiments using different parasite subpopulations
(clones) showed that they were not protective, although not all the clones could be tested
because of the expense involved.
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Vaccine delivery
The infection and treatment method of
immunisation: Practice and problems
S. Mbogo
National Veterinary Research Centre (NVRC)-Muguga,
P.O. Box 32, Kikuyu, Kenya
The infection and treatment method (ITM) is currently the only effective means available to
immunise cattle against theileriosis, although laboratory results using recombinant antigens
are promising (Musoke et al 1992). The method involves inoculation of live, potentially
lethal parasites into healthy cattle followed immediately by an injection of a long-acting
oxytetracycline (TLA) at 20 mg per kg body weight. A mild infection of Theileria parva occurs
in the immunised cattle, which stimulates cell-mediated immunity to schizont-infected
cells. This immunity can last up to 36 months in the absence of further challenge (Burridge
et al 1972) but may be expected to become lifelong through boosting from the continuous
challenge expected in areas where ITM is necessary.
Most of the problems associated with ITM (Morzaria 1996) and the possible solutions
(Mbogo et al 1996) have been discussed in previous meetings. They include:
• The requirement for a cold chain: for the parasite to remain viable, it must be stored in
liquid nitrogen and, unless the diluent is vacuum packed, it should be stored at 20°C
which may not be readily available in the field.
• The fact that some animals suffer clinical theileriosis after ITM. This may be caused by
using a low dose of TLA (poor estimation of weight), using expired TLA, using a higher
dose of stabilate (incorrect dilution) or immunising immunocompromised or stressed
cattle. In addition, if the vaccine is titrated in cattle, which are inherently less
susceptible to theileriosis, it may cause disease when used to vaccinate more susceptible
cattle. Therefore, highly susceptible cattle should be used for all production stages of the
vaccine. If immunised animals were incubating the disease at the time of immunisation,
clinical disease still results since immunity takes time to develop. In this situation,
molecular and immunological tools differentiating the immunising parasite from field
ones would be very useful. Approximately 3% of immunised cattle react after ITM. To
identify and treat these animals, cattle are monitored during days 1428 after
immunisation. Prolonged monitoring after immunisation is useful as it helps to
identify breakthroughs and allows studies on the effects of immunisation on the
epidemiology of Theileria parva infections. However, for it to be effective, all relevant
field data should be recorded.
• Theileria parva parasites establish a carrier state in immunised cattle. Since many
different strains exist, immunisation can result in the introduction of new strains of
parasites into an area. However, this may not be a major concern where cattle
movement is poorly restricted. The introduced immunising parasite can undergo sexual
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recombination with the resident parasite population and produce new genotypes that
may not be protected against by the vaccine stock.
• By maintaining the vaccine live, contaminating pathogens may also be maintained.
This may cause serious disease problems, particularly with blood vaccines.
• The presence of many immunological types which may not cross-protect. In addition,
due to free cattle movement, these immunological types are not geographically
distributed, indeed a single farm may have more than one immunological type of T.
parva. Fortunately, about 70% homology occurs in cattle-derived parasites.
• The lack of in vitro cross-immunity tests to indicate potential for protection in vivo
necessitates the use of cross-immunity trials. Since cattle are the only experimental
animals that can be used, this becomes an excessively expensive exercise.
• The use of TLA may suppress some parasite subpopulations and thereby reduce the
protective ability of the vaccine (Hove et al 1995). Unfortunately, there is no test to
determine whether this occurs.
• There is inadequate transfer of maternal immunity by immune dams to calves, which
necessitates immunisation of calves.
• ITM may occasionally fail to invoke protective immunity. This may be due to loss of
vaccine infectivity as a result of exposure to heat, poor handling or excessive pH
changes, all of which affect the viability of the immunising parasite. It may also be
caused by the vaccine and challenge parasites having different immunological types or
possibly by overwhelming challenge in times of stress.
Apart from the scientific problems discussed above, ITM has several other limitations. It
requires more expertise than other immunisations for it to be safely delivered. Mistakes
such as poor handling or dilution may result in either no protection or severe disease.
Secondly, the facilities required for diagnosis of haemoparasites to identify reactors,
breakthroughs and other TBDs and haemoparasites are not always available.
Farmers who plan to use ITM must be given information about the advantages and
disadvantages of the method. They must understand that cattle are vaccinated against T.
parva infections only and can possibly suffer, and even die, from other diseases. For field
delivery of ITM as a private good, there are three major key players; namely, the farmer, the
veterinarian and the veterinary department. The needs and expectations of these major key
players should be met.
For farmers to request for ITM, they must be made to appreciate that the method is
reliable, affordable, available, appropriate and sustainable (Irvin 1996). The delivery
mechanism must also be efficient, convenient, socially acceptable and efficacious.
Marketing of farm produce should be liberalised to attract better prices and enable farmers
to cover their production costs, which could include purchasing ITM. Extension linkages
should be improved and participatory rural appraisal meetings held to assist farmers in
making decisions. Farmers should be helped to understand the root cause of their problems
and the potential interventions available. For ITM to be sustainable, the farmers need to see
clear benefits of the technology in terms of improved productivity, increased profits and
reduced risk of ECF.
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For veterinarians, however, delivery of ITM must be safe and effective to help improve
their relationship with farmers and avoid litigation. They must be conversant with the
technology related to ITM. The ITM must be robust and manageable and use equipment
and drugs, which are readily available.
From the point of view of a veterinary department, ECF a notifiable disease is for the
public good. However, immunisation against ECF is for private good with farmers
meeting all associated costs. To allow farmers to get maximum benefits from ITM and
therefore help create demand for it, the veterinary department should introduce a change of
policy to allow adoption of alternative control strategies. The department should be
prepared to change the current tick-control policy, which may mean abandoning the cattle-
cleansing act.
In conclusion, in spite of the problems described above, ITM is currently the only
effective method of immunising cattle against theileriosis. Indeed, it is advantageous to
control theileriosis by an integrated method using a combination of tick control,
chemotherapy and ITM, yet the ITM remains the cheapest component. The benefits of ITM
include provision of effective long-term immunity, reduced reliance on acaricide use, and
reduced risk of losing cattle to theileriosis.
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Livestock Research Institute (LIRI), National Agriculture Research
Organisation (NARO), P.O. Box 24, Entebbe, Uganda
Following a series of successful trials during 199092, which showed that the trivalent East
Coast fever (ECF) vaccine, Muguga cocktail, offered satisfactory protection against locally
occurring strains of Theileria parva, Uganda decided to introduce the vaccine to private
farms. Precautions were taken because the vaccine is live, contains parasite stocks foreign to
Uganda and the target cattle for immunisation are valuable exotic and crossbred dairy
populations. It was decided that the vaccination technology would be introduced in two
phases; first by demonstrations in each district followed by delivery (with partial cost-
recovery arrangement) and recommendations for adjustment in tick control.
Demonstration of ECF vaccination technology
A stepwise procedure has been adopted involving:
1. Training of selected staff from each district where the vaccine is to be used in all aspects
of tick-borne disease control with particular emphasis on immunisation.
2. Sensitisation of interested farmers within the districts. The farmers are provided with all
the basic information about the technology. The contribution required from those
interested in participating is spelt out, the most important being the commitment to
monitor the temperature of each immunised animal daily for 28 days.
3. Selection of farmers according to the following criteria:
• farmers with at least 50% exotic blood in their cattle who practise dairy farming as a
business
• farmers personally involved in the day-to-day management of the farm
• farmers with good management experience in carrying out regular disease control
and record keeping
• farmers with healthy, well-fed animals
• farms with appropriate infrastructure, particularly crushes.
4. Demonstration of the vaccination technology is performed on selected farms belonging
to the selected farmers, situated close together to ease monitoring. Between 40 and 160
cattle are immunised in each district that served to train staff and sensitise farmers. The
demonstration includes:
• standard preparation of the vaccine (thawing, equilibration for 40 minutes and
mixing)
80 FAO/OAU–IBAR/ILRI Workshop
• measuring rectal temperature, while also training farmers to read a thermometer
and record results
• estimating weight, calculating the oxytetracycline (OTC) dose and administering an
intramuscular injection
• collecting blood for serum
• vaccine inoculating and applying ECF identification tags
• collecting data on animals (farm, animal number, breed, age, body weight,
temperature, body condition, OTC dose given).
The details for each district are given in Table 1.
Table 1. ECF immunisation demonstrations in Uganda.
District
Number of
demonstrations
Number of
farms
Number of cattle
immunised
Mukono 2 6 89
Mpigi 2 6 107
Mubende 2 5 141
Mbarara 2 5 173
Masaka 2 2 125
Jinja 1 5 31
Kabarole 1 8 155
Bushenyi 1 7 133
Tororo 1 4 47
Mbale 1 14 33
Kiboga 1 9 146
Hoima 1 8 152
Total 17 79 1332
5. Monitoring for 28 days:
• farmer takes and records daily temperature and monitors the animal’s condition
and reports any abnormal behaviour
• participating veterinary officer (VO) makes about 6 visits to ensure temperatures are
being correctly taken and recorded (around day 4); to reassure farmers when the
temperature starts to rise (around day 10); and, where necessary, to take
blood/lymph node samples and treat animals (between days 14 and 22)
• project staff make 23 visits between days 14 and 35 to reassure and give more
advice on expected reactions and to collect blood for serum on day 35 post-
immunisation
• laboratory staff examines slides and carry out indirect fluorescent antibody tests on
day 0 and 35 serum to determine serological status pre- and post-immunisation
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• data analysis is carried out by project staff using data collected on immunised cattle
and data recorded on temperature, treatment and laboratory charts. This assists in
grading the animals reactions to the vaccine: as non-reactors (NR), mild-reactors
(MiR), moderate-reactors (MoR) or severe-reactors (SR).
The demonstration is usually closely followed-up on these farms to immunise any
animals left out for any reason during the first round.
Delivery at partial cost recovery
Farmers who then wish to continue with immunisation initiated the second phase of the
introduction of ECF vaccination. Particular interest was given to the safety of the exercise in
this phase. The programme is organised such that farmers contribute US$ 5 in advance for
each animal to be vaccinated. This money covers the cost of the drugs used during
immunisation and monitoring, transportation and subsistence for the VO. The project staff
also assist with immunisation, blood collection and monitoring. However, the frequency of
their visits can be reduced as veterinary staff and farmers gain experience. After three or four
joint immunisation exercises, the field staff usually take over the task with minimal
supervision. The immunisations delivered on a partial cost-recovery basis are indicated in
Table 2.
Table 2. ECF immunisation at partial cost-recovery.
District
Number of
programmes
Number of
farms
Number of cattle
immunised
Mubende 3 45 514
Mukono 3 16 158
Total 6 61 672
Tick control following immunisation
The project staff conducted an assessment of the requirements for post-immunisation tick
control on four farms that were practising different forms of intensive tick-control pre-
immunisation. These farmers agreed to reduce tick-control and were shown appropriate
levels of tick infestation: project staff emphasised that tick engorgement should not be
allowed (see Table 3).
From this exercise, it is recommended that a 50% to 60% reduction in tick-control
would be safe. The extent to which the tick control can be reduced, mainly depends on
maintaining adequate control against the appearance of the tick vectors for other tick-borne
diseases. However, selection of appropriate tick control for immunised cattle must take into
account the different farming systems, management practices, types of acaricides in use,
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environment and tick populations present. In addition, success of ECF vaccine delivery also
depends on the level of initiative shown by immunisation staff and the degree of confidence
that the farmers have in this staff.
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Vaccine delivery in Tanzania
M. Majaliwa,1 J. Melewas1 and G. Lynen2
1 Livestock Development, P.O. Box 9152, Dar es Salaam, Tanzania
2 Veterinary Investigation Centre, P.O. Box 1068, Arusha, Tanzania
Introduction
Veterinary services in many African countries are in a state of transition with an increasing
call for the withdrawal of government from continuing to provide services and privatise the
whole sector. In Tanzania, the transfer of certain activities, which in the past were
traditionally carried out by the government, is being discussed among the various
stakeholders; government, producers and private practitioners. This selective privatisation
of veterinary services will involve establishing:
• a legal framework to streamline private and public (government) delivered veterinary
services
• clearly defined obligations, responsibilities and roles for both public veterinary services
and private practices
• regulatory mechanisms for the control and financing of a system where official health
mandates are subcontracted to private veterinarians.
Delivery of East Coast fever (ECF) immunisation
Delivery of ECF immunisation is taking place in the Northern regions (Lakezone, Arusha,
Kilimanjaro and Tanga), Dar es Salaam and Coastal regions, Morogoro region and the
Southern highland regions of Iringa and Mbeya.
Immunisation is targeted at improved dairy cattle and their crosses on both commercial
farms and in the smallholder sector. Farmers are reached through existing extension
networks of dairy projects which have participated in tick-borne disease (TBD) workshops.
The project is now at the stage where farmers request ECF immunisation, which is
administered by selected and trained veterinarians and professionals.
At present, only government veterinarians and paraveterinarians are involved in
delivering ECF immunisation services. The few private practitioners who have previously
participated in the delivery have shifted interest from provision of clinical services to the
more profitable ventures of consultancy and import of pharmaceuticals.
Two full-time veterinarians who receive transport support run the project. Eighteen
veterinary professionals are also delivering ECF immunisation on a part-time basis and are
responsible for organising the delivery themselves. Most of the veterinarians work
individually, although some are organised into teams. Three paraveterinarians have likewise
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been trained in the delivery of ECF immunisation in areas where the government
veterinarians were few or were fully occupied with administrative functions.
The major constraints faced by the delivery veterinarians are:
• transport problems
• fear of immunisation reactors and time spent monitoring although this decreases with
experience
• reluctance in some farming systems to pay for the services
• concerns about adopting a new technology.
Cost recovery
Cost recovery for ECF immunisation has made a promising start in Tanzania, with farmers
paying between US$ 9 and 17 for one immunisation. The delivery package, which includes
vaccine, buparvaquone, oxytetracycline (OTC) and ear tags, is given to the veterinarians
who pay 4000 Tanzanian Shilling (Tsh) (US$ 7) per adult and Tsh 3000 (US$ 5) per calf
into the ECF account.
The veterinarians or the paraprofessionals associated with them collect revenue from
smallholders and pay it into the ECF account. In the Southern highlands, the Heifer In
Trust Project (HIT) helps pay for immunisation in the area. Smallholder farmers cover the
price of the vaccine, while the HIT project pays for the delivery costs (transport and
allowances). Most commercial farms pay directly to regional ECF accounts though there are
marked delays in payment. Experience indicates that immunisation services are more
readily paid for by the smallholder dairy sector, especially in those areas where ECF accounts
for high mortality in the dairy population.
Sustainable cost recovery and privatisation
Sustaining cost-recovery mechanisms for livestock disease control, including ECF
immunisation, in Tanzania depends on several factors:
• the existence of continued demand from the livestock sector for veterinary service
• the ability to meet the demand and provide the quality of service required
• the apparent cost of the service provided in relation to the economic value of the
livestock industry
• the provision of parallel livestock development programmes aimed at increasing
livestock farming returns through increased productivity, marketing etc.
The principle of cost recovery has been practised within the livestock industry in
Tanzania, but with limited success. One of the main problems is the ability and/or
willingness of some livestock owners to pay for the services. To date, most cost-recovery
schemes have been introduced too rapidly and on too large a scale. Schemes that begin with
gradual cost recovery help overcome initial resistance to payment, although, each price
increase may still be faced with reluctance to pay.
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The most important group of livestock owners is the pastoralists that produces most of
beef and an increasing amount of the milk consumed in Tanzania. Pastoralists are, by
definition, dependent on their livestock for survival and are thus prepared to invest in
preventive and curative services to protect their living banks and seek available services.
The project has not started ECF immunisation in the traditional sector due to logistical
problems although requests have already been received.
Second in importance to the pastoralists are the sedentary smallholder farmers with 23
zebu cattle. They practise mixed farming of livestock and crops. Until market conditions
exist where livestock production is competitive with crop production in terms of farm-gate
economic return, this sector is unlikely to pay for a privatised veterinary service.
A relatively small portion of the livestock sector (less than 2%) is that of the smallholder
dairy farms. Currently, this sector is the only group that is economically viable, and
potentially therefore, with the pastoralists, likely to both want and be able to pay for a
privatised veterinary service.
The fourth sector includes the Livestock Multiplication Units and commercial farms.
Although not all of these are interested in ECF immunisation, they may in future provide
the best opportunity for private veterinary practice due to the concentration of the animals.
It will also be essential to involve livestock farmers, through their appropriate
representatives and organisations, to solicit their views on the required type of animal
health service.
Future objective: Improved cost recovery and increased
privatisation
New models for the delivery of veterinary services are being developed for sub-Saharan
Africa, involving an appropriate mix of state (public good sector) and private (private good
sector) veterinary services. Privatisation of livestock services usually takes one of two forms;
delivery by private veterinarians operating independently, or contracting of private
veterinarians by the public sector. Contracting private veterinarians is often used to deliver
services in production systems where the farmer-perceived value of the service is below the
actual cost.
Personnel involved in the delivery of ECF immunisation
In Tanzania, with only a limited number of private veterinarians active in the delivery of
clinical services, government veterinarians could be allowed to practise privately within the
terms and conditions provided by the Tanzanian Veterinary Association (TVA).
Incorporating the traditional livestock sector in ECF immunisation could be achieved
on a contractual basis, or by using government veterinarians based in duty stations along
livestock marketing routes.
Whatever model is adopted, all envisage active participation of paraprofessionals in the
ECF immunisation delivery. This must, however, be under the close supervision of the
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veterinarian authorised to immunise. The use of trained and licensed paraprofessionals
needs to be encouraged, in areas where no professional veterinarian is available.
The success of large-scale ECF delivery critically depends on proper support and
remuneration of paraprofessional staff to ensure their continued motivation and
effectiveness.
To provide support for the private delivery of ECF immunisation, instituting fully
operational and effective Veterinary Investigation Centres (VIC) is also required.
Involvement of commercial agents in the distribution of the ECF immunisation
package, extension of the cold chain, designing awareness campaigns and establishing close
links with practitioners would be desirable.
Cost recovery and revenue collection
Evaluation of the current base-line delivery price will be carried out. Although veterinarians
have been left free to charge their own farm-gate delivery prices, and this is a self-regulating
exercise, a module on business management practices to new recruits needs to be
incorporated into the training programme.
Existing revenue collection methods from ECF immunisation will be strengthened and
a valid accountancy body needs to be established. Clear guidelines are required to ensure a
transparent process.
Revenue collection and an expenditure control mechanism for the ECF fund may, in
future, be controlled by the private sector.
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Immunisation against theileriosis in
Zimbabwe using the Bolvac vaccine
without oxytetracycline
J. Mutugi
Food and Agriculture Organization of the United Nations,
P.O. Box 30750, Lilongwe 3, Malawi
An investigation was undertaken to validate earlier indications that at low concentrations
Theileria parva Boleni sporozoites can be used for immunisation against January Disease in
Zimbabwe without the usual concurrent oxytetracycline treatment. Groups of 50
susceptible Friesian steers from the same source were matched for weight and age and
infected with varying doses of T. parva sporozoites (stabilate 24). This was to determine the
most appropriate vaccine dose to use for immunisation without concurrent
oxytetracycline blockage. After immunisation, cattle were challenged with potentially
lethal inocula of homologous and/or heterologous T. parva sporozoites. The
investigation, carried out during 3 immunisation experiments, spanned a period of 5
months.
Experiment 1
In the first experiment, 30 steers were randomly categorised into 5 groups (AE) of 6
animals each and given 1.0 ml stabilate at dilutions of 1:10, 1:20, 1:30, 1:40 and undiluted,
respectively. Group A animals were also injected concurrently with long-acting
oxytetracycline (20 mg/kg as in standard vaccination method). The immunisation reaction
was then monitored both clinically and parasitologically.
Cattle in groups A, B, C and D experienced no apparent immunisation reactions but
developed significant antibody titres to T. parva in the indirect fluorescent antibody test
(IFAT). Cattle in group E had moderate to severe theilerial reactions and required
treatment. Group E cattle developed very strong serological responses to immunisation.
The 30 steers were subsequently, challenged with a potentially lethal inoculum of the
homologous stabilate together with susceptible controls.
All cattle in groups A, B, C and D responded to the homologous challenge with low-
grade schizont parasitosis and transient febrile reactions. All underwent mild theilerial
reactions and were considered immune. Group E cattle were all solidly immune to the
challenge (no schizonts and no fever). Three months after the initial infection, the cattle
were challenged with heterologous T. parva Avery, a highly virulent theilerial stock. All cattle
were solidly immune to this potentially lethal heterologous challenge.
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Experiment 2
In experiment 2, selected doses of T. parva Boleni, 1:10, 1:20 and 1:30 were investigated
further to determine the most appropriate vaccine dose for use in the field. It was confirmed
that all three dilutions could effect immunity to T. parva with no adverse theilerial reactions,
and without the need for oxytetracycline treatment to obviate the vaccine reaction. Most
vaccination reactions were not apparent although some cattle underwent moderate
reactions in the lower 1:20 dilution of the vaccine.
Experiment 3
Experiment 3 was undertaken to select the optimal immunising dose from 1:20 and 1:30
dilutions. In the previous experiments, both dilutions gave a high degree of safety in cattle
by inducing mainly no apparent theilerial reactions. However, following challenge of
vaccinated cattle with the heterologous T. parva Avery stock, 93.4% and 75% of cattle
inoculated with the 1:20 and the 1:30 doses, respectively, gave solid immunity to this
potentially lethal challenge. The 1:20 dilution was deemed to provide better protection in
cattle than the 1:30 dose, perhaps by inducing a better T. parva vaccine take during the
immunisation. Some of the reactions that were not apparent after immunisation with the
1:30 dilution, were later shown by heterologous challenge to have been in cattle, which were
not, in fact, effectively immunised. This lack of uniform infection in cattle with the 1:30
dose is attributed to the higher sporozoite dilution and poorer vaccine take than with the
1:20 dose.
Following a successful validation trial, the 1:20 dilution of the T. parva Boleni vaccine
(Bolvac) is now recommended for use in the field for T. parva immunisation, with no
oxytetracycline chemoprophylaxis.
The Drug Control Council of Zimbabwe was satisfied with the results of the experiment
and has registered this method of immunisation. Recently, some 13,000 cattle have been
vaccinated this way in the field with no adverse reports. Since cross-protection has been
observed by several workers between the vaccine stock T. parva Boleni and several
representative virulent T. parva stocks from East Africa, it is strongly recommended that the
Bolvac vaccine be explored for possible use in ECF immunisation.
The successful use of the Bolvac vaccine without oxytetracycline treatment for ECF
vaccination, as reported in this study for January Disease, would constitute a quantum leap
in minimising the adverse effects imposed by ECF on livestock production in the region.
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Immunisation against theileriosis in Zimbabwe using the Bolvac vaccine without oxytetracycline
Practical aspects of regional East Coast
fever vaccine delivery
J. de Castro and M. Leneman
Food and Agriculture Organization of the United Nations (FAO),
Via delle terme di Caracalla, 00100 Rome, Italy
Background
For many years, the Food and Agriculture Organization of the United Nations (FAO) has
advocated a regional approach to the control of tick and tick-borne diseases (TBD) in
central, eastern and southern Africa with emphasis on the production and effective delivery
of TBD vaccines, East Coast fever (ECF) vaccines in particular. The concept is based on the
implementation of a regional programme for the integrated control of ticks and TBD. The
programme, known as A Co-ordinated Multi-Donor Programme for Integrated Tick and
Tick-borne Disease Control in Eastern, Central and Southern Africa, was developed in
1990. It was subsequently, endorsed in September 1991 by the FAO/Danish International
Development Agency (DANIDA) Review Meeting, which recommended that: the
proposed Regional Project (RAF/88/017, East Coast Fever Vaccine Production, Quality
Control and Immunisation) should be re-designed as a pre-investment pilot vaccine
production and delivery project.
The Organization of African Unity (OAU)/FAO/International Laboratory for Research
on Animal Diseases (ILRAD, now International Livestock Research Institute (ILRI)) meeting
held at the same time also recommended that: a pre-investment (implementation) phase be
initiated for TBD control by immunisation based on quality-controlled vaccines, produced on
a commercial cost-recovery basis and delivered in a sustainable manner.
A regional programme was then developed. Its structure is presented below.
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The broad objectives of the programme were to establish an effective and a sustainable
vaccine delivery system in the countries within an integrated national tick and TBD control
programme, to train field veterinarians, laboratory staff and farmers in the delivery and
monitoring of the use of vaccines and associated tick control methods and to develop a
regional database on integrated tick and TBD control. The goal in the different countries
was the creation of an effective, sustainable and environmentally friendly integrated tick
and TBD control programme.
However, the donors that initially showed interest in the initiative (Belgium, Denmark
and The Netherlands) disagreed with some of its components. To date, the programme has
not been fully implemented, despite a dedicated vaccine production facility in Malawi, built
and officially opened in 1994. At present, the programme is in a transitional stage
developing a new structure and functions.
This paper emphasises the importance of maintaining a regional approach to TBD
vaccine delivery. For a thorough analysis of vaccine delivery consult McDermott (1996);
Musisi (this proceedings) details aspects of vaccine production.
Vaccine delivery: general considerations
The driving force for successful vaccine delivery is the existence of a demand for the vaccine.
If the demand is there, cost recovery can be expected. An important aspect is that the
governments are committed to the programme and help create a more enabling
environment by adopting the immunisation methodology in their tick and TBD control
policies.
The immunisation package to be delivered contains a live parasite and, in most cases, a
long-acting tetracycline. Its delivery consists of a long and vulnerable chain of services and
follow-ups. For the package to function successfully, it has to be as simple and robust as
possible and with a high degree of flexibility. Most importantly, the delivery of the product
has to be advantageous to all parties involved.
McDermott (1996) described different levels of vaccine delivery. These are the regional,
national, provincial and farm levels. The comparative benefits determine who are the key
players within the different levels. If the key players are made stakeholders of the process, it
will greatly enhance the sustainability of the system, since their own success will then
depend on the success of the delivery system as a whole. Linkages between the key players,
especially with the farmers, further improve the functioning of the delivery chain
(McDermott 1996).
Vaccine delivery: practical aspects
Even if the general conditions are met, there will still be several practical issues to be
addressed before a vaccine delivery system has been established. The most important are
mentioned below.
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Vaccine delivery starts at the vaccine production site. A central production of ECF
vaccines, apart from the obvious economic advantages, offers the best opportunity of having
a concentration of technical knowledge and skills. This is beneficial, not only for the
production and control aspects of the vaccine, but also to follow up the use of the vaccines in
the field and to give assistance to the training of the users as part of its support services.
It leaves the various governments the chance to mainly deal with public goods such as
the road infrastructure, support services, banking, and to set the import and export
requirements. The exporting country of the ECF vaccine (i.e. Malawi) must meet the import
requirements of the recipient countries. The product will then have to be registered under
the relevant legislation in both the exporting and importing countries. The country
exporting the vaccine must also be able to rely on a banking system that can receive and pay
foreign currencies and carry out international transfers.
The governments of the vaccine-importing countries should provide a capacity for
storing liquid nitrogen and an infrastructure, either existing or newly created, to distribute
it. They too must have a reliable banking system and an immediate cash flow. Good
communications between the exporting and importing country are, of course, of vital
importance.
Regarding transportation, there is the need to obtain the necessary insurance,
acceptable containers and to secure delivery and receipts of the consignments in time and
under suitable conditions of conservation.
Finally, we should be aware that the delivery of any vaccine, be it for animal or human
health, is a complex operation. In the case of the present ECF vaccine, the situation is
further complicated by the need for liquid nitrogen, the vaccines high cost and the
possibility of post-immunisation reactions that require strict and careful monitoring. It is,
therefore, crucial that the regional approach to ECF vaccine delivery is maintained to share
regional facilities, experience and knowledge and, in this way, make vaccine delivery a viable
option.
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Commercialisation of vaccine delivery
N. McHardy
National Veterinary Research Institute (NVRI), Muguga,
P.O. Box 32, Kikuyu, Kenya
Summary
I gave a paper on the commercialisation of the Infection and Treatment System of
immunisation against ECF at a meeting in Malawi in 1994. It examined the likely attitudes
of the pharmaceutical industry to the product and the demands they might make of its
manufacturer, and it suggested the course that negotiations towards commercialisation
might take. In Kenya, KARI has decided to pursue commercialisation of the product,
ECFiM, and the process is conforming closely to those predictions. I presented the Malawi
paper as a former Research, Development and Marketing Manager in a major
pharmaceutical company, who had recently joined the ECFiM team at Muguga as a
Technical Co-operation Officer (TCO) . This time my paper is in the form of a memo that I
might now write to my Commercial Director if I was still somewhere in the industry. I hope
that it will raise some new points for discussion.
Subject: New product opportunity–Vaccine against
East Coast fever
Background
About five years ago I ran an appraisal of an emerging technology to develop a vaccine
against East Coast fever (ECF) of cattle in eastern Africa that the technology had
demonstrated effective immunisation but it did not then constitute a marketable product.
My opinion now is that a saleable product has been developed and I recommend that we
should seek marketing rights to it.
The product
The product is a cryopreserved live suspension of the infective stage of the organism which
causes ECF, harvested from the vector tick. It is injected into cattle together with long-acting
tetracycline which blocks the development of the infection. Vaccinated cattle develop a
limited disease episode from which they recover and become immune to ECF for life. The
system is unorthodox, but it is effective. Limited field trials have demonstrated acceptability
among veterinarians and farmers. But:
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• in about 5% of cattle the vaccine is not blocked by the tetracycline. These animals must
be treated with a curative drug, but they do then become immune
• the vaccine does not confer 100% protection against ECF, (about 95% is claimed) and
gives no protection against the closely related condition Corridor Disease which is
common in areas encroached by buffalo
• vaccinated cattle become carriers of ECF and are therefore a potential risk to
unvaccinated cattle, though this is said not to be a significant problem under field
conditions
• the product must be stored and transported in liquid nitrogen to preserve its viability.
The veterinarian thaws and dilutes it, on farm, before injection while, we would be
required to manufacture and supply the diluent
• field trials will not be completed until the end of 1997; while the development team is
optimistic that these will be successful, there is a risk that the areas in which the product
can be sold will be restricted
• the product has been developed in government laboratories, supported by aid funding.
Manufacture is complex, requiring specialised facilities and expertise not available
within the company. It is proposed, therefore, that manufacture should be contracted
to the government laboratory. The company would have full access to the
manufacturing process and product would be sold to us at cost plus a retained margin,
perhaps 25%. Technical support to the product would be shared with the development
team.
Analysis: With the exception of the possible restriction of market size, all of the difficulties
are manageable. The opportunity is thus worth pursuing.
The market
ECF is a significant problem in eight African countries. The principal market would be in
pure- and crossbred dairy cattle, which are very susceptible to ECF. About 60% of the
market is in Kenya where a dairy cow is worth between US$ 700 and US$ 1000. At least
100,000 cattle die of ECF in Kenya each year. Veterinarians would deliver the vaccine.
The dairying areas are fairly well covered by private practitioners, whose numbers are
increasing.
Various appraisals of market size have been made, mostly by research workers, who tend
to be optimistic. For Kenya alone, they suggest 100,000 doses in year 1, with a potential of
rising to 500,000 doses in year 5. Commercial launch in Kenya should be achievable early in
1998, with test marketing in 1997.
Analysis: We should restrict our interest in the first instance to Kenya with a sales forecast
of 20,000 doses in year 1, 100,000 in year 5 ( low ), and 50,000 in year 1, 250,000 in year 5 (
high ).
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SWOT (Strengths, Weaknesses, Opportunities and Threats)
Strengths
Effective 95% protection is claimed
Single dose Life-long protection
Safe If used according to directions
Novel First product in market sector
Acceptance Product and price acceptable to veterinarians and
farmers
Product fit Fits existing range and capabilities
Weaknesses
Liquid nitrogen cold chain Essential to maintain viability and efficacy
Safety Dependent on strict veterinary compliance
Preparation Need to prepare injection on farm
Spectrum Not effective against Corridor Disease
Market size Relatively small, possibly restricted
Withhold Use of tetracycline requires 3-day milk withhold
Two-tier market Veterinarian and farmer must be accessed
Opportunities
Increased market share Large market sector of which we have a modest share
Customer contact Increased tetracycline sales, and acaricides to small
farmers
Leverage Increased access to veterinarians and farmers
Image Enhances image as an innovative company
Threats
Product conflict Potential negative impact on acaricide sales to large farms
Product quality Needs close monitoring of production in government
facility
Veterinary input Veterinarians will need technical and promotional
support
Product liability Responsibilities must be clarified
Bogus products Product appearance, but not efficacy, easy to copy
Competing products p67 subunit vaccine, at least 5 years from
marketpossiblyover-hyped to attract funding
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Analysis: ECFiM will need strong technical and marketing support. Monthly reports are
essential. Agreement with Kenya Government must be watertight.
Positioning and promotion
ECFiM is a high-profile product. Veterinarian and farmer awareness needs to be
streamlined to obviate some out-dated perceptions. Promotional literature for farmers and
veterinarians, and a veterinarian training manual, have been produced and are already
available. The name ECFiM is established and should be incorporated in the companys
product name. The existing pack is 20 doses but a smaller pack could be specified.
ECFiM will be sold to the veterinarian (primary market) who must also be helped to
promote it to the farmer (the end user). Two positioning statements are, therefore, required.
The author suggests the key word opportunity for the veterinarian, to signify the
opportunity to make additional money, based on these features and benefits:
Feature Benefit
Radically new product Opportunity to expand practice
Effective protection against ECF Farmer will want to buy
Inexpensive compared with
acaricide or drugs
Price acceptable to farmers
Supply from local depots Product readily available
Easily applied Opportunity for new practice recruits
Large potential market Major profit opportunity
For farmers, the author suggests the key word security. The features and benefits focus
on the farmers fear of ECF and the profitability of his/her business. If the farmer uses
ECFiM, he/she will increase his/her security and income.
Feature Benefit
Prevents ECF Security against cattle dying, lower veterinary
bills
Cost effective More milk, more calves for sale, more money
Reduced tick control Saves money, saves time
Protects exotic breeds of cattle Security of investment in improved breeds
These promotional messages will be continually delivered through farmer and
veterinarian meetings, at which our local company will provide the experts. The KARI team
will be involved in promotion, and in veterinary training and technical support. The
company should also produce a promotional video.
Analysis: ECFiM should be positioned as a novel element in an integrated strategy for the
control of ECF, targeting both veterinarians and farmers.
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Financial
ECFiM should initially be managed as a profit-neutral product. Financial benefit will come
from increased sales of other products which are used in the ECFiM system, particularly
tetracycline and through leverage to the rest of the companys range from increased access to
farmers and veterinarians.
For the time being, the greatest uncertainty remains the effect that ECFiM will have on
acaricide sales. The pessimistic view is that they will fall significantly, because a key element
in the ECFiM promotion is reduced tick control using acaricide. However, ECFiM will
make small farmers more aware of strategic tick control that should make it possible at least
to maintain acaricide sales in this sector. Acaricide sales will fall in the medium- and large-
farm sector. However, penetration of ECFiM onto large farms will probably lag behind that
on small farms because larger farmers will be reluctant to make radical changes to their
strategies until they are convinced that ECFiM works.
The authors prediction, therefore, is that profit from products other than ECFiM in
the smallholder sector will show a sustained rise in direct relation to sales of ECFiM. With
the exception of acaricides, the same will happen in the large farm sector. Acaricide sales
here will remain little changed while ECFiM sales are low, but they will fall significantly as
ECFiM sales to the sector increase. Losses will then be off-set by increased profits from other
products. Competitors acaricide sales will, of course, show an uncompensated fall and
could lead to an aggressive reaction. The financial appraisal is shown in the appended table.
Purchase price of ECFiM from KARI is likely to be US$ 1.52.0 per dose. Manufacture
and packaging of diluent will cost US$ 1.0/20-dose vial, i.e. US$ 0.05 per dose. Assumed
cost of ECFiM plus diluent, therefore, is US$ 2.0/dose. The author proposes a retained
margin of 33% of selling price. Selling price to the veterinarian, therefore, is about US$
3.0/dose. Cost to the farmer essentially depends on the margin that the veterinarian takes to
cover his inputs and professional fee. We must encourage the veterinarian to go for high
volume sales rather than high profit margin.
Fixed costs total US$ 419,000 to year 5. Pre-launch costs include a sales forecast, test
marketing in Coast Province, establishment of a distribution system, diluent manufacture,
staff training and product promotion. Promotion will be through veterinarian and farmer
meetings, technical support and training for veterinarians, promotional literature for
veterinarians and farmers, advertisements and features in the media, plus, of course, a
launch seminar and party.
Analysis: ECFiM should be initially managed as profit-neutral over five years,
assumingactual sales mid-way between high and low forecast. Financial benefit will come
from increased peripheral business. Product failure would have an adverse effect on all
other products, and company image. ECFiM, therefore, must be managed as a high risk
product. However, the greater risk is that a competitor acquires ECFiM and makes a success
of it!
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ECFiM  Summary of costs and revenue (US$ 000, 1997 constant)
Year (relative to launch) 1 1 2 3 4 5 6 10
Fixed costs
Pre-launch work/test market 50 0 0 0 0 0 0
Distribution 40 30 15 20 20 20 100
Diluent manufacture 10 3 5 7 7 7 35
Technical support/training 20 30 15 15 15 15 75
Promotion/publicity 20 50 25 10 10 10 40
Total fixed costs 140 113 60 52 52 52 250
Low sales forecast
Cost of product 0 (40) (80) (120) (160) (200) (1000)
Fixed costs (140) (113) (60) (52) (52) (52) (250)
Revenue 0 60 120 180 240 300 1,500
Balance (annual) (140) (93) (20) 8 28 48 250
Balance (cumulative) (140) (233) (253) (245) (217) (169) 81
Interest on debt @ 20% 0 (28) (47) (51) (49) (43) (34)
Balance, ECFiM A/c. (140) (261) (300) (296) (266) (212) 47
Profit, other products 0 10 20 30 40 50 250
Net balance (low sales) (140) (251) (280) (266) (226) (162) 297
High sales forecast
Cost of product 0 (100) (200) (300) (400) (500) (2500)
Fixed costs (140) (113) (60) (52) (52) (52) (250)
Revenue 0 150 300 450 600 750 3750
Balance (annual) (140) (63) 40 92 148 198 1000
Balance (cumulative) (140) (203) (163) (71) 77 275 1275
Interest on debt @ 20% 0 (28) (41) (33) (14) 0 0
Balance, ECFiM A/c. (140) (231) (204) (104) 63 275 1275
Profit, other products 0 25 50 50 50 50 250
Net balance (high sales) (140) (206) (154) (54) 113 325 1525
Financial summary
Scenario
NPV
(US$)
IRR
(%)
Payback period
(years)
Low sales forecast 140,000 2.7 8
High sales forecast 592,000 36.8 3.3
NPV = net present value; IRR = internal rate of return.
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Summary of principal points
• The industry can handle ECFiM and they are aware of most of the difficulties.
• Distribution, support to veterinarians and promotion to farmers are manageable.
• The commercial partner will not necessarily seek to make a profit from ECFiM itself.
• Increased sales of other products and market capture from competitors are key
objectives.
• The biggest uncertainty in the industry is the effect of ECFiM on acaricide sales.
• The commercial partner will have a strong incentive to maximise ECFiM sales.
• Their sales forecasts for ECFiM will be conservative.
• ECFiM will alter the tick-borne disease (TBD) product market radically, whoever
secures marketing rights to it.
• The potential effects of a competitor acquiring ECFiM are widely recognised, and
feared.
• An integrated strategy and product range for ticks and TBDs is attractive to industry.
• If ECFiM fails, the whole business of its marketing company will suffer.
• Industry will demand a clear and robust agreement with the manufacturers of ECFiM.
• KARIs negotiating position is fairly strong  the industry wants ECFiM.
But
• Some companies genuinely want ECFiM, others merely want to assess the threat it
poses.
• The clever bit will be to distinguish between the two.
Because
• Selection of the right commercial partner is critically important to the success of
ECFiM.
Note: The views expressed in this paper are my own. It is unlikely that they are shared by
either KARI or ODA. I hope, however, that a Marketing Manager in the pharmaceutical
industry would be comfortable with most of what I have suggested.
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Summary of discussion: Vaccine delivery
Facilitator: N. McHardy
Rapporteurs: L. Lynen and T. Dolan
The papers presented in this session highlighted the practical aspects of vaccine delivery in
the field, the potential problems, the approaches taken to introduce the technology to new
areas and the issues likely to be considered in commercialisation of ECF vaccine delivery.
Transport, thawing and diluting of vaccine
The issues of transport, thawing and diluting constitute important components of an
efficient vaccine delivery system in the field. Participants pointed out that it is essential to
avoid contact between water or moisture from outside the vial/container and the stabilate
during thawing, dilution and dispensing. It was noted that when straws are used they could
not be held in water/melting ice because they are open at one end. The Muguga cocktail
stabilate, prepared at the International Livestock Research Institute (ILRI), is stored in
straws and requires a different handling procedure for those accustomed to vaccine
cryopreserved in tubes. Likewise, the need to improve the diluent was emphasised. The
diluent should have good buffering capacity and contain a pH indicator. It should also be
dispensed in capped bottles and not require to be stored frozen.
Selection of cattle for immunisation
When immunising calves of 12 months of age, care must be taken to assess their health and
nutritional status. Calves with umbilical abscesses were reported to show a serious flare up
of the abscess following immunisation. It is therefore important to provide clear advice to
the farmers about management of calves so that immunisation is not compromised.
Seropositive calves can, however, be immunised without problems.
On farms where strict tick control is maintained after immunisation, re-vaccination may
be required after 36 months. Participants agreed that situations that allow immunisation of
larger numbers of animals at the same time, e.g. multiplication centres, were the ideal places
to apply immunisation. The panel also discussed potential complications during
immunisation involving levamisole. Levamisole has been reported to release the infection
in situations where it was used during the week before or after immunisation using
buparvaquone, thus causing a high reactor rate. There was, however, no recorded
interaction when levamisole was used at the time as treatment during the development of
buparvaquone. No such problem has been reported when using oxytetracycline for
immunisation. More work may be required on this possible enhancing effect of levamisole
and its potential influence on ECF treatment.
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Vaccine inoculation and follow-up
Participants sought clarity which tetracycline should be used. They agreed that a particular
oxytetracycline product should be recommended for use in the vaccine package. They also
agreed that the efficacy of other products must be demonstrated before they can be
introduced. The site of stabilate inoculation, either in the mid-neck or over the prescapular
lymph node, was discussed. Some argued that since the nature of the tissues at the
prescapular site varies between different breeds and types, they prefer the mid-neck area.
Vaccination against other diseases should be avoided during ECF immunisation, while
other TBD vaccines should not be applied during the 35 days following ECF immunisation.
The impact of using more than one TBD vaccine in an integrated tick control was discussed
at a Zimbabwe Veterinary Association meeting earlier and access to the outcome of the
consultation would be helpful to all programmes in the region.
Delivery and price
Reduced delivery costs help sustain immunisation services. Such services are also
economically sound when organised in the form of campaigns, routine vaccination rounds
or immunisation to be performed in clusters of farms. Similarly, the use of promotional
literature in helping farmers to take on ECF immunisation would certainly assist.
Participants pointed out that the preparation of standard promotional literature was agreed
at a meeting last year but had not been taken any further. Most countries have developed
such literature, and it was felt that it would be helpful to exchange this information. Data
recording systems should be standardised to provide useful feedback to departments of
veterinary services (and commercial companies) to determine the uptake and impact of
immunisation. This will also generate quantitative data for use in promoting and
encouraging the use of immunisation.
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Socio-economics and
impact assessment
ECF immunisation in the smallholder
sector: Points to consider in funding and
sustainability
B. van Munster1 and L. Lynen2
1 Tanga Smallholder Dairy Development Project, P.O. Box 1474, Tanga, Tanzania
2 Veterinary Investigation Centre, P.O. Box 1068, Arusha, Tanzania
Assumptions
A number of conditions are crucial for the success of immunisation against East Coast fever
(ECF) in smallholder farms. Many of these issues have been addressed in other
presentations. This paper concentrates on the final link of the delivery chain, from the
regional store to the animal, which involves veterinary staff, paraprofessionals and village
Animal Health Workers (AHW), farmers and their organisations. It is assumed that:
• the available product, the infection and treatment method (ITM) using the trivalent
vaccine, will effectively immunise cattle against ECF if used according to the
manufacturers recommendations
• the delivery agent is able to answer basic questions from clients, for example, what tick
control regime to follow after immunisation, how long the protective effect of the
immunisation lasts under zero-grazing
• the delivery system guarantees the safe delivery of the vaccine up to regional level, where
a storage facility is provided
• the store-gate price at regional level in Tanzanian shillings (Tsh) is 3000 (US$ 5.0) for
young stock and Tsh 4000 (US$ 6.7) for adult cattle. The store-gate price includes the
cost of the stabilate, oxytetracycline, buparvaquone treatment for an average 3.9%
immunisation reactors, compensation for 0.03% deaths due to anaphylactic shock,
import duties, transport, storage and cooling facilities
• the store-gate price is paid to the national delivery system, be it a private company, a non-
governmental organisation (NGO) or a special revolving fund, which will ensure a
continued supply of the items and facilities required for immunisation up to regional level.
Cost recovery
The system will only be sustainable if it is fully financed and if all stakeholders perceive that
benefits (including financial ones) are derived from their involvement in the immunisation
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activities. Otherwise, money leakage along the chain will sooner or later disrupt the system.
The issue is not so much that full cost recovery is necessary to sustain the service, but more,
who will pay the bill, and how to return the recovered money to the system. Farmers,
government and donors (bilateral aid programmes, NGOs) should between them pay for
the vaccine.
What is the cost?
The price for immunisation at the farm level will be determined by the following
components:1
• store-gate price at regional level
• payment of paraprofessional or AHW responsible for pre-immunisation extension visit
and organisation of a sufficient number of animals to be immunised per visit (extension
materials, transport, wages, allowances)
• payment of veterinary professional to carry out the immunisation (equipment, e.g.
liquid nitrogen flask to carry stabilate, syringes, needles, slides, transport,
remuneration)
• payment of paraprofessional or AHW responsible for post-immunisation monitoring
(transport, wages, allowances)
• payment of veterinary professional to treat immunisation reactors (equipment,
transport, remuneration).
How can the cost be reduced?
The price will be substantially lower if the actual immunisation and the treatment of
reactors can be handled by paraprofessionals who, in many areas, are already responsible for
diagnosis and treatment of ECF cases. This would probably help improve the sustainability
of the system, especially in areas with no veterinary officer nearby. Because of the nature of
the ITM, often perceived as complicated, and legal issues, this option has not yet been
incorporated into the current policy.
Who will pay the cost?
Obviously, immunisation principally benefits the farmer, whose cattle run less risk of
succumbing to ECF and who may save money otherwise spent on tick control and ECF
treatments. Experience in Tanzania and elsewhere shows that urban farmers (who often
have several cash earning activities) are willing and able to pay for immunisation, as long as
they believe it reduces the ECF risk. Urban farmers pay up to Tsh 10,000 (US$ 16.70) per
immunisation.
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1. Thefarmingcommunitybearsthrisktolosea imalsasaconsequenceoftheimmu isation(0.3%inTanz nia,
equivalenttoUS$0.501.50perimmunisation).Itisahiddencostanot ncludedintheimmunisationprice.
A different situation exists in the rural and peri-urban areas, where the profit margins in a
dairy enterprise are smaller because of a lower milk price and higher input prices. Even if the
farmer believes in the profitability of the immunisation, shortage of cash makes it necessary to
set other priorities. In addition, the cost of immunisation may be higher in these areas, as the
veterinary professional will encounter higher transport and, possibly, accommodation costs.
The introduction of one standard price for immunisation would make the urban farmer
subsidise his/her non-urban colleagues, which might not be appreciated by the urban
farmers. Immunisation in non-urban areas could otherwise be subsidised (i.e. part of the
cost donated) by aid programmes, NGOs or the government. This would help accom-
modate equity issues in the immunisation policy.
The farmers could pay either direct, or, where these exist, make their contributions
through milk marketing organisations. These organisations would probably help facilitate
collection of payments.
In Tanzania, payment for immunisation in two regions is through a Heifer In Trust
(HIT) programme. The farmers pay a fee before they receive their heifer, which includes the
regional store-gate price of the immunisation ingredients (Tsh 30004000). The
programme covers the balance. HIT programmes could be encouraged to play such a role in
immunisation activities in other areas as well. The farmers contribution to the actual cost of
immunisation could then be gradually increased.
Hidden payment of cost through quasi-privatisation
In Tanzania, immunisation is carried out by government employees. The few existing
private veterinarians either have not engaged in immunisation activities or otherwise had
started and then stopped. The official policy aims at shifting animal health services that are
for the private good (which would include ECF immunisation) to the private sector.
Private professionals will only step into the vacuum created by a withdrawing government
service if their activities are likely to be profitable.
In the meantime, government employees provide services in return for personal
payment which increases their low income. Relying on government facilities and the
privileges of their position also gives them an advantage over their private competitors.
Government employees fulfil part of the demand for animal health services by making it
more difficult for private veterinarians to reach the minimum level of business required to
earn a reasonable income. Thus, this quasi-privatisation hinders the growth of strong
private sector service providers and undermines the sustainability of the system.
Private practitioners could be stimulated to take part in the delivery of immunisation, if
donors or government covered part of their costs. The subsidy could be an estimated equivalent
of the amount the government puts into its employees private activities (transport, equipment,
salary).
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Do benefits warrant the cost?
It is essential that all stakeholders perceive their involvement in the immunisation delivery
system as beneficial. For professional staff the benefits will be primarily financial, although
successful immunisations may increase farmers confidence in the practitioner. Farmers will
appreciate reduced ECF risk and reduced expenditure on tick control and treatment of ECF
cases.
The success of ECF immunisation will essentially depend on a clearly demonstrated
efficacy. This again requires an effective means of advertising. Long-term monitoring
(exceeding the 40 days after immunisation) must therefore, be carried out either by the
government, special task forces or the manufacturer, while financial assistance can be
obtained from donor agencies.
If farmers see the benefits of immunisation, they will pay for the services. A follow-up of
a small group of immunised animals in Tanzania, revealed that the ECF morbidity in
immunised animals was twice as high as that in non-immunised animals on the same farms.
One may argue that this is due to poor diagnosis. Immunised animals, become piroplasm
carriers, and if they fall ill for any reason since laboratory diagnosis is often restricted to
blood smears, they may, wrongly be diagnosed as suffering from ECF. Nevertheless, in most
cases the animals had been treated with costly buparvaquone, at the expense of the farmer.
Misdiagnosis or not, these farmers will no longer believe in the beneficial effects of
immunisation.
Training professionals, whether they are involved in immunisation or not and
increasing the knowledge of farmers, is therefore, vital to prevent the situation described
above. Such training is likely be funded by the donor community.
Animal health delivery system
The ITM has often been linked to the privatisation of veterinary services. Indeed, the
delivery of ECF immunisation to smallholder farms can only be consolidated if a cost-
effective and sustainable delivery system for animal health services is established.
A key feature in planning the delivery system will be to co-ordinate tick-borne disease
control with the provision of other services to livestock farmers (Walse et al 1991, cited in
McDermott 1996). Immunisation activities may act as a catalyst in further developing a
system for provision of services and disease monitoring.
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Demand and supply for a vaccine
Demand refers to the amount of vaccine that buyers are willing and able to purchase at a
particular moment at each possible price. Demand is more than a desire to purchase; it is the
ability to purchase as well. Supply describes the amount of a vaccine that sellers (producers)
are willing and able to sell at a particular moment at each possible price.
Demand and supply relationship
The relationship between demand and supply for a vaccine can be explained by Figure 1.
At a high price, P1, the buyers will demand a lower quantity, Q1, but the suppliers will be
willing to supply a higher quantity, Q2. Similarly, at a lower price, P2, the suppliers will be
willing to sell a lower quantity, Q3, but the buyers will demand a higher quantity, Q4. When
the quantity supplied is equal to the quantity demanded, an equilibrium exists (Qe) and the
price that the buyers will be willing to pay will just equal the price at which the sellers will be
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Figure 1. Relationship between supply and demand for a vaccine.
willing to sell (Pe). The price of a vaccine will, therefore, affect the amount that buyers are
willing and able to buy, and the amount that sellers will be willing to offer for sale.
Other determinants of demand and supply for a vaccine
In addition to the price of the vaccine, there are other factors that will affect the demand for
or the supply of a vaccine. These factors, which may shift the demand curve up (increase
demand) or down (decrease demand), include:
• the price (cost) of a substitute (another vaccine or an alternative control option); the
higher the price of the substitute, the higher the demand for the vaccine and vice versa
• quality of the vaccine (efficacy, safety, packaging); the higher the quality, the higher the
demand for the vaccine,
• economic cost (impact) of the disease constraint; the higher it is, the higher the demand
for the vaccine,
• production system; the more commercially oriented, the higher the demand for the
vaccine,
• transaction costs; the higher the transaction costs (of access or delivery), the lower the
demand for the vaccine,
• number of boosters per animal vaccinated; the greater the number, the higher the cost
per vaccinated animal and the lower the demand.
The supply of a private good (whose benefits accrue to individuals rather than to the
public) will depend very much upon demand, as well as on the cost of production, which
may shift the supply curve up (decrease supply) or down (increase supply). For a public good
(whose benefits accrue to the public rather than to individuals), supply (usually by
government) will depend upon the social benefits to be gained rather than on demand. A
vaccine for theileriosis is more of a private than a public good.
Estimating potential demand
Method
An attempt has been made to estimate the potential demand for the infection and
treatment method (ITM) of immunisation against theileriosis. The method is based upon
estimated numbers of cattle at risk from theileriosis in each of the 11 countries
(determined by Geographic Information System (GIS) from the distribution of cattle and
Theileria parva in each country), and assumed rates of adoption for the vaccine. In this
analysis, national cattle populations were assumed to be homogeneous with respect to the
effects of theileriosis. More detailed analysis of the potential demand for vaccine in
selected countries (Kenya, Tanzania, Uganda and Zimbabwe) is currently under way at the
International Livestock Research Institute (ILRI) in which an attempt is made to
differentiate cattle populations by breed and management system. Using a computer-based
spreadsheet model and the Food and Agriculture Organization of the United Nations
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(FAO) Production Yearbook for national cattle populations for 1994, estimates of the
potential demand for the ITM were obtained by country and for the whole affected region
(Table 1).
Preliminary results
Estimates of the annual potential demand for an ITM vaccine by country and for the
whole region are given in Table 1. A basic assumption was made that 80% of the calf
population (less than one year) and 10% of the cattle population above one year are at the
risk of theileriosis and would be targets for immunisation. Out of an estimated cattle
population of nearly 65 million head in 1994, 38% are estimated to have been at risk of
theileriosis, with 11% (about 7 million head) being the target number for immunisation
by ITM.
Table 1. Country and regional estimates of the annual potential demand for a theileriosis
vaccine.
Country
Cattle
population
1994 (x103)
Population at risk Target population for ITM*
No. (x103) Total (%) No. (x103) Total (%)
Burundi 420 420 100 120 29
Kenya 12500 8263 66 2407 19
Malawi 980 738 75 210 21
Mozambique 1270 622 49 177 14
Rwanda 454 447 98 127 28
Sudan 21750 413 2 118 0.5
Tanzania 13376 4073 30 1160 9
Uganda 5150 4267 83 1011 20
Zaire 1475 255 17 73 5
Zambia 3300 2333 71 664 20
Zimbabwe 4300 3094 72 881 20
Total 64975 24925 38 6948 11
ITM = Infection and treatment method.
Table 2 provides the estimate of the annual potential demnad for an ITM vaccine for the
whole region assuming different rates of adoption. In the early years of vaccine availability, it
can be assumed that the adoption rate would be low, but would steadily increase over time as
livestock keepers become more aware of the availability of the vaccine and the benefits (if
any) from its application.
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Table 2. Regional estimates of the annual
potential demnad for a theileriosis vaccine at
different rates of adoption.
Calves for ITM
(%)
Cattle 1 year
for ITM
(%)
Total cattle for
ITM
(million head)
10 1 0.8
20 2 1.6
30 3 2.4
40 4 3.2
50 5 4.0
60 6 4.8
70 7 5.6
80 8 6.4
90 9 7.3
90 10 7.5
ITM = Infection and treatment method
Future research needs
The more detailed study mentioned above needs to be continued in order to cover a
representative number of countries in the theileriosis region. The results would be used to
help extrapolate the potential demand for the vaccine for the whole region. Country case
studies of past ITM immunisation sites should be undertaken to establish effective demand
and supply pattern for the vaccine. Such studies will also yield valuable data on the impact of
the ITM at the farm level.
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Assessing the impact of ECF vaccination:
Implications of structural adjustment
A. McLeod
Kenya Agricultural Research Institute (KARI),
P.O. Box 30465, Nairobi, Kenya
Introduction
It is a daunting task to write about impact assessment given two detailed previous research
papers on the subject by Perry (1996) and Mukhebi (1996) at the Tick-borne Diseases
Meeting in Harare, Zimbabwe, and a number of relevant points dealt with by McDermott
(1996), and during working group discussions.
Among the issues raised at the Harare meeting were: the apparent impact assessment;
the importance of a client or stakeholder focus; the need for careful selection of impact
indicators; the variation in impact with production system and disease risk; the need for and
lack of relevant data; the need to prepare for impact assessment in planning and training.
Looking at this comprehensive list, at first it seemed as if there would be nothing new to
discuss. However, the author believes, it may be possible to add something to the ongoing
debate by developing a theme around what McDermott (1996) referred to as the rapid
changes in animal health services delivery. The issue was widely debated in the recent e-mail
conference on principles for rational delivery of public and private veterinary services
organised by the Food and Agriculture Organization of the United Nations (FAO).
Contributors to this conference have published papers on animal health services delivery;
papers presented by policy makers at the Kenya Agricultural Research Institute (KARI)
workshop on structural adjustment in 1996, and at the Intermediate Technology
Development Group (ITDG) veterinarians workshop discussed the progress of structural
adjustment in Kenya.
In this paper I intend to briefly highlight restructuring in the animal health sector and
examine some of the implications of the process on impact assessment of East Coast fever
(ECF) vaccination. Apparent short-term measures have also been suggested to reflect the
present transitional state. Hopefully the paper will stimulate lively discussion during
working group sessions and encourage the formulation of relevant and topical proposals for
action.
Effects of restructuring
The majority of sub-Saharan Africa is undergoing some form of structural adjustment that
reflects on the form and function of animal health delivery. It would, however, be naive to
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suggest that all veterinary services in sub-Saharan Africa are at the same stage of evolution or
that they will follow the same development paths. But, it was apparent in the FAO e-mail
conference that certain concerns are shared by many.
Structural adjustment, whether subscribed by the International Monetary Fund (IMF)
or spontaneously adopted, generally involves downsizing and a shrinking budget for public
services combined with an increasing demand for greater accountability and the
requirement to encourage the growth of the private sector. The expected impact on the
animal health sector involves downsizing the government veterinary service to a lean, mean
advisory and regulatory body, with responsibility limited to public good elements of animal
health care, some of which may be contracted to the private sector. Any elements which are
clearly private goods will be taken over by a range of professionals and paraprofessionals in
the private sector, functioning in a policy environment designed to create competition and
accountability.
However, animal health care delivery services in sub-Saharan African countries are in a
fluid state with neither the public nor the private sector functioning as the country would
wish them to.
Implications for impact assessment
This section takes two themes related to structural adjustment and suggests the likely effects
on impact assessment when restructuring is well-advanced. Some of these effects can already
be observed in Africa while others can be predicted from common sense or experience in the
developed world.
As the public sector budget diminishes, fewer resources are available to collect data, yet
at the same time there is a demand for greater accuracy in assessment and prediction.
Implications
• Impact assessment will take a high profile. Strategic research into a vaccine is generally
funded by public money and here financing will become increasingly dependent on the
ability of the researcher to demonstrate high returns to investment. In countries that
choose to deliver the vaccine through the public sector, the competition with other
technologies will be fierce. If decision is made instead to distribute and deliver through
the private sector, manufacturers and veterinarians will want to be convinced of safety,
efficacy and adoption potential.
• The use of models will assume increasing importance. They must be used creatively for
ex ante assessment and to highlight critical datathose to which the model is most
sensitive. This has implications for training and recruitment since three specific types of
expertise are required: a) modellers and model users, whom it may be more efficient to
recruit than to train, b) data collectors, who need to understand the use and data
requirements of a model but not the complexities of its design, and c) policy makers,
who need to understand the output of economic and biological models but not their
design or the data gathering process.
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• The choice of indicators will be crucial as will the level of precision required in their
estimation; where resources are constrained need to know becomes much more
important than wish to know. Choices need to be made between empirical and
contingent evaluation methods, longitudinal and cross-sectional studies. For example,
production data are needed for any economic assessment and longitudinal monitoring
is undoubtedly the best collection method for accurate and detailed data. However,
longitudinal monitoring is resource-hungry and, in most countries, can only be
conducted in a few carefully chosen sites as part of a larger research effort.
• The choice of impact zones will be very important because this affects the efficiency of
data gathering. Where the data collection system is resource-constrained, it makes sense
to select high disease risk areas and target groups where considerable benefits can be
expected, on the assumption that if these groups do not generate a sufficiently high rate
of return it will be pointless to examine more marginal areas.
• Minimum data sets may be adopted for certain types of impact assessment. This is an
elegant concept that has instant appeal to researchers and policy makers, but there are
few successful examples. Taken in conjunction with the three previous points, a
minimum data set would contain data from critical impact zones, on critical indicators,
and would focus on variables needed to run models. However, the word minimum
tends to conceal the enormous effort needed to organise and sustain any database. It
will be argued below that minimum data sets are most appropriate for public sector data
and that it may be hard to introduce a standard format.
Government veterinary services are relinquishing their role as providers of clinical
services and taking on a regulatory function. Correspondingly, the private sector is
becoming increasingly important in distributing and delivering private goods. Arguably
ECF vaccination, with its few externalities, can be made exclusive, is in high demand and is a
private good (the case of immunisation and treatment is less clear-cut because of the carrier
state). The direct involvement of the public sector in production and distribution of
vaccines should be minimal in a liberalised market.
Implications
• Different stakeholders will have widely different and often competing needs for impact
assessment (the government will place emphasis on safetyefficacy and environmental
impact and possibly on quality of life of consumerssocial impact; private distributors
will concentrate on information necessary for marketing; research financiers will
continue to require the traditional assessments of returns to research). Since data
collection will be done by stakeholders for their own monitoring and evaluation
purposes, the quality and quantity of data collected can improve. The total cost of data
collection under a free market economy is likely to be higher than that under a
centralised economy but its quality is ensured.
• At the same time, the availability of data will decrease. Players in a competitive market
may be willing to invest in data collection but unwilling to share it with others, for
reasons of industrial secrecy and the understandable reluctance of the private sector to
116 FAO/OAU–IBAR/ILRI Workshop
Assessing the impact of ECF vaccination: Implications of structural adjustment
appreciate the obligation to provide information to the public. Governments will need
to be very clear on the required standard methods of data collection and analysis, while
also demanding the return of information by the private sector to the government.
Regulations concerning the accessibility of data, with the understanding that public
control of or access to data has an associated management cost, need to be clarified.
• The need for and funding of impact assessment data may be separated from its
collection. This is analogous to the delivery of the ECF vaccine, where each country will
make its own decision about the balance between private and public financing, but in
the absence of a large public field service, delivery must be made by the private sector.
The same reasoning applies to impact assessment data. Even those elements required
for government regulation may need to be contracted out to third parties: where
appropriate these will be private animal health professionals, for certain data it will be
necessary to employ neutral third parties.
• It will become more difficult to standardise data collection, storage and analysis for
anything but public goodsregulation and quality control. In consequence, a minimum
data set might concentrate on safety, efficacy and environmental impact and contain
very little economic data. Private sector stakeholders might decide to standardise or
share methods for reasons of efficiency but it will be difficult and ultimately
unproductive to constrain them to do so.
It follows that a possible scenario could be where each government held a modest
minimum data set to an internationally approved design, with the maximum use of models,
a modest routine data collection effort and rapid turnover of information. Research would
follow a system similar to the present funding approval process in the Consultative Group
on International Agricultural Research (CGIAR) and international development
community. At the same time, the private manufacturing and delivery sector would take
charge of impact assessment for marketing purposes with sharing of certain data made
mandatory and the accuracy of published results screened by third parties. Farmer groups
would carry out their own impact assessment with the help of public or private extension
agents. This could, however, be kept for the future.
The immediate need is for an impact assessment which addresses the limitations and
fluctuations of existing animal health sectors. During this transition phase, it will be
important for each of the stakeholders to recognise their own comparative advantage and
future needs and concentrate on those elements of the system, while at the same time
making efforts to collaborate and share information. To some extent this was anticipated
from the conclusions of the Harare workshop. Our workshop could take the process a step
further, by defining more clearly what is expected of each stakeholder and making a plan to
achieve it. It can probably be assumed that impact assessment methods for research are well
developed and that priority should be given to: the changing role of the government and the
information that its minimum data set will be expected to supply; the training needs for
those moving to the private sector to be able to take responsibility for their own impact
assessment; and the impact assessment needed for the consumer during and after the
transition.
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Summary of discussion: Socio-economics
and impact assessment
Facilitator: A. Mukhebi
Rapporteurs: J. Mutugi and E. Peeler
In this session, the factors influencing the uptake, sustainability and impact of ECF
immunisation, and the data required to assess these issues were described.
Tick control after ECF immunisation
Following immunisation tick control is required to control tick damage, reduce risk of ECF
breakthroughs due to high challenge and to control other tick-borne diseases (TBDs).
Where there is a history of intensive dipping and the presence of other TBDs, the potential
risk of these diseases must be thoroughly considered before reducing tick control measures.
Creating endemic stability by strategic dipping to allow the development of natural
immunity or by immunisation may be necessary. Where there is a history of less intensive
dipping, tick control can be reduced to threshold dipping when engorging ticks are
detected, to limit tick infestation and tick damage. Experience in Uganda has shown that
tick control can be relaxed safely by 5060%, for example, from dipping twice to once a
week. Acaricide is applied when engorging females are seen, and this helps to prevent the
pasture being repopulated. Boophilus species are easily controlled by acaricide application
every three weeks. However, if other TBDs are present, acaricide use may have to be
intensified.
The question of what degree of reduction in acaricide use would ensure sufficient field
challenge to boost ECF immunity following immunisation remains to be seen. It was
generally felt that there is insufficient data to allow a general recommendation on this. In
addition, factors such as ecological zone, cattle type and management system would affect
the level of reduction. A pragmatic approach makes better sense, where a progressive
reduction in acaricide use is made following immunisation until a safe minimum level is
reached, suitable for a given circumstance. The issue of whether recommendations about
tick control should appear on the immunisation product label was also raised. Participants
felt that the farmer should be informed of the benefits and risks involved in immunisation
to help him/her make a rational decision whether or not to adopt the technology. They
concluded that there is insufficient information currently available on which to base
recommendations. However, the view was expressed that, with the current state of
knowledge, it should be possible to formulate recommendations on tick control for
situations where Babesia bigemina, B. bovis or heartwater are present. Some participants felt
the product should not be released until tick control recommendations were formulated.
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Initially, the main target group for immunisation is farmers whose first priority is to
reduce the risk of ECF, before reducing acaricide use. As the product becomes established
in the market, some farmers will adopt the technology primarily to reduce the pattern of
acaricide usage. In general, recommendations on reduced tick control will vary greatly
between ecological zones, cattle types, management systems and tick challenge,
complicating the effort to produce clear-cut guidelines. It was concluded that a pragmatic
approach to reduced acaricide use was required, but that appropriate data is generated
through controlled investigations to provide recommendations for varying conditions.
Participants further noted that there was no way of managing the use of acaricides so that
tick resistance is prevented.
Costs of vaccine and immunisation
Currently, the farm gate price for ECF immunisation ranges between US$ 9 and 25 per
adult cow. The cost largely depends on the clustering or density of cattle to be immunised
and the use or non-use of a long-acting tetracycline formulation (mild vaccine strain, e.g.
Boleni). Costs could be reduced in several areas including production, drug use and
monitoring. The cost of treating reactors is built into the current price of the vaccine. As the
number of reactors varies with different vaccines, batches of vaccine and cattle type, this may
influence price greatly. When full cost recovery becomes a reality, the cost of treatment of
reactors with buparvaquone may need to be separated from the vaccine cost. Monitoring
costs could be significantly reduced if paraveterinarians and farmers are fully involved in
monitoring, and if the number of visits is reduced or combined with complementary farm
activities or services. Currently, some countries are making partial cost-recovery for ECF
immunisation. However, in the long-term, there should be movement towards full cost-
recovery or privatisation, in line with macro-economic policy reforms under structural
adjustment programmes. It was pointed out that the ex-factory stabilate price was fairly easy
to estimate accurately, and several estimates are available. The stabilate cost is a very small
proportion of the final price to the farmer. It will vary a little depending on the number of
doses available from each batch. In the production of Katete strain, fairly consistent batch
sizes have been achieved. However, the farm-gate price of the stabilate will vary more
depending on delivery systems (private or public) and transaction costs. In Zimbabwe, the
overall price of tick control has been given to the farmer, which has meant the introduction
of a combined immunisation and dipping levy.
Policy, legislation and legal issues
National policies should provide a framework to an integrated approach to the control of
ticks and TBDs while also promoting the establishment of endemic stability. In addition,
the policies should provide for a pattern of acaricide use that does not lead to the
development of resistance or environmental pollution and animal product residues. The
relevant legislation should also be revised to reflect the overall policy framework and include
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the registration of vaccines. Legislation should also be extended to cover areas such as
personnel administering the vaccine, classification of the vaccine, compensation and
indemnity, and carrier state with respect to exporting cattle. There was general agreement
that compensation and indemnity were unworkable. Instead, participants felt that the risk
of reactors and breakthroughs should be described in the product data sheet and explained
to the farmer. It was considered unrealistic to make immunisation compulsory, particularly
as immunisation is a private good for which beneficiaries are expected to pay.
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Alternative vaccines
Subunit vaccines for the control of Theileria
parva
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International Livestock Research Institute (ILRI),
P.O. Box 30709, Nairobi, Kenya
Introduction
Improvement of the livestock industry in many developing countries has been severely
constrained by tick-borne diseases. The major protozoan pathogens responsible for these
diseases in cattle are Theileria parva and T. annulata which cause East Coast fever (ECF) and
tropical theileriosis, respectively, and Babesia bigemina and B. bovis, which cause redwater
fever. The rickettsial organisms, Cowdria ruminantium and Anaplasma marginale are
responsible for heartwater and anaplasmosis, respectively. East Coast fever is of great
economic importance throughout eastern, central and southern Africa, with losses in 1989
estimated at US$ 168 million (Mukhebi et al 1992). Theileria annulata is of even greater
importance and occurs from North Africa to China (see review by Irvin and Morrison
1987). Though there are no recent figures for losses due to T. annulata, over 100 million
cattle are at risk of contracting the disease. Babesiosis has a world-wide distribution.
Anaplasmosis is also a disease with significant impact on the cattle industry throughout the
world. It has been estimated that, in the USA alone, mortality approaches 100,000 cattle
annually (Goodger et al 1979). Heartwater is widespread in sub-Saharan Africa and has been
introduced to the Caribbean Islands (see review by Uilenberg 1993). The close proximity of
these islands to the USA and South and Central America poses a threat to these countries.
The disease ranks third in importance behind theileriosis and trypanosomosis in Africa but
its economic importance has not been evaluated. All of the above tick-borne pathogens
constitute a major impediment to the introduction of highly susceptible Bos taurus cattle
into endemic areas and are the cause of high morbidity and mortality. This review will focus
on recent research towards the development of a subunit vaccine against T. parva.
Current methods of control
The prevailing strategy of tick-borne disease control is based on the control of the tick vector
using acaricides. This strategy is unreliable for a number of reasons including lack of funds
for the purchase of acaricides, poor maintenance of control facilities (e.g. dips) and the
development of acaricide resistance in tick populations. Additional concerns relate to
environmental contamination. The major disadvantage of available vaccines against tick-
borne diseases is that they are all based on the use of live organisms.
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Currently, the only practical method of immunisation against ECF is infection with
cryopreserved sporozoites and simultaneous treatment with long-acting formulations of
oxytetracycline (Radley 1981). There are two major limitations to this method: firstly,
because live organisms are used, a cold chain is required; secondly, protection is only
ensured against the immunising stocks (Radley 1981). Attempts to develop a schizont-
infected cell vaccine for T. parva were frustrated by the requirement for large numbers of
cells to effect immunisation and observations of severe parasitosis in a proportion of cattle
following inoculation (Brown et al 1978; Dolan et al 1982).
Progress towards development of a subunit vaccine
The approaches used to identify antigens for subunit vaccine development are, in general,
guided by the type of immune responses that are likely to mediate protection. Two such
immune mechanisms have been identified for T. parva. The immunity that protects the
animal against the pathogenic schizont stage of this parasite is not dependent on antibody
(Mohammed et al 1975). The development of techniques for in vitro transformation of
bovine lymphocytes with T. parva and the maintenance of infected cell lines in culture
(Brown et al 1973) were the most significant advances in allowing the elucidation of cellular
immune mechanisms against the parasite. It was quickly demonstrated that immune
peripheral blood lymphocytes proliferated in the presence of autologous infected cells, and
that these cultures contained parasite-specific killing activity (Pearson et al 1979). The
availability of a comprehensive range of bovine tissue typing sera allowed the demonstration
that this activity was restricted by class I elements of the bovine MHC (Morrison et al 1987).
It was also established that the effector cells were CD8+ T lymphocytes, which confirmed
that cattle deploy classical cytolytic T lymphocytes against T. parva (Goddeeris et al 1986).
Prominent parasite-specific CD4+ T cell responses have also been detected in immune cattle
(Baldwin et al 1987; Brown et al 1989), although the contribution of these cells to immunity
has not been established. Kinetic analyses of parasite-specific cytotoxic T lymphocytes (CTL)
activity revealed that it is temporally associated with the clearance of parasitosis in immune
cattle (Morrison et al 1987), which was consistent with its being involved in the resolution of
infection. More direct evidence for the role of CTL in parasite clearance was provided by the
observation that protection could be transferred between immune and naive monozygotic
twin calves undergoing lethal challenge in the CD8+ fraction of responding efferent lymph
(McKeever et al 1994).
Although humoral responses are not implicated in immunity of recovered cattle,
animals do develop sporozoite neutralising antibodies after multiple exposure to the
parasite. This observation gave rise to the belief that sporozoite surface antigens might
constitute neutralising vaccine candidates. The techniques for the identification of antigens
recognised by antibodies are well established and for this reason considerable progress has
been made in determining the immunising potential of sporozoite antigens of T. parva.
Antisera from cattle in ECF-endemic areas are polyspecific and on immunoblots bind to
several sporozoite molecules which include proteins of relative molecular weights (Mr) 105,
85, 67, 55, and 31, kilo-Daltons (kDa). Candidate vaccine antigens were identified from this
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repertoire of sporozoite antigens by raising monoclonal antibodies (MAbs) that neutralised
sporozoite infectivity (Musoke et al 1984; Dobbelaere et al 1984). The majority of the MAbs
bound to a sporozoite stage-specific 67 kDa molecule (p67) that is expressed on the surface
membrane of the parasite. DNA coding for p67 was identified by immunoscreening a
lambda gt11 cDNA expression library derived from sporoblasts of the Muguga stock of T.
parva. It was established that the gene encoding p67 is present in a single copy and is split
into two exons by a 29 bp intron (Nene et al 1992).
An Escherichia coli recombinant fusion protein, NS1-p67, containing all 709 amino acid
residues of p67 fused to the first 85 residues of NS1, a non-structural protein of influenza
virus A, has been used in cattle immunisation experiments. A semi-purified preparation of
NS1-p67 formulated in saponin was used to immunise 9 cattle. All cattle developed high
titres of IgG antibodies that bound to native p67 on immunoblots and neutralised
sporozoite infectivity (Musoke et al 1992). The immunised animals together with 9
unimmunised controls were challenged with a 70% lethal dose of a T. parva (Muguga)
sporozoite stabilate. Of the 9 immunised animals, 4 did not react to challenge and had no
detectable parasitosis. Two cattle underwent a mild febrile reaction with transient schizont
parasitosis. The remaining 3 immunised cattle and the 9 control animals all developed
severe ECF (Musoke et al 1992). Hence, 6 of 9 cattle were immune to ECF. Current efforts
are directed towards increasing the degree of protection by improving the immunisation
scheme. Additional studies are focused on the immune mechanisms responsible for
protection in these cattle, since immunity does not appear to correlate with antibody titres
(Musoke et al 1992).
Immunity engendered by recombinant p67 is likely to be directed against the sporozoite
stage of the parasite, since the antigen is not expressed by the subsequent stages. Antigenic
diversity between different populations of T. parva is well recognised and is believed to be
responsible for breakthrough infections in cattle immunised by infection and treatment
(Radley 1981). An important feature of p67 that relates to its use as a vaccine is that its
sequence is highly conserved among different isolates of T. parva and we have recently
demonstrated that cattle immunised with recombinant p67 are protected against challenge
with heterologous cattle-derived parasite (Nene et al 1996). However, the p67 gene
sequence of buffalo-derived parasites contains two small regions of polymorphism (Nene V.
and Gobright E. unpublished observations) and the impact of this finding, if any, on
vaccine effectiveness is under investigation.
While attempts are being made to increase the level of protection achieved with
recombinant p67, a vaccine that incorporates antigens of the schizont, the target of parasite-
specific CTL, may provide more long-lasting immunity in the field. Two methods are
currently available for identifying antigens that are expressed in the context of MHC class I
molecules. The most direct approach is the isolation, fractionation and sequence analysis of
peptides associated with MHC class I molecules. Once a peptide of defined sequence is
shown to sensitise target cells to lysis by specific CTLs, then the gene encoding the peptide
can be isolated using synthetic oligonucleotides as probes. The second approach depends
on gene expression in a transfected target cell. This strategy uses cDNAs expressed in
transiently transfected cells expressing appropriate MHC molecules, in combination with
lytic or cytokine release assays. Both of these strategies have been successfully applied to the
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identification of tumour antigens, and are applicable to the search for antigens of T. parva
that provoke parasite-specific CTL responses. In terms of vaccine potential, ideally the
schizont antigen should be conserved among different parasite stocks. Should this not be
the case, a cocktail of antigens would be required to give as wide a cover as possible. In
addition, because of the processing requirements of class I, MHC-restricted antigen
presentation, incorporation of a schizont antigen component in recombinant vaccine
against T. parva will require the use of appropriate antigen delivery systems such as those
based on recombinant viruses or bacteria.
Concluding remarks
A successful recombinant tick-borne disease vaccine should ideally induce immunity, at
least comparable to that engendered by available live vaccines in the degree of protection
and longevity of immunity. The failure of recombinant of p67 to induce solid protection
may result from the inability of the expression systems currently employed to make
secondary modifications to the expressed products that are important for immune
recognition.
A major consideration in designing vaccines for haemoparasites is that many of these
organisms have at least two life cycle stages in the host animal. A successful vaccine may need
to include antigens of different life cycle stages. For example, an effective vaccine for ECF
might require sporozoite and schizont antigen components (Musoke et al 1992). Similarly,
for tick-borne parasites where polymorphic antigens have been identified it may be useful to
expand the search for conserved antigens expressed by other life cycle stages, in particular
the tick derived stages.
As candidate vaccine antigens are identified, the identification of appropriate antigen
delivery systems will become increasingly important. With the expansion of knowledge of
the inductive requirements of the immune responses, delivery systems are available that
engender the appropriate humoral or cellular immune responses. The choice of
formulation is heavily influenced by the nature of the desired response. Additional criteria
that must be applied relate to the infrastructure and financial capacity in developing
countries. Most of the diseases under discussion are prevalent in countries where resources
are limited. The live antigen delivery systems, based on recombinant viruses and bacteria,
hold many advantages for these countries. Expression constructs can be manipulated to
optimise the desired immune mechanisms, and, in theory at least, multiple antigen vaccines
can be constructed with relative ease. More importantly, live antigen delivery vectors
abrogate the need for production and purification of large quantities of antigen, and so are
inherently less expensive. Current fears of environmental contamination with genetically
engineered micro-organisms are likely to diminish with the development of highly
attenuated vector strains coupled with successful field trials of existing live recombinant
vaccines. For example, rabies vaccines based on recombinant pox viruses have now been
deployed successfully in the field in both Europe and the USA (Brochier et al 1991; Pastoret
and Brochier 1992 ).
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Multi-component subunit vaccines against
Theileria parva
D. McKeever
International Livestock Research Institute (ILRI),
P.O. Box 30709, Nairobi, Kenya
Background
Cattle that recover from Theileria parva infection are solidly immune to rechallenge with
homologous parasites. Most of the International Laboratory Research on Animal
Diseases/International Livestock Research Institutes (ILRAD/ILRI) immunological
research into the disease has focused on defining the basis of this protection. Over 15 years
of basic and applied immunological research at ILRAD/ILRI have demonstrated that
protection in T. parva-immune cattle is primarily mediated by parasite-specific cytotoxic T
lymphocytes (CTL). Available evidence suggests that these responses require the input of
specific helper cells and endure for the life of the animal. Although CTL immunity can be
induced by infection of cattle in the face of tetracycline treatment, for a number of reasons
this method is not considered sustainable. Development of a subunit vaccine for generating
parasite-specific CTL has therefore, been a major focus of the East Coast fever (ECF) vaccine
development programme for several years.
Status
Research has focused on three areas:
• identifying T. parva antigens recognised by bovine CTL and associated helper cells
• understanding how bovine CTL responses are activated in vivo
• identifying antigen delivery systems capable of generating specific CTL responses in
cattle.
Options
Antigens
The two major strategies that have been reported for identification of CTL antigens involve
complex technologies known as peptide stripping and COS cell screening. Both approaches
are well under way at ILRI and are supported by collaboration with appropriate leading
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research institutes. An additional opportunity arises from a recently initiated Japanese-
funded T. parva genome-sequencing project at ILRI. Antigens recognised by helper cell
populations can be identified by more traditional methods in which ILRI has much
experience.
In vivo activation requirements
ILRI has substantial expertise in dissecting cellular immune mechanisms and is focused on
the interactions between CTL and associated helper cells.
Antigen delivery systems
A number of systems have been reported to provoke CTL responses in vivo, among which
the use of live recombinant micro-organisms has proved most consistently effective. In view
of their potential for use under conditions where ECF is endemic, ILRI research has
focused largely on the evaluation of recombinant viruses, bacteria and naked DNA vectors.
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Training requirements
for vaccine delivery
ECF immunisation: Training requirements
for veterinarians and field staff
R. Rumberia
National Veterinary Research Centre (NVRC), Muguga,
P.O. Box 32, Kikuyu, Kenya
Introduction
Over the years, various methods of immunisation have been used in an effort to protect cattle
against East Coast fever (ECF) (Purnell 1977). However, only immunisation by infection and
treatment has so far proven suitable. The method involves inoculation of live Theileria parva
sporozoites and concomitant treatment with tetracyclines (Radley 1981). For a number of
reasons, there has been some reluctance to adopt infection and treatment (ITM) as a control
method against ECF. These include the lack of a single vaccine stock that will protect against a
wide range of heterologous parasites, the fear of introducing new parasites to areas where they
do not exist, concern about the carrier state and the effect of immunisation on productivity.
Most of these concerns have been recognised and studies have been undertaken to address
them. For example, Radley et al (1975) explored the possibility of using a combination of three
T. parva stocks and showed that they could protect cattle against a range of parasites far
removed from the source of immunising strains. This parasite combination, referred to as the
Muguga Cocktail, is used in parts of eastern, central and southern Africa for immunisation.
Mutugi et al (1990a) showed that a single isolate (T. parva Marikebuni) protected against 28 T.
parva isolates from widely scattered regions of Kenya. This stock is currently the
recommended material for immunisation in Kenya. Conclusive evidence has been presented
showing that animals that recover from ECF remain carriers (Young 1981; Kariuki 1991) thus
removing earlier concerns on the role of carrier status in the epidemiology of the disease.
Other studies have revealed that immunisation has no effect on productivity (Mutugi et al
1990b) or fertility (Dolan and Mutugi 1989; Rumberia et al 1993). One of the major problems
associated with the infection and treatment method against ECF is the possibility of creating
clinical reactions (reactors) due to the use of pathogenic vaccine material, which, unlike most
other animal vaccines, neither attenuated nor killed. This is not unique for ECF since other
diseases, like heartwater, employ a similar approach.
Training
Why is training necessary?
There are two main reasons for providing training on ECF immunisation. Firstly,
veterinarians and their assistants need to update their knowledge on the disease to help
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accurately assess the success or failure of the vaccine. Although considerable literature exists
on the causative agent, the epidemiology of the disease, immune mechanisms and control,
this knowledge may not be readily available to practitioners resulting in misunderstanding
of the efficacy and safety of the vaccine. Secondly, since the ITM is based on live and
pathogenic material, the method involves follow-up monitoring of immunised animals for
reactions. Professionals and their assistants involved in the delivery system thus need to be
trained in handling the vaccine and its delivery and in identifying and treating reactors.
Over the last three years, the National Veterinary Research Centre (NVRC) has carried out
5 training sessions involving a total of 49 veterinarians and 56 technical health personnel in
Kenya. It was evident that there was a serious need for theoretical and practical training for
veterinarians and support personnel involved in the delivery system to help successfully
deliver the technology. This may also be true in other countries where ITM is being
practised. The ITM is a relatively new technology and farmers also need basic information
on the nature, delivery and the associated risks and advantages of the exercise.
Who should be trained?
The policy in Kenya provides that immunisation will be carried out privately either by
veterinarians in private practice or in government service in their private capacity. Although
veterinarians should be the primary target group for training, there is also need to train
technical personnel (paraveterinarians and laboratory technicians) who may assist during the
immunisation and laboratory back-up and agricultural extension personnel who will help
sensitise farmers on the technology. Students at tertiary level institutions (university and
colleges) could also be potential targets to help reach a wider audience. One of the major
constraints of the method is the need for close monitoring of animals after immunisation.
Training of farmers and their workers in monitoring for reactors would thus substantially
contribute to reducing the cost of immunisation and help make it more affordable.
Training curriculum
The training should focus on both the theoretical and practical aspects of the disease, tackling
issues associated with vaccine delivery and post-immunisation monitoring. It is envisaged
that, in the long term, the trained veterinarians will become trainers of technical-support and
extension staff and farmers. The course content may vary depending on the role played by the
trainees in the delivery system. For example, veterinarians need more detailed theoretical
training sessions than the technical staff although both will require similar practical exposure.
In Kenya, a training manual developed by Mbogo et al (1995) has been used for training.
The theoretical session covers such issues as the aetiology, life cycle of the parasite in the
bovine and the tick vector, transmission, clinical signs, pathology and immunity and the
basics of infection and treatment. Other tick-borne diseases (anaplasmosis, babesiosis and
heartwater) are also covered in a similar format but in less detail. A series of questions follow
each section to evaluate the trainees understanding of the issues. Practical sessions include
preparation and handling of stabilates, immunisation and monitoring. Practicals consist of
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demonstrations as well as participation by the trainees. In addition to group training,
project staff work closely with the trained personnel during their first immunisation
projects as a way of building their competence and confidence.
The programme has yet to be evaluated. Some of the considerations include the course
content for the different groups, course duration and training of the trainers. Currently, the
trainers are scientists who may not have adequate communication skills to sufficiently fulfil
their role as trainers.
Training venues
Due to the nature of the vaccine, training in ECF immunisation must be thorough. The
available human and physical resources to be used for the training must be clearly identified.
The various categories of trainees involved in the delivery system require different facilities.
Rooms with adequate facilities will be needed for teaching the theoretical aspects of the
disease for all cadres. Simpler facilities like open grounds may be adequate during
sensitisation of farmers and extension staff in the form of barazas or field days. Practical
training will require laboratories and suitable animal facilities. Ideally, the theoretical and
practical training should be done where the technology and expertise for the ITM exist. Such
facilities may be found in international (e.g. International Livestock Research Institute
(ILRI)), regional (e.g. Vaccine Production Centre (VPC), Malawi) or national (e.g. NVRC,
Kenya Agricultural Research Institute (KARI)) institutions. Training may also be moved to
other centres with adequate facilities like veterinary investigation laboratories, farmer training
institutes or tertiary institutions. From the classroom, training should be extended to become
on farm where the trainees will work alongside the trainers during all phases. This is essential
due to the close individual contact between the trainers and trainees. Farmers can also be
trained, particularly in clinical monitoring, if a decision has been made to involve them in the
process. Other avenues like radio, farmers bulletins, the press and leaflets may also be used to
reach and sensitise the farmers to ECF immunisation.
Funding
Training sessions require financial inputs like remuneration of trainers, hiring of facilities
and training material. Funding could be obtained from donor agencies, non-governmental
organisations (NGOs), governments or the private sector particularly those involved in the
sale of the vaccine.
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Extension programme development for the
delivery of East Coast fever (ECF) vaccines
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Food and Agriculture Organization of the United Nations (FAO), Representative Office,
P.O. Box 521, Kampala, Uganda
General
Extension can be defined as the method of transmitting a specific message or technology to a
particular target group of beneficiaries.
Target population (beneficiaries)
The group of people to benefit from the new technology should be carefully identified.
Their perception and understanding of the subject matter require evaluation.
Extension theme (message)
The message of a particular extension programme should remain as simple and
straightforward as possible. All attempts should be made to avoid controversial issues that
would only create confusion. Some messages are designed to provide specific information
while others may be required to help convince a particular beneficiary group that a
problem actually exists and that there is a new technology available to improve the
situation.
Communication
This is the channel though which the extension theme is transmitted to the target
population. A number of channels could be used to transmit messages but the most
appropriate means to get the information across should be selected. Some examples are:
• Verbal: farmer meetings and demonstrations
• Written: explanatory handouts, brochures, posters, animated stories, technical
manuals, newspaper articles etc
• Audio: radio messages and cassette recordings
• Audio-visual: flipchart programmes, slide or filmstrip presentations, videocassette,
television etc.
Most extension campaigns combine several communication methods in an attempt to
provide maximum exposure to the target group.
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delivery
Target population
In most situations, this will be farmers attempting to increase production by introducing
improved cattle breeds (both dairy and beef).
Extension theme
An alternative approach to ECF control is available which includes the use of ECF vaccines
coupled with relaxed tick control strategies. The message should provide information
covering the target population of cattle, immunisation procedure, post-immunisation
monitoring requirements, benefits, potential risks involved and the total cost of vaccine
delivery. Most of the target population (beneficiary group) thoroughly understands the
economic impact of ECF and intensive tick control. Therefore, the message probably does
not require a detailed discussion on the negative impact of ECF disease in improved cattle.
The message should focus attention on this alternative approach to ECF control.
Communication
This will be highly variable depending on the resources available and will involve a variety of
communication techniques.
It should be noted that extension campaigns should be developed to support vaccine
delivery after the services have been adequately institutionalised.
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Recommendations
Recommendations
General
1. The participants agreed to compile and circulate a summary of recommendations
from all previous meetings, including those under the regional programme since
1984. This summary of recommendations should be made available during future
meetings, which could begin by reviewing potential follow-up activities and evaluate
progress made.
2. Members of the technical training manual and farmer brochure production groups
should be identified from different country projects. These groups should meet and
continue with the preparation of standard material for use at the regional level. The
literature produced must also be adaptable to local requirements, particularly with
reference to language.
3. The region should move towards establishing a central (regional) vaccine production
laboratory that provides standard vaccine stabilates to national projects. These
stabilates must be prepared according to agreed minimum standards and pass through
defined quality control criteria.
4. It is vital that a repository (or repositories) is created to store key immunising stocks for
the region and also important reagents related to vaccine deployment and
characterisation.
5. There is an urgent need to formulate post-immunisation tick control strategies using
already existing knowledge. Information describing the various strategies and advice on
how to select the most appropriate for a particular situation must be made available to
field veterinarians and cattle owners.
6. The regulatory and monitoring capacity of governments should be strengthened as the
technology of immunisation moves toward the private sector. This would assist issues,
such as, the licensing of both vaccines and personnel involved in immunisation.
8. Institute a working group responsible to prepare an action plan for the training
requirements of the region with particular emphasis on vaccine delivery. In some areas,
skilled veterinarians and animal health assistants are not currently available for training
in vaccine delivery. The question of fair distribution of trained personnel in these areas,
which is primarily a funding issue, must be addressed.
7. Previous meetings have recommended that a minimal data set be formulated which
would identify the minimum information required to give useful post-immunisation
surveillance. This has not yet been done and the recommendation was reiterated at this
meeting.
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9. An action group should be set up to help find the means to retain trained national
staff. This group should identify the various fundamental issues involved in loss of
staff and recommend possible solutions. There has been some success in South
America and Asia where mechanisms have been developed to help retain trained
national staff.
10. The region should be proactive to obtain additional funding. It should formulate an
action plan for the control of ticks and tick-borne diseases (TBDs) to target at donors,
particularly donors who have not previously provided funding for the region.
Research
1. More information is required from different epidemiological zones, where different
combinations of TBD occur, to help recommend appropriate integrated tick and TBD
control strategy following immunisation.
2. Post-immunisation surveillance is essential for several reasons:
• To continue to monitor possible breakthroughs in the field. Isolation,
characterisation and cross-immunity evaluation of breakthrough parasites is
desirable, but is not logistically or financially feasible. This makes pursing a rational
approach to the investigation of possible breakthroughs more important.
• To assist in assessing the relative benefits of the different tick control strategies
adopted after immunisation in different epidemiological zones.
• To help impact assessment studies determine the effects of immunisation (such
studies require pre-immunisation data to determine the impact of ECF before
immunisation).
• To look at the impact of immunisation on the productivity of the livestock industry
and the epidemiology of ECF.
3. Each vaccine stock in use requires a unique marker to differentiate it from other
vaccines and field parasites. These markers are likely to be the products of current
research at the International Livestock Research Institute (ILRI).
4. Studies are required to determine the earliest age at which calves can be immunised
safely and effectively.
5. The search for mild strains of Theileria parva, which could be used for vaccination
without oxytetracycline, should continue.
6. Complications resulting from the use of levamisole together with available vaccines
should be a research area of high priority.
7. Cross-immunity trials between vaccine stocks in use (Muguga cocktail, Marikebuni,
Boleni and Katete) should be a top priority in ECF vaccine development.
8. The vaccine diluent needs to be improved to make it more user-friendly with less pH
lability and, if possible, without the 20oC storage requirement.
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9. Policy research relating to TBD immunisation is important, as the current policies in
many countries of the region need updating to accommodate the principles of
integrated control. Examples include the cattle cleansing act and the fact that ECF is a
notifiable disease in some countries.
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Summary of recommendations from Regional
Tick and Tick-borne Disease Control
Workshops held between 1976 and 1997
T. Dolan
Livestock Services, P.O. Box 24720, Nairobi, Kenya
The regional workshop in March 1997 agreed that the recommendations made at all
previous workshops in this series should be compiled and circulated. Participants at this
workshop felt that the process of making recommendations was becoming more an exercise
in wishful thinking than one likely to bring about the actions required. Having a summary
of the recommendations would thus serve as an easy reference that could be updated or
amended. It could also be used to assess the importance or priority given to the
recommendations and review the actions taken.
The workshop participants recommended that the summary be limited to the
recommendations of the regional workshops in this series, held in 1984 (Nairobi, Kenya),
1985 (Nairobi), 1988 (Lilongwe, Malawi), 1991 (Kampala, Uganda), 1994 (Lilongwe) and
this one (Nairobi, 1997). However, a workshop sponsored by the International
Development Research Centre (IDRC) was held in Nairobi in 1976. Eight countries from
the region were represented, together with the Organization of African Unity (OAU) and
the International Livestock Research Institute (ILRAD/ILRI), and specific recommend-
ations were made on Theileria parva and tick control. In addition, a workshop was held on
the epidemiology of ticks and tick-borne diseases in the region in Harare in 1996, co-
sponsored by the Food and Agricultural Organization of the United Nations (FAO) and
ILRI at which 10 countries were representd. The recommendations from these two
workshops have also been incorporated to the summery.
The summary highlights only those issues for which specific recommendations were
made. They are summarised in (Tables 114) with Theileria parva as the focal point for
control, particularly by infection and treatment immunisation, and with ticks and other
Theileria species and tick-borne disease parasites categorised by each of the workshops. The
tables contain topic headings from the workshops and the individual recommendations are
included to provide a consistent linking across the different meetings. In some instances it
has been necessary to interpret the intention of the recommendation to maintain the
consistency of the format, while others have been included under a simple heading based
upon the perceived intention. Recommendations might also appear in more than one table.
This was unavoidable because the nature of some issues has changed between meetings
necessitating a more specific recommendation. An example of this is data management
under (vii) Training, (x) Epidemiology and (xi) Impact and productivity. Suggested research
topics have also been presented as elements within the appropriate table.
The recommendations from regional workshops from 1976 have been extracted and
compiled on diskette and in hard copy for future reference. These sets of information will be
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lodged with the Programme Steering Committee through OAU for reference at future
workshops and at ILRI.
Summary tables of recommendations made by Regional Workshops 197697
Table 1. Acaricides and vector control.
Topics 1976 1984 1985 1988 1991 1994 1996 1997
Tick counts and identification +
Management training (dipping) +
Resistance testing +
Cost/benefit analysis + + +
Strategic/threshold application + + + +
Cattle movement control +
Biological/novel control + +
Wild animal hosts of tick species + +
Financial support + +
Table 2. Immunisation: infection and treatment method.
Topics 1976 1984 1985 1988 1991 1994 1996 1997
Investigate efficacy + + + +
Implement + + +
Use three component vaccine + +
Use local isolate vaccine + +
Attention to risk of introduction of
parasites through vaccination
+ + +
Investigate breakdown breakthrough
parasites
+ + + +
Produce vaccines centrally + +* + +
Explore buffalo-derived parasites +
Investigate earliest age at which to
vaccinate
+
Conduct cross-immunity among major
immunising stocks
+ +
 unrelated and potentially pathogenic Theileria parva.
* as pre-investment phase.
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Table 3. Immunisation: new and improved vaccines.
Topics 1976 1984 1985 1988 1991 1994 1996 1997
Tissue culture +
Different parasite stages +
Other blocking agents + +
Improve diluent +
Mild stocks +
Antigenic variation of
vaccine and buffalo-
derived stocks
+
Novel antigens +
Examine effect of
levamisole
+
Other TBDs + +
TBDs = tick-borne diseases.
Table 4. Characterisation of parasites.
Topics 1976 1984 1985 1988 1991 1994 1996 1997
Stock/strain + + + + + + +
Buffalo-derived +
Carrier + +
Field and
immunising
+ + + +
FAO/OAU–IBAR/ILRI Workshop 149
T. Dolan
Table 5. Safety and vaccine standards.
Topics 1976 1984 1985 1988 1991 1994 1996 1997
Safety testing for extraneous agents + +
Safety for staff handling ticks +
Thawing and long-term storage +
Infection rates in ticks +
Formal standards for vaccines + + + +
Deterioration of stabilates over
time
+
Reference stabilates of critical
stocks
+ +
Repository laboratories for
stabilates and reagents
+ +
Storage and labelling +
Licensing and regulation + +
Funding + +
Table 6. Chemotherapy.
Topic 1976 1984 1985 1988 1991 1994 1996 1997
New drugs +
Table 7. Standardised diagnostic tests.
Topic 1976 1984 1985 1988 1991 1994 1996 1997
Major TBDs + + +
TBDs = tick-borne diseases.
Table 8. Training.
Topics 1976 1984 1985 1988 1991 1994 1996 1997
TBD control + + + + +
Immunisation + + + +
Data management + +
Impact assessment +
TBD = tick-borne disease.
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Table 9. Definitions and nomenclature.
Topic 1976 1984 1985 1988 1991 1994 1996 1997
Definitions/terms
and nomenclature
+ + +
Table 10. Integrated strategies.
Topics 1976 1984 1985 1988 1991 1994 1996 1997
Optimal integrated
control
+ + +
Policy research on
legislation
+
Improve and
harmonise technical
and farmer manuals
+ +
Table 11. Epidemiology.
Topics 1976 1984 1985 1988 1991 1994 1996 1997
Parasite identification and
characterisation
+ + + +
Survey TBDs before immunisation
and relaxation of tick control
+ + +
Define important Theileria diseases +
Investigate (i) natural carrier state and
(ii) following immunisation
+
+ +
Monitor evolving parasite populations
following immunisation
+ +
Investigate changing epidemiology of
TBDs through control
+ +
Study chronic disease +
Study tick ecology +
Structured data sets and management + + + + +
Model construction and use + +
Decision support systems + +
TBDs = tick-borne diseases.
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Table 12. Impact and productivity.
Topics 1976 1984 1985 1988 1991 1994 1996 1997
Standardised procedure for vaccine
delivery
+ + +
Assess productivity following
immunisation
+ + + + +
Standardised data sets + + + + + +
Standardised methods for impact
assessment
+ + + + +
Precision in measurement of parameters + +
Feedback on efficacy of control + +
Central design and analysis of data + +
Financial support +
Table 13. Regional programme and co-ordination.
Topics 1976 1984 1985 1988 1991 1994 1996 1997
Support regional programme + + + + +
Ensure national programme
management
+ + + +
Develop delivery strategies + +
Support for applied research + +
Conduct impact assessment +
Retain trained national staff + + +
Prepare summary of
recommendations
+
Ensure donor support + + +
Table 14. Networks and information exchange.
Topics 1976 1984 1985 1988 1991 1994 1996 1997
Information
exchange/networks
+ + + + + +
Regular workshops + +
Regional programme
role
+ + +
Training + +
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Comment
In reviewing the recommendations, it became apparent that many of them were repeated
and, even when action had been taken on a particular recommendation, it might be
repeated again. Thus, the summary will be important both for rationalisation of the
recommendations and for planning and organisation of the Regional Programme. It should
become a responsibility of the Regional Programme, either of the co-ordinator or of the
Centre, to keep track of these recommendations and possible actions to be taken to address
them. It might also be worthwhile to have action on the recommendations as an item on
the agenda for the Programme Steering Committee (PSC) to help keep up the momentum.
The follow-up should, however, not be left to subsequent regional workshops, usually
irregular and held at two- to three-year intervals. The summary of the recommendations
should provide an opportunity for the participants at the regional workshop to gauge the
level of progress of their inputs since they last met.
The changing nature of the Regional Programme and the transfer of ownership to the
countries of the region (formally in June 1997 with OAU/IBAR as the executing agency)
means that the countries themselves will be responsible, through the PSC, for ensuring that
recommendations are acted upon. Thus, the regional workshop will no longer ask for donor
support through an agency, it has direct access to the donor and responsibility for the
programme through its own PSC.
Although recommendations have been repeated over the years, as if nothing had
happened, progress has been made. For instance, the meeting of 1976 urged continued
work on chemotherapy (which was showing promise at the time) and three effective
compounds are now on the market. Standards have since been developed for vaccines
(recommended in 1988 and 1991) and these regional standards largely determine those
adopted by the Office International des Epizooties (OIE) (see OIE Manual of Standards for
Diagnostic Tests and Vaccines, 1996, Theileriosis, pp. 321330). The adoption of a
standard terminology has also been achieved as recommended by the meeting of 1988,
based on those of Irvin et al (1983, Research in Veterinary Science 35:341346). In
addition, the nomenclature issues that were being debated in 1988 were brought to the
attention of the International Commission on Zoological Nomenclature. The Commission
agreed that the proposed nomenclature was acceptable and that the expertise in the region
was competent to determine appropriate nomenclature in keeping with the systems being
adopted internationally.
The workshop in September 1984 on the collection, handling and analysis of
performance and productivity data was the most specific of all the regional workshops, and
while its intention was worthwhile, it did not achieve its objective. Much of what was
intended from that workshop was repeated in an abbreviated form in the recommendations
in 1994, and in considerable detail by the epidemiology workshop in 1996. It is hoped that
with the new programme at the Centre for Ticks and Tick-borne Diseases (formerly the
Vaccine Production Centre, Lilongwe, Malawi), with much of its emphasis on epidemiology
training for the region, these most necessary of recommendations will become realities.
Occasionally a recommendation has been made which was not universally acceptable
and which was revoked or modified later. An example is the recommendation from 1984
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that a central, computerised data storage and software development system be set up.
Similarly, in 1994 the rider that results must be fed back to participating countries and that
the data remain the property of the country is yet another. The original recommendation
recognised the confidentiality of such data but failed to clearly establish the question of
subsequent ownership that undermined follow-up action. It is therefore important to clarify
both the intention and the wording of issues in future recommendations.
Finally, recommendations on networks and information exchange have been made at
six of the eight workshops and despite action being taken, those directly involved in tick-
borne disease control do not seem to be receiving information and the recommendation is
repeated. The regional workshops are being held and the proceedings have been and are
being produced, the Vaccine Production Centre produced and circulated a useful
newsletter and, more recently, the University of Florida/United States Agency for
International Development (USAID)/Southern African Development Co-operation
(SADC) Heartwater project has been producing its newsletter, The Tickler, which has been
widely circulated, although it is not strictly a regional programme document. It was
recognised in the discussions at some of the workshops that proceedings and other
information may be reaching the upper echelons of the national programmes but not
finding their way down to those actually doing the work. Ensuring the effective flow of
information will be an important issue for the new Regional Programme to tackle.
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